Nel ASA: Settlement agreement with Iwatani Corporation of America

(June 6, 2026 – Oslo, Norway) Reference is made to the press release dated February 7, 2024, in which Nel ASA (Nel, OSE: NEL) announced that Iwatani Corporation of America had filed a lawsuit against Nel and certain entities that were, at the time, part of the Nel group, in connection with agreements for the delivery of fueling equipment and services. Besides Nel, the defendants included entities that are now part of Cavendish Hydrogen ASA (Cavendish Hydrogen, OSE: CAVEN), as well as four individuals. Iwatani, Nel, and Cavendish Hydrogen have resolved their dispute, and related lawsuit, involving Iwatani’s hydrogen fueling stations in California. The dispute arose from technical and operational challenges in a developing industry and has been resolved amicably and in the best interests of all parties. With the issues now resolved to each party’s satisfaction, Iwatani, Nel, and Cavendish can confidently affirm each other’s continuing commitment to advancing the hydrogen fueling industry and remain open to future collaboration. The settlement amount for Nel ASA is USD 7.5 million. The settlement eliminates further legal costs and mitigates litigation risk in the US. ENDS  For additional information, please contact:Kjell Christian Bjørnsen, CFO, +47 917 02 097Wilhelm Flinder, Head of IR, Communications and Marketing, +47 936 11 350 About Nel ASA | www.nelhydrogen.comNel has a history tracing back to 1927 and is today a leading pure play hydrogen technology company with a global presence. The company specializes in PEM and Alkaline electrolyser technology for production of renewable hydrogen. Nel's product offerings are key enablers for a green hydrogen economy, making it possible to decarbonize various industries such as transportation, refining, steel, and ammonia. This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act. This information was issued as inside information pursuant to the EU Market Abuse Regulation, and was published by Wilhelm Flinder, Head of Investor Relations, Communications and Marketing, at Nel ASA on the date and time provided.

Inside information: Terveystalo updates its strategic focus, financial targets for the medium term and dividend policy

Terveystalo Plc, INSIDE INFORMATION, 8 June 2026 at 08:00 (EEST) Inside information: Terveystalo updates its strategic focus, financial targets for the medium term and dividend policy Terveystalo Plc’s ("Terveystalo") Board of Directors has approved the company’s updated strategic focus, financial targets, and profit distribution policy for the medium term. The updated targets reflect the company's renewed focus on growth in selected healthcare verticals and on scaling its leading digital solutions across healthcare retail to drive value creation. Renewed strategic focus on growth and digital engagement Terveystalo updates its strategic focus and introduces a new strategic framework, ARC: AI and data-powered, Reach through growth and access and Customer-centricity. In this new framework, Terveystalo will focus on four strategic shifts: · · · Value creation: Terveystalo is shifting its focus from margin optimisation alone to pursuing profitable growth in selected healthcare verticals. · · · Services and pricing: On the services and pricing side, the company is moving from a transactional service model to an easy-to-use retail approach that is more accessible to customers. · · · Delivery model: In terms of its delivery model, Terveystalo is sharpening its focus from a broad generalist offering to outpatient specialist care and digital growth. · · · Customer engagement: On customer engagement, the company is transitioning from reactive service provision to building proactive customer engagement and loyalty. Together, these shifts provide the foundation for sustainable value creation for customers and investors alike. Updated medium term financial targets and dividend policy Terveystalo’s updated [medium term] financial targets and dividend policy are as follows: Profitable growth: · Terveystalo targets Adjusted EPS growth of 10% p.a. on average Moderate leverage ratio: · Terveystalo Group's leverage target (Net Debt/Adj. EBITDA) is set at no more than 3x. · Indebtedness may temporarily surpass the target level, particularly in conjunction with large acquisitions. Profit distribution: · Terveystalo aims annually to distribute at least 50% of net result, either as dividends or through share buy-backs, and to deliver growing, attractive shareholder returns in line with growing EPS. · The dividend proposal must consider the company's long-term potential and financial status. Previous financial targets set in 2024 were: · EPS to grow on average by 10% p.a. · Net debt to EBITDA not to exceed 2.5x. Indebtedness may temporarily surpass the target level, particularly in conjunction with acquisitions. · At least 80% of net result to be distributed as dividends. The dividend proposal must consider the company's long-term potential and financial status. President and CEO Ville Iho: “With our updated Strategy, ARC, we are taking the next step in Terveystalo’s growth journey. We are shifting our focus from margin improvement alone to profitable growth in the most attractive verticals. At the same time, we are strengthening our model through a more accessible retail approach, a sharper focus on outpatient specialist and digital services, and deeper customer engagement and loyalty. We see significant opportunities to expand selected specialities, such as dental and eye care and to scale digital health retail into a stronger growth engine for the group. These are growth areas where customers value quality, accessibility, and convenience – and where our brand, professional excellence, and digital capabilities give us a strong foundation for growth. The updated financial targets reflect our renewed focus on growth along with sustainable value creation for customers and investors alike.” Chair of the Board of Directors Kari Kauniskangas: “The Board’s priority is to ensure that Terveystalo allocates capital to the most attractive opportunities to create long-term shareholder value. The updated strategic direction sharpens the company’s focus on scalable growth areas, such as dental, eye care and digital health retail, where we see strong market potential and opportunities to build competitive advantage. Combined with disciplined capital allocation and clear financial targets, this strategy provides a strong foundation for sustainable value creation.” Terveystalo plans to host a Capital Markets Day in November 2026 to discuss the next steps of the growth strategy and the updated financial targets. Helsinki 8 June 2026 Terveystalo PlcBoard of Directors For more information, please contact: Kati Kaksonen,Vice President, Investor Relations and SustainabilityTel. 010 345 2034kati.kaksonen@terveystalo.com Distribution: Nasdaq Helsinki OyPrincipal mediawww.terveystalo.com

Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT[®] in Aggressive Brain Cancer (Glioblastoma)

“The preliminary readout of our Phase 1 clinical trial with uTREAT[®] in glioblastoma is encouraging and supports the ability of our technology to safely deliver therapeutically relevant radiation doses to the tumor without reaching dose limits for healthy organs. With these data, we are confident in moving forward with the Phase 1 trial and the development program for uTREAT[®], with the ambition of developing a potentially game-changing radioligand therapy for patients with glioblastoma,” said Curasight’s CEO Ulrich Krasilnikoff. About the Phase 1 trial with uTREAT® in brain cancer The trial aims to investigate Curasight’s uTREAT[®] as a new targeted radioligand therapy for patients with glioblastoma. Participants in the trial are patients with newly diagnosed, verified or suspected GBM. uTREAT[®] is administered via a catheter directly into the vessels that feed the tumor (super SIACI). To enhance tumor targeting, the blood-brain barrier is transiently opened with the osmotic compound mannitol. The mode of administration is designed to achieve high binding of uTREAT[®] in tumors while minimizing radiation exposure to healthy organs. About Curasight’s uPAR theranostic platform Curasight’s uPAR theranostic platform combines two key technologies - uTRACE[®] and uTREAT[®] - both targeting uPAR. uTRACE[®] is designed to deliver sensitive imaging for diagnosis, while uTREAT[®] offers a targeted radiopharmaceutical therapy solution. Together, they form an integrated approach to improving the diagnosis and treatment of cancers that express uPAR. Curasight’s ambition is to develop both uTRACE[®] and uTREAT[®] to improve diagnosis and treatment of uPAR-expressing cancers. About high-grade glioma Treatment of glioblastoma and other high-grade gliomas (WHO grades 3 or 4) presents a significant unmet medical need, necessitating innovative and effective treatments. A total of approx. 65,000 patients are diagnosed with primary brain tumors, and more than 30,000 patients are diagnosed annually with the most aggressive form, glioblastoma, in the US and EU. Approximately 10% of patients with primary brain tumors are children. The prognosis for individuals with glioblastoma is very poor, as approximately 50% of patients die within 14 months, and after five years from diagnosis, only 5% are still alive. External beam radiation is a cornerstone in the therapy of brain cancers. uTREAT[®] could potentially complement current radiation strategies and reduce radiation exposure to healthy brain tissue due to more specific tumor tissue targeting.

Inside information: Terveystalo to acquire Silmäasema to accelerate growth and increase presence in the growing eye care market

Terveystalo Plc INSIDE INFORMATION 8 June 2026 at 08:05 EEST Inside information: Terveystalo to acquire Silmäasema to accelerate growth and increase presence in the growing eye care market Terveystalo Plc ("Terveystalo") and its subsidiary, Terveystalo Healthcare Oy, have today signed a share purchase agreement to acquire all shares in Silmäasema Oy ("Silmäasema") (the "Transaction") with Coronaria Oy ("Coronaria"), the institutional shareholders and certain management team members and other shareholders of Silmäasema (the "Main Sellers"). The purchase price, cash- and debt-free, is approx. EUR 574 million, consisting of an initial cash payment of EUR 275 million and 36.5 million new shares in Terveystalo valued at the closing share price of Terveystalo on 5 June 2026 of EUR 8.20 per share (the "Consideration Shares"). Subject to the completion of the Transaction, Coronaria will become the largest shareholder of Terveystalo with a holding of approximately 15.1% of outstanding shares and voting rights in Terveystalo. Subject to the completion of the Transaction, the Sellers (as defined below) will in aggregate hold approximately 22.4% of outstanding shares and voting rights in Terveystalo. · Silmäasema in brief: Silmäasema is the leading vision and eye health company in Finland in both private eye care and optical retail.[1] An important element of Silmäasema's strong growth and high profitability over the years has been its unique integrated operational model, which covers the entire eye health and vision care value chain and features multiple customer touchpoints across Silmäasema's optical retail, eye clinic and hospital network. The model facilitates seamless and integrated customer paths between the optical retail and ophthalmology businesses. · Creating a market leader in a growing market: The Transaction strengthens Terveystalo's position in the growing eye care market by adding material scale and forming a broader platform for faster growth and stronger profitability. The combined company will benefit from a highly complementary and diverse private customer base, creating significant cross-selling opportunities and broader value creation potential. The Transaction has a strong industrial logic as it combines two high-quality Finnish companies with strong cultural and operational compatibility. The combined company would serve a total of approximately two million customers with an even more versatile range of services and products, and would be well positioned to capitalise on attractive market opportunities, including internationally. · Strategic new owner: Due to the consideration structure, and subject to the completion of the Transaction, Coronaria will become Terveystalo’s largest shareholder and hence will remain invested in Terveystalo and aligned with its long-term value creation. Coronaria brings deep industry expertise and an excellent track record in value creation. The Terveystalo Board of Directors is looking forward to Coronaria’s strong participation and contribution in board work following the completion of the Transaction. · Material scale: On an illustrative basis for the 2025 financial year, the combined company would have approximately EUR 1.55 billion in annual revenue, and EUR 193 million in adjusted EBIT (excluding synergies). · Synergistic EPS-accretive Transaction: The Transaction is expected to create substantial value through estimated annual pre-tax run-rate synergies of approximately EUR 11–15 million. The full run-rate effect is expected by the end of year three following completion of the Transaction. In the estimate, the synergies are expected to arise primarily from cost synergies (estimated to be approximately 70% of the run-rate synergies), which are expected to be mainly realised within 18 months of the completion of the Transaction, and to a lesser extent from direct revenue synergies. One-off integration costs are expected to total EUR 7–9 million. The Transaction is expected to be adjusted earnings per share (EPS)[2] accretive in the first full year following the completion of the Transaction. · For customers and patients, the combined company will be a stronger partner, supported by Terveystalo's digital capabilities and comprehensive healthcare service offering, Silmäasema's vision care and eye health platform, and combined integrated care pathways and customer engagement. Silmäasema will continue under its current brand. · For the employees of both companies, the Transaction will offer broader opportunities for development across a larger and more diverse organisation, supported by developing career paths, access to a wider professional network and the long-term growth prospects of a combined company. · The initial cash payment is subject to certain adjustments, including post-closing adjustments for actual net debt and net working capital of the Silmäasema group, while the number of Consideration Shares is not subject to any adjustments. The consideration structure is designed to support shareholder value creation by maintaining Terveystalo's financial flexibility, while aligning the interests of Terveystalo and the Sellers (as defined below) through the share consideration component. · The Transaction values Silmäasema at an enterprise value / 2025 adjusted EBIT multiple of 11.5x[3], including the estimated full run-rate synergies at the midpoint of the estimate, reflecting the strong market position, growth profile and profitability of Silmäasema, as well as the expected value creation from the Transaction. Ville Iho, President and CEO of Terveystalo, said: "Terveystalo and Silmäasema will form a unique European combination with a compelling value proposition for an expanding customer base. I warmly welcome Silmäasema's employees and professionals, and I look forward to both teams embarking together on this exciting next phase as part of the new Terveystalo. I am convinced that, by working together, we can provide even better customer service and care, while creating an even more attractive work environment for vision care health professionals. This Transaction is highly compelling from both a strategic and financial perspective. Silmäasema strengthens Terveystalo's position in the attractive and growing eye care market, adds significant scale in a resilient private-pay business, and further diversifies Terveystalo's revenue mix. The Transaction offers a clear path to value creation, underpinned by meaningful long-term revenue growth potential, synergies, and expected accretion to adjusted earnings per share from the first full year following completion. Our cultures and operational model are well aligned, which supports disciplined integration and the delivery of the Transaction’s full value potential for customers, professionals and shareholders." Teppo Lindén, CEO of COR Group Oy, Coronaria and Silmäasema, said: "By joining forces with Terveystalo we can offer much broader health services to our customers and new career opportunities for our employees and professionals. We believe the Transaction brings together two high-quality companies with a strong strategic and operational fit, and creates an attractive platform for long-term value creation. As a significant shareholder in Terveystalo following completion, Coronaria intends to be an active, growth-oriented owner, supporting Terveystalo and its management in executing its strategy and capturing the value-creation opportunities of the Transaction. We see substantial opportunities in the combined company's strong market position, agile business mix and ability to drive profitable growth over time both domestically and internationally. We will support Terveystalo as a long-term Finnish shareholder in its next phase of development." Kari Kauniskangas, Chair of the Board of Directors of Terveystalo, said: "For Terveystalo, the acquisition of Silmäasema is based on solid industrial synergies and the Transaction establishes an attractive basis for clear value creation potential. I am delighted that Terveystalo's key shareholders support this milestone transaction for Terveystalo and have committed to voting in favour of the Board of Directors' proposal to authorise the share issue at the Extraordinary General Meeting. Upon the completion of the Transaction, we will welcome Coronaria as Terveystalo's largest shareholder. I am confident that Coronaria's extensive industry expertise will bring significant value to supporting Terveystalo's long-term growth." Silmäasema in brief Silmäasema is the leading company in Finland in both optical retail and private eye care.[4] In 2025, Silmäasema generated EUR 267 million in revenue and EUR 37 million in adjusted EBIT[5]. Silmäasema has demonstrated a strong and steady, above-market revenue growth of approximately 16% CAGR per annum between 2020 and 2025 during the ownership of Coronaria. Silmäasema uses its strong optical retail presence as an effective gateway to both eye health and surgical services. Silmäasema offers a complete range of services across the entire eye health value chain and seeks to effectively utilise the referral potential and customer flows between its optical retail and ophthalmology businesses. Silmäasema serves approximately 1 million customers each year. Silmäasema is Finland's most respected eye health provider and has the highest customer satisfaction in the industry.[6] Silmäasema's strong private-pay foundation has resulted in a strong market position and the leading brand in the industry. The company operates in a stable, non-cyclical environment supported by structural growth drivers and a demonstrated long-term growth track record. Silmäasema's unique business model combines self-reinforcing characteristics with digital capabilities, providing unique positioning at the intersection of healthcare services and optical retail with considerable earnings leverage. Silmäasema has a proven service concept with a strong execution track record, underpinning a low-risk company profile. In ophthalmology, Silmäasema is a leading private eye care provider in Finland[7] and holds approximately a 15% share of the public pay eye care market. Silmäasema has 20 private eye hospitals (of which 16 co-located with optical retail and 4 standalone) and 5 locations that serve public healthcare. These handle more than 320,000 eye doctor visits and operations each year, with a 90% out-of-pocket share. Silmäasema's locations employ around 350 eye doctors and more than 200 other professionals in eyesight and eye health. In optical retail, Silmäasema operates 155 stores in Finland and 10 in Estonia. Silmäasema sells approximately 360,000 pairs of eyeglasses each year from a network of around 50 major suppliers, with 97% of sales paid out-of-pocket. Of the 155 stores in Finland, 104 are optical retail stores, 35 combine optical retail and an ophthalmology clinic, and 16 combine optical retail and an eye hospital. Silmäasema holds approximately 7.3% of shares in Synsam AB (publ). The shares are not part of the Transaction. Strategic rationale: Making Terveystalo the market leader in the growing Finnish eye care market Silmäasema is expected to provide material scale to Terveystalo's eye care franchise in a growing market, making it the number one in Finland, and improve the growth and profitability outlook, reinforce the private-pay platform, and add a complementary customer mix with revenue derived mainly from out-of-pocket payments. The Transaction is significant, strategic, and enables synergies, supported by Silmäasema's proven service model, consistent growth in revenue and profitability, and scalable business structure. Upon completion of the Transaction, Terveystalo's current eye health units will be integrated into Silmäasema, and the resulting entity will be managed within the group structure as a new independent business segment. Silmäasema's brand will be retained in the Transaction. The integration is expected to proceed smoothly, supported by Silmäasema's extensive experience in bolt-on integrations and its management team's success in expanding eye health services profitably. The Transaction is synergistic and Silmäasema's business is "plug and play" in nature, offering Terveystalo future growth prospects and strategic flexibility, making this a highly compelling acquisition with strong value-creation potential. Terveystalo anticipates significant cost and revenue synergies and expects to grow sales through optical retail expansion, attract more customers, and improve customer referrals to eye health services. The Transaction enhances Terveystalo's strategic options for both organic and inorganic growth in Finland and internationally by increasing opportunities for synergistic bolt-on acquisitions in the eye care space and internationally by enabling larger platform acquisitions. Both companies have a strong customer-centric culture and high medical quality standards, and they focus on continuous improvement and operational excellence, providing a solid foundation for successful integration. The combined company will offer an even more attractive platform for healthcare professionals, combining scale, professional development opportunities, and even more robust capabilities to improve treatment outcomes through more integrated offering and care pathways. The ophthalmology and optical retail market[8] in the Nordics was estimated at approximately EUR 4.0 billion in 2024, of which optical retail accounted for EUR 2.1 billion and ophthalmology for EUR 1.9 billion. The market is expected to grow to approximately EUR 5 billion by 2029 (optical retail EUR 2.4 billion and ophthalmology EUR 2.5 billion), representing a compound annual growth rate (CAGR) of approximately 4%. Growth is supported by structural demand growth from demographic development and ageing, prevalence of certain eye conditions, privatisation and increasing demand for high-quality services and products. Silmäasema's historical financial performance and financial standing In 2025, Silmäasema generated EUR 267 million in revenue and EUR 37 million in adjusted EBIT[9], with approximately 43% of revenues (EUR 116 million) coming from ophthalmology and 57% (EUR 154 million) from optical retail[10]. Revenues of Silmäasema have grown steadily from EUR 60 million in 2012 to EUR 267 million in 2025, reflecting a strong long-term growth trajectory of approximately 12% CAGR per annum between 2012 and 2019 and approximately 16% CAGR per annum between 2020 and 2025, during the ownership of Coronaria, representing above-market growth. This financial track record is underpinned by strong profitability and cash flow generation, driven by clear and concrete operational drivers. Silmäasema has significant opportunities for continued growth and value creation by leveraging its platform, including further growth opportunities in Finland and internationally. Silmäasema's growth has been supported by significant strategic and operational actions, including the consolidation of eye care operations and businesses into Silmäasema, the introduction of the "Retail clinic" concept with increased integration of optical retail and ophthalmology, a three-year capital expenditure programme for diagnostics, digitalization and AI, acquisitions of selected franchise and independent stores, discontinuation of certain retail and ophthalmology units, and the start of new management as well as implementation of new management systems and key performance indicators (KPIs) across both businesses. At a segment level, Silmäasema's adjusted EBIT[11] margins have improved between 2021 and 2025, with ophthalmology margins consistently increasing from 6.7% to 11.5% and optical retail margins ranging between 15.3% and 17.8% over the same period. Further information on Silmäasema's historical financial performance and financial standing is presented in the Appendix to this release. Terveystalo and Silmäasema combined The following table provides certain illustrative financial information of Terveystalo and Silmäasema based on their respective audited consolidated financial statements for 2025 as prepared in accordance with IFRS(1). EUR million, except for Terveystalo Silmäasema Combined companypercentages, ratios and number ofprofessionalsRevenue 1,279 267 1,546Adjusted EBITDA 252 56 308Adjusted EBITDA-% 20% 21% 20%Adjusted EBIT 156 37 193Adjusted EBIT-% 12% 14% 13%Net debt (incl. IFRS 16 leases) 508 - 783(3)Net debt / EBITDA(2) (incl. IFRS 16 2.1x - Around 2.7x(3)leases)Number of professionals(4) Around Around Around 16,100 14,400 1,700 (1) Does not include impact from the acquisition of Hohde Group.(2) Unadjusted EBITDA.(3) Illustrative net debt calculated by adding the Transaction’s cash consideration of EUR 275 million to Terveystalo's net debt.(4) Includes employees and private practitioners. Terveystalo estimates that the Transaction would increase Terveystalo's adjusted earnings per share (EPS) in the first full year following completion of the Transaction. Considering the purchase price and estimated synergies, Terveystalo estimates that the Transaction would create value for shareholders of Terveystalo. Financial rationale and shareholder value creation: Synergistic EPS-accretive Transaction The Transaction supports profitable growth of the combined company and is expected to be adjusted earnings per share (EPS) accretive for Terveystalo in the first full year following the completion of the Transaction. The Transaction is expected to create substantial value through estimated annual pre-tax run-rate synergies of approximately EUR 11–15 million. The full run-rate effect is expected by the end of year three following the completion of the Transaction. In the estimate, the synergies are expected to arise primarily from cost synergies (estimated to be approximately 70% of the run-rate synergies), such as network optimisation, procurement efficiencies and savings in selling, general and administrative expenses and to a lesser extent from direct revenue synergies from cross-selling of Silmäasema's vision and eye health retail customers' product and service offering to Terveystalo's customer base. Cost synergies are expected to be mainly realised within 18 months of completion of the Transaction. The Transaction is also expected to deliver further material revenue upside through broader cross- and upselling opportunities, which are not included in the synergy estimate. One-off integration costs are expected to total EUR 7–9 million. Financing of the Transaction Terveystalo's current partner banks, Danske Bank A/S, Nordea Bank Abp, OP Corporate Bank plc and Skandinaviska Enskilda Banken AB (publ), have signed a firm commitment letter, subject to customary conditions, under which they have committed to arranging debt financing to finance the Transaction. The debt financing will be provided in the form of a term loan facility of up to EUR 350 million and the amounts borrowed under the facility will be used towards the payment of the purchase price of the Transaction and acquisition costs. The facility will have a tenor of four years, subject to two one-year extension options. Shareholder support: strong commitment from Terveystalo's key shareholders Terveystalo will publish a notice today to convene the Extraordinary General Meeting on 30 June 2026. Terveystalo's shareholders Rettig Investment AB, Varma Mutual Pension Insurance Company, OP Cooperative, Hartwall Capital (HC Holding Oy Ab), Ilmarinen Mutual Pension Insurance Company and Elo Mutual Pension Insurance Company, who in aggregate hold approximately 59.3% of all outstanding shares and votes (excluding treasury shares) in Terveystalo, have irrevocably undertaken, subject to certain customary conditions, to attend Terveystalo's Extraordinary General Meeting and vote in favour of the proposal of the Terveystalo Board of Directors for the share issue authorisation in respect of all the shares in Terveystalo held by such shareholders on the record date of the Extraordinary General Meeting. Timing and conditions The completion of the Transaction is subject to approval by the Finnish Competition and Consumer Authority and Terveystalo's Extraordinary General Meeting resolving to authorise the Terveystalo Board of Directors to issue the Consideration Shares, as well as other customary conditions. Terveystalo estimates that, subject to the above conditions being satisfied or waived, the Transaction will be completed by the end of 2026 or in the first quarter of 2027. The Sellers and lock-up The Main Sellers include Coronaria, Elo Mutual Pension Insurance Company, CapMan Growth Equity Fund II Ky, Varma Mutual Pension Insurance Company, Ilmarinen Mutual Pension Insurance Company, Valtion Eläkerahasto and Amos Andersons fond as institutional sellers and certain members of Silmäasema's board of directors and management team and certain other shareholders of Silmäasema, who together hold more than 95% of the shares on a fully diluted basis in Silmäasema. Certain minority shareholders of Silmäasema, holding less than 5% of the shares in Silmäasema on a fully diluted basis (the "Minority Sellers" and together with the Main Sellers, the "Sellers"), are expected to accede to the share purchase agreement prior to the completion of the Transaction. The Minority Sellers include Silmäasema's key persons, doctors working as private practitioners and other individuals directly or through their companies. Coronaria has agreed to a customary transfer restriction (lock-up) concerning the Consideration Shares for a period of 12 months from the completion of the Transaction, except for transferring the Consideration Shares to Coronaria's affiliates subject to certain conditions. The institutional sellers have agreed to a customary transfer restriction (lock-up) concerning the Consideration Shares for a period of 6 months from the completion of the Transaction, except for transferring the Consideration Shares to such institutional seller's affiliates subject to certain conditions. The Consideration Shares issued to the other Sellers are not subject to any transfer restrictions. Advisors SEB Corporate Finance is acting as financial advisor to Terveystalo. Krogerus Attorneys Ltd is acting as legal advisor to Terveystalo. Burson Finland Oy is acting as communications advisor to Terveystalo. DNB Carnegie is acting as financial advisor to Silmäasema. Roschier, Attorneys Ltd. is acting as legal advisor to Coronaria. Astrea Attorneys at Law Ltd is acting as legal advisor to Coronaria and Silmäasema. Briefing and webcast Terveystalo and Silmäasema will arrange a press conference on 8 June 2026 at 10:30 EEST in Helsinki, Studio Eliel, Sanomatalo (address: Töölönlahdenkatu 2, Helsinki). The event will be held in Finnish and will also be streamed live at https://terveystalo.events.inderes.com/2026-06-08-webcast. A briefing for investors and analysts will be held on 8 June 2026 at 12:00 noon EEST. The event will be held in English and streamed at https://terveystalo.events.inderes.com/2026-06-08-webcast-2. Conference call: https://events.inderes.com/terveystalo/2026-06-08-webcast-2/dial-in. The conference call can be accessed by registering through the link. After registration, the phone number and a conference ID will be provided. Recordings of the events and the presentation slides will be made available at https://www.terveystalo.com/terveystalo-silmaasema-en later on the same day. Terveystalo Plc Board of Directors More information: CFO Juuso PajunenTel. +358 40 584 9722 Vice President, Investor Relations & Sustainability, Kati KaksonenTel. +358 10 345 2034kati.kaksonen@terveystalo.com Distribution:Nasdaq Helsinki OyMain mediawww.terveystalo.com Terveystalo in brief Terveystalo is the largest private healthcare service provider in Finland in terms of revenue and one of the leading occupational health providers in both Finland and Sweden. We aim to create seamless, compassionate, and effective healthcare of the future. We offer comprehensive primary care, specialised care, and well-being services for corporate clients, insurance companies, consumers and public-sector customers. Terveystalo's digital appointments are available anytime, anywhere, 24/7. The Terveystalo app has around 2.7 million registered users. We provide services through our extensive network of clinics and hospitals across Finland. In Sweden, we offer preventive occupational health services through our subsidiary, Feelgood. In 2025, Terveystalo served approximately 1.2 million individual customers, and there were around 7.2 million customer visits in Finland. Terveystalo employs around 14,400 professionals in healthcare and other fields. Terveystalo is listed on Nasdaq Helsinki and has a strong Finnish ownership base. www.terveystalo.com Silmäasema in brief Silmäasema is the leading company in Finland in both optical retail and private eye care. We see the full picture from every customer interaction and treatment to the eye health of the Finnish people. Silmäasema's more than 1,700 vision and eye health professionals serve close to one million customers each year. Silmäasema operates 155 optical retail stores and eye clinics, 20 private eye hospitals and 5 public eye care units across Finland. Silmäasema generated EUR 267 million in revenue in 2025. In Estonia, Silmäasema operates 10 optical retail locations under the Eagle Vision brand. Coronaria in brief Coronaria is one of the top 5 private healthcare providers in Finland. We offer high-quality, impactful services in rehabilitation, oral health, and healthcare across the country. Silmäasema, a provider of eye care and optical services, is part of Coronaria. In 2025, our revenue was EUR 418.6 million, and we employ over 5,000 professionals and nurses. Coronaria is part of the Finnish Cor Group. IMPORTANT INFORMATION The information contained herein shall not constitute a notice of any general meeting, an offer document, a prospectus, an offer to sell or a solicitation of an offer to purchase or subscribe for any securities in any jurisdiction. Certain statements in this release are "forward-looking statements." Forward-looking statements include statements concerning the Transaction and its effects on Terveystalo, and Terveystalo's plans, assumptions, projections, objectives, targets, goals, strategies, future events, future revenues or performance, plans or intentions relating to acquisitions, Terveystalo's competitive strengths and weaknesses, plans or goals relating to financial position, future operations and development, its business strategy and the anticipated trends in the industry and the political and legal environment in which it operates and other information that is not historical information. In some instances, they can be identified by the use of forward-looking terminology, including the terms "believes", "anticipates", "would", "intends," "may," "will" or "should" or, in each case, their negative or variations on comparable terminology. Forward-looking statements in this release are based on assumptions. Forward-looking statements involve inherent risks, uncertainties and assumptions, both general and specific, and the risk exists that the predictions, forecasts, projections, plans and other forward-looking statements will not be achieved. Given these risks, uncertainties and assumptions, you are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements contained herein speak only as at the date of this release. Save as required by law, Terveystalo does not intend to, and does not assume any obligation to, update or correct any forward-looking statement contained in this release. Appendix This appendix presents additional information on Silmäasema's financial figures. Silmäasema Group's revenue Silmäasema's revenue between 2012 and 2025. Silmäasema transitioned to consolidated financial statements prepared in accordance with IFRS standards on 1 January 2015. [][][]Year (IFRS, unless otherwise stated) Revenue (EUR million)2025 2672024 2492023 2312022 2032021 1732020 1302019 1312018 1232017 1182016 1012015 932014[(1)] 762013[(1)] 682012[(1)] 60 (1) Before the IFRS transition; prepared in accordance with Finnish accounting standards (FAS). Silmäasema Group’s per segment revenue, adjusted EBITDA, adjusted EBITDA-%, adjusted EBIT and adjusted EBIT-% for 2021–2025 Optical retail Year Revenue Adjusted Adjusted Adjusted EBIT Adjusted EBIT-%(IFRS) (EUR EBITDA (EUR EBITDA-% (EUR million) million) million)2025 154 37 24.3% 24 15.5%2024 140 34 24.3% 22 15.8%2023 131 34 25.9% 23 17.7%2022 116 27 23.6% 18 15.3%2021 104 27 25.9% 19 17.8% Ophthalmology Year Revenue Adjusted Adjusted Adjusted EBIT Adjusted EBIT-%(IFRS) (EUR EBITDA (EUR EBITDA-% (EUR million) million) million)2025 116 19 16.1% 13 11.5%2024 112 17 15.6% 12 10.6%2023 102 16 15.4% 10 9.9%2022 90 13 14.4% 8 9.0%2021 70 9 12.2% 5 6.7% [1] Silmäasema management estimate based on multiple sources, including an ophthalmology market study by a global management consultancy, industry statistics, NÄE ry, Terveyskirjasto and Statistics Finland Population Projection. [2] Adjusted EPS refers to EPS adjusted for amortisation of intangibles resulting from the Transaction and one-off transaction and integration costs. [3] Adjusted EBIT based on Silmäasema's audited consolidated financial statements for 2025. [4] Silmäasema management estimate based on multiple sources, including an ophthalmology market study by a global management consultancy, industry statistics, NÄE ry, Terveyskirjasto and Statistics Finland Population Projection. [5] Adjusting items are material items that deviate from ordinary business operations, such as advisory and other transaction costs related to acquisitions, exceptional advisory fees, and certain other non-recurring items. [6] Source: Taloustutkimus and Alma Media: Brändien arvostus 2025. [7] Silmäasema management estimate based on multiple sources, including an ophthalmology market study by a global management consultancy, industry statistics, NÄE ry, Terveyskirjasto and Statistics Finland Population Projection. [8] Estimates for 2024 and 2029 are based on Silmäasema management estimate using multiple sources, including an ophthalmology market study by a global management consultancy, industry statistics, NÄE ry, Terveyskirjasto and Statistics Finland Population Projection. [9] Adjusting items are material items that deviate from ordinary business operations, such as advisory and other transaction costs related to acquisitions, exceptional advisory fees, and certain other non-recurring items. [10] The presented revenue figures exclude internal and unallocated revenues. [11] Adjusting items are material items that deviate from ordinary business operations, such as advisory and other transaction costs related to acquisitions, exceptional advisory fees, and certain other non-recurring items.

Notice of Extraordinary General Meeting of Terveystalo Plc

Notice of Extraordinary General Meeting of Terveystalo Plc Notice is given to the shareholders of Terveystalo Plc (the "Company") to an Extraordinary General Meeting to be held on 30 June 2026 at 2:30 p.m. (EEST) without a meeting venue as a real-time virtual meeting in accordance with Article 7 of the Articles of Association of the Company and Chapter 5, Section 16, Subsection 3 of the Finnish Companies Act. Instructions for participation are presented in this notice under section C "Instructions for the participants in the Extraordinary General Meeting". A. Matters on the agenda of the Extraordinary General Meeting At the Extraordinary General Meeting, the following matters will be considered: 1. Opening of the meeting 2. Calling the meeting to order 3. Election of persons to scrutinise the minutes and to supervise the counting of votes 4. Recording the legality of the meeting 5. Recording the attendance at the meeting and adoption of the list of votes 6. Authorising the Board of Directors to resolve on the issuance of shares in connection with the Company's proposed acquisition of Silmäasema Oy 1. Introduction The Company announced on 8 June 2026 that the Company and its subsidiary, Terveystalo Healthcare Oy, have signed a share purchase agreement (the "Share Purchase Agreement") to acquire Silmäasema Oy (the "Transaction") from its current shareholders (the "Sellers"). The Transaction is expected to create substantial value through estimated annual pre-tax run-rate synergies of approximately EUR 11–15 million. Reference is made to the public announcement on the Transaction on 8 June 2026 for further information about the rationale, details, and terms of the Transaction. Pursuant to the Share Purchase Agreement, the consideration to be paid by the Company to the Sellers upon completion of the Transaction would consist of a combination of an initial cash payment of EUR 275 million (the "Cash Consideration") and 36,500,000 new shares in the Company to be issued to the Sellers (the "Share Consideration") as further described in the Transaction announcement of 8 June 2026. The Cash Consideration is subject to certain adjustments, but the number of shares issued as Share Consideration is not subject to any adjustments. The completion of the Transaction is currently expected to take place by the end of 2026 or in the first quarter of 2027. The completion of the Transaction is subject to the satisfaction or waiver of all conditions to completion under the Share Purchase Agreement, including the approval of this resolution on the proposed share issue authorisation and approval by the Finnish Competition and Consumer Authority. The Board of Directors of the Company has unanimously concluded that the Transaction is in the best interests of the Company and all of its shareholders and recommends that the Extraordinary General Meeting of the Company approve all proposals by the Board of Directors included in this notice. The Company's shareholders Rettig Investment AB, Varma Mutual Pension Insurance Company, OP Cooperative, Hartwall Capital (HC Holding Oy Ab), Ilmarinen Mutual Pension Insurance Company and Elo Mutual Pension Insurance Company, who in aggregate hold approximately 59.3 per cent of all outstanding shares and votes (excluding treasury shares) in the Company, have irrevocably undertaken, subject to certain customary conditions, to attend the Extraordinary General Meeting and vote in favour of the proposal of the Board of Directors of the Company for the share issue authorisation in respect of all the shares in the Company held by such shareholders on the record date of the Extraordinary General Meeting. The resolution regarding the proposed share issue authorisation requires support by shareholders holding at least a qualified majority (2/3) of both the votes cast and of all shares represented at the meeting. 1. 2. Authorising the Board of Directors to resolve upon the directed issuance of shares to the Sellers In order to enable the issuance of the Share Consideration to the Sellers, the Board of Directors of the Company proposes that the Extraordinary General Meeting authorise the Board of Directors of the Company to resolve, on one or several occasions, upon the issuance of up to 36,500,000 new shares in the Company in deviation from the shareholders' pre-emptive rights (directed share issue). Assuming issuance of the maximum number of new shares under the authorisation, the Sellers would, based on the number of shares in the Company at the date of this notice, receive new shares representing up to approximately 22.4 per cent of all issued shares, excluding treasury shares, in the Company following completion of the Transaction. The authorisation may only be used for the issuance of the Share Consideration to the Sellers in connection with the completion of the Transaction in accordance with the Share Purchase Agreement. The Board of Directors shall be authorised to decide on all other terms relating to the issuance of new shares in the Company pursuant to this authorisation, including the issuance of shares against consideration in kind or set-off. The authorisation is proposed to remain valid until 30 September 2027 and, if granted, this authorisation will not revoke the authorisation to resolve upon the issuance of shares and the issuance of special rights entitling to shares granted to the Board of Directors by the Annual General Meeting held on 24 March 2026. 7. Closing of the meeting B. Documents of the Extraordinary General Meeting This notice, including the abovementioned proposals for resolutions on the matters on the agenda of the Extraordinary General Meeting, along with other required documents referred to in Chapter 5, Section 21 of the Finnish Companies Act, is available and printable on the Company's website at https://www.terveystalo.com/Extraordinary-General-Meeting-2026 as of 8 June 2026, at the latest. The proposals for resolutions and other abovementioned documents will also be made available at the Extraordinary General Meeting. The meeting minutes of the Extraordinary General Meeting will be available on the Company's website no later than on 14 July 2026. C. Instructions for the participants in the Extraordinary General Meeting 1. Shareholder registered in the shareholders' register Each shareholder, who on the record date of the Extraordinary General Meeting, 17 June 2026, is entered in the Company's shareholders' register maintained by Euroclear Finland Oy, has the right to participate in the Extraordinary General Meeting. A shareholder whose shares are registered on his/her personal Finnish book-entry account or equity savings account is registered in the Company's shareholders' register. A shareholder may also participate in the Extraordinary General Meeting by way of proxy representation. The use of proxy representatives is described below in section C.4. 2. Registration for the meeting Registration for the meeting will begin on 9 June 2026 at 10:00 a.m. (EEST) and a shareholder who is registered in the Company's shareholders' register and who wishes to participate in the Extraordinary General Meeting must register for the meeting no later than by 23 June 2026 at 4:00 p.m. (EEST), by which time the registration must be received by the Company or Innovatics Oy. Shareholders with a Finnish book-entry account may register from 10:00 a.m. (EEST) on 9 June 2026 until 4:00 p.m. (EEST) on 23 June 2026 by the following manners: a. through the Company's website at https://www.terveystalo.com/Extraordinary-General-Meeting-2026 Electronic registration through the website requires strong electronic authentication of the shareholder or the shareholder's proxy representative or legal representative with a Finnish, Swedish or Danish bank ID or mobile certificate. b. by email or regular mail A shareholder may send a notice of attendance to Innovatics Oy by email addressed to egm@innovatics.fi or by regular mail addressed to Innovatics Oy, General Meeting/Terveystalo Oyj, Ratamestarinkatu 13 A, FI-00520 Helsinki, Finland. A shareholder intending to register by mail or email shall submit the registration form available on the Company's website at https://www.terveystalo.com/Extraordinary-General-Meeting-2026 or equivalent information to Innovatics Oy. In connection with the registration, a shareholder is required to provide the requested information, such as his/her name, date of birth or business ID, address, as well as telephone number and/or email address as well as the name, date of birth as well as telephone number and/or email address of a possible authorised proxy representative or legal representative and the name of a possible assistant. The personal data given to the Company or Innovatics Oy will only be used in connection with the Extraordinary General Meeting and with the processing of related registrations. A shareholder, their possible authorised proxy representative or legal representative must be able to prove their identity and/or right of representation at the Extraordinary General Meeting. Further information on registration is available by telephone during the registration period for the Extraordinary General Meeting by calling Innovatics Oy at +358 10 2818 909 on weekdays from 9:00 a.m. to 12:00 noon and from 1:00 p.m. to 4:00 p.m. (EEST). 3. Holders of nominee-registered shares A holder of nominee-registered shares has the right to participate in the Extraordinary General Meeting by virtue of such shares, based on which he/she on the record date of the Extraordinary General Meeting, i.e., on 17 June 2026, would be entitled to be registered in the shareholders' register of the Company maintained by Euroclear Finland Oy. The right to participate in the Extraordinary General Meeting requires, in addition, that the shareholder on the basis of such shares has been temporarily registered into the shareholders' register maintained by Euroclear Finland Oy at the latest by 25 June 2026 by 10:00 a.m. (EEST). As regards nominee-registered shares, this constitutes registration for the Extraordinary General Meeting. A holder of nominee-registered shares is advised to request without delay necessary instructions regarding the temporary registration in the shareholders' register of the Company, the issuing of proxy documents and voting instructions as well as registration for the Extraordinary General Meeting from his/her custodian bank. The account management organisation of the custodian bank shall temporarily register a holder of nominee-registered shares, who wants to participate in the Extraordinary General Meeting, into the shareholders' register of the Company at the latest by the time stated above. A holder of nominee-registered shares who has registered for the Extraordinary General Meeting may also participate in the meeting in real time using telecommunication connection and technical means. In addition to the temporary registration in the Company's shareholders' register, the real-time participation in the meeting requires the submission of the shareholder's email address and telephone number and, if necessary, a proxy document and other documents necessary to prove the right of representation by regular mail to Innovatics Oy, General Meeting/Terveystalo Oyj, Ratamestarinkatu 13 A, FI-00520 Helsinki, Finland or by email to egm@innovatics.fi before the end of the registration period for the holders of nominee-registered shares, so that the shareholders can be sent a participation link and password to participate in the meeting. 4. Proxy representatives and powers of attorney A shareholder may also participate and use their rights in the Extraordinary General Meeting through a proxy representative. A proxy representative shall provide a dated proxy document or otherwise in a reliable manner demonstrate his/her right to represent the shareholder. Proxy representatives registering electronically for the Extraordinary General Meeting must identify themselves personally through strong electronic authentication, after which they can register on behalf of the shareholder they represent. Should a shareholder participate in the Extraordinary General Meeting by means of several proxy representatives representing the shareholder with shares in different book-entry accounts, the shares by which each proxy representative represents the shareholder shall be identified in connection with the registration. Natural persons may appoint a proxy representative in connection with the electronic registration to the Extraordinary General Meeting at the Company's website. Otherwise, a proxy document must be used. A template proxy document is available on the Company's website at https://www.terveystalo.com/Extraordinary-General-Meeting-2026. Possible proxy authorisation documents are requested to be submitted preferably as attachments in connection with electronic registration or alternatively by email to egm@innovatics.fi or as original copies by mail to Innovatics Oy, General Meeting/Terveystalo Oyj, Ratamestarinkatu 13 A, FI-00520 Helsinki, Finland, so that the proxy authorisation documents are received before the end of the registration period. In addition to delivering a proxy authorisation document, a shareholder or their proxy representative must register for the Extraordinary General Meeting in the manner described in section C.2. Delivering a proxy authorisation document in the manner described above will constitute due registration for the Extraordinary General Meeting if it contains the information required for the registration described in section C.2. Shareholders can also use suomi.fi electronic authorisation service instead of a traditional proxy document. In this case, the shareholder authorises the nominated proxy representative in the suomi.fi service by using the proxy form "Representation at the General Meeting". When registering, proxy representatives must authenticate themselves by strong electronic authentication. Strong electronic authentication can be conducted with online banking codes or a mobile certificate. 5. Participation instructions A shareholder who has the right to participate in the Extraordinary General Meeting can participate in the meeting and use their rights in full and in real-time during the meeting via remote connection. The remote connection to the Extraordinary General Meeting will be provided through Inderes Plc's virtual general meeting service on the Videosync platform, which includes a video and audio connection to the Extraordinary General Meeting. Participating in the virtual Extraordinary General Meeting does not require paid software or downloads. In addition to an internet connection, participation requires a computer, smartphone or tablet with speakers or headphones for sound reproduction and a microphone if you wish to speak. One of the following browsers is recommended for participation: Chrome, Firefox, Edge, Safari, or Opera. It is advisable to log in to the meeting system well in advance of the meeting. The participation link and password for remote participation will be sent by email and/or text message to the email address and/or mobile phone number provided during registration to all those registered for the Extraordinary General Meeting no later than the day before the meeting. For more information on the general meeting service, additional instructions for proxies representing more than one shareholder, contact details of the service provider and instructions in case of possible disruptions can be found here: https://vagm.fi/support. The link to test the compatibility of your computer, smartphone or tablet and the network connection can be found at https://b2b.inderes.com/knowledge-base/compatibility-testing. It is recommended that you familiarise yourself with the more detailed participation instructions before the start of the Extraordinary General Meeting. 6. Other instructions/information The language of the Extraordinary General Meeting is Finnish, and the meeting will be simultaneously translated into English. A shareholder present at the Extraordinary General Meeting has the right to ask questions pursuant to Chapter 5, Section 25 of the Finnish Companies Act with respect to the matters to be considered at the Extraordinary General Meeting. Information on the Extraordinary General Meeting required by the Finnish Companies Act and the Securities Markets Act is available on the Company's website at https://www.terveystalo.com/Extraordinary-General-Meeting-2026. On the date of this notice, the total number of shares in the Company and votes represented by such shares is 127,036,531. On the date of this notice the Company and its subsidiaries hold a total of 227,067 of the Company's own shares that are not entitled to vote at the Extraordinary General Meeting. Changes in shareholding after the record date of the Extraordinary General Meeting do not affect the right to participate in the Extraordinary General Meeting or the number of voting rights held by a shareholder in the Extraordinary General Meeting. In Helsinki, 8 June 2026 TERVEYSTALO PLCThe Board of Directors

Saga Pure ASA: Launch of conditional offer to buy back own shares

The final purchase price per share will be set within the Price Range based on the sales offers received at a level representing a satisfactory price and offer volume (to be determined by the Company at its sole discretion). The final purchase price will be identical for all selling shareholders. The bookbuilding period commences today, Monday 8 June 2026, at 09:00 (CEST) and is expected to close on Friday, 12 June 2026 at 15:00 (CEST) (the “Bookbuilding Period”). Notification of allocation and pricing is expected to be made on or about 15 June 2026, and settlement is expected to take place on or about 17 June 2026 on a normal delivery versus payment basis (DVP). The Company reserves the right to accept sales offers received after the end of the Bookbuilding Period, as well as to close or extend the Bookbuilding Period at any time and for any reason in its sole discretion without further notice. In the event that the total volume offered by selling shareholders in the Offer exceeds 67,487,842 shares at or below the final purchase price, the allocation will, to the extent possible, be made on a pro rata basis relative to the volume offered by each selling shareholder, with the objective of treating all shareholders equally based on their sales offers at or below the final purchase price. The selling shareholders will be bound to sell up to the number of shares offered on the terms submitted if and at such time the offer is accepted by the Company, irrespective of whether the Company elects to purchase a lower number of shares from such selling shareholder than offered for sale by the respective shareholder. The Company reserves the right, at its sole discretion, to amend, terminate or withdraw the Offer at any time prior to its completion. Completion of the Offer is subject to approval by the Company’s board of directors. The Offer will be based on the authorization granted to the board of directors by the Company’s annual general meeting held on 26 May 2026. The Company has not prepared, and will not prepare, any offer document in connection with the Offer. Reference is also made to the stock exchange notice 28 May 2026 regarding the sale of Eilert Sundtsgate 39 AS. The board of directors of the Company is not aware of any other event having occurred following the period covered by the Company’s first quarter 2026 financial results that are expected to have a material impact on the Company’s profit and loss or financial position. The Company has a total of 674,878,423 shares issued. Prior to the Offer, the Company does not hold any own shares. Arctic Securities AS (the “Manager”) acts as sole bookrunner in connection with the Offer. Existing shareholders in the Company wishing to sell shares in the Offer can contact the Manager at +47 971 83 609 in order to place a sales offer before the end of the Bookbuilding Period. For further information, please contact: Henrik A. Christensen, Chairperson +47 909 67 683 This information is considered to be inside information pursuant to the EU Market Abuse Regulation. This stock exchange notice was published by Eldar Paulsrud, on the date and time as set out in the release. This information is subject to the disclosure requirements under the EU Market Abuse Regulation art. 17 and Section 5-12 of the Norwegian Securities Trading Act. Important note The Offer contemplated herein and the distribution of this announcement and other information in connection with the Offer may be restricted by law in certain jurisdictions, and the Offer is not made in any jurisdiction in which this would be unlawful, require registration or other measures. The Company does not assume any responsibility in the event there is a violation by any person of such restrictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions. This announcement is not an offer document and, as such, does not constitute an offer or the solicitation of an offer to subscribe to, acquire, or sell, shares in the Company. This announcement contains forward-looking statements. All statements, other than statements of historical fact, included herein, including without limitation, statements regarding the Offer, are forward-looking statements that involve risk and uncertainties. There can be no assurances that such statements will prove to be accurate, and actual results could differ materially from those anticipated in such statements.

Hexagon Composites ASA: Commencement of subscription period for Subsequent Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. 8 June 2026: Reference is made to the stock exchange announcement made by Hexagon Composites ASA (the "Company") on 5 June 2026 regarding the approval of a prospectus (the "Prospectus") for the subsequent offering (the "Subsequent Offering") of up to 15,625,000 new shares in the Company (the "Offer Shares") at a subscription price of NOK 8.00 per share (being the same subscription price as in the private placement announced by the Company on 7 May 2026 (the "Private Placement")). The subscription period for the Subsequent Offering commences today, 8 June 2026 at 09:00 (CEST) and, subject to any extension, expires on 19 June 2026 at 16:30 (CEST) (the "Subscription Period"). The Subsequent Offering will be directed towards shareholders in the Company as of 7 May 2026 (as registered in the VPS on 11 May 2026), who (i) were not included in the pre-sounding phase of the Private Placement; (ii) were not allocated shares in the Private Placement and (iii) are not resident in a jurisdiction where such offering would be unlawful, or for jurisdictions other than Norway, would require any prospectus filing, registration or similar action ("Eligible Shareholders"). Each Eligible Shareholder will receive 0.12 non-tradeable subscription right (the "Subscription Rights") for each share held by such Eligible Shareholder in the Company as of the Record Date, rounded down to the nearest whole right. Each Subscription Right will, subject to applicable securities laws, give the preferential right to subscribe for, and be allocated, one Offer Share in the Subsequent Offering. Over-subscription will be permitted, but there can be no assurance that Offer Shares will be allocated for such subscriptions. Subscription without Subscription Rights will not be permitted. The Subscription Rights must be used to subscribe for Offer Shares before the end of the Subscription Period. Subscription Rights which are not exercised before the end of the Subscription Period will have no value and will lapse without compensation to the holder. Subscriptions for Offer Shares must be made by submitting a correctly completed copy of the subscription form attached to the Prospectus to the Manager during the Subscription Period. Subscribers who are residents of Norway with a Norwegian personal identification number may also subscribe for Offer Shares through the VPS online subscription system (or by following the link on www.dnb.no/emisjoner, which will redirect the subscriber to the VPS online subscription system). Complete information on the terms and conditions of the Subsequent Offering, including subscription procedures, is set out in the Prospectus. Subscriptions may only be made on the basis of the Prospectus.   The Prospectus, including the subscription form for the Subsequent Offering, is, subject to regulatory restrictions in certain jurisdictions, available at www.dnb.no/emisjoner. AdvisorsDNB Carnegie, a part of DNB Bank ASA, is acting as manager for the Subsequent Offering (the "Manager"). Advokatfirmaet Schjødt AS is acting as legal counsel to the Company.   For more information:Berit-Cathrin Høyvik, Senior Director, Communications, Hexagon CompositesTelephone: +47 988 92 161 | berit-cathrin.hoyvik@hexagongroup.com Eirik Løhre, CFO, Hexagon CompositesTelephone: +1 704 777 5171 (US Eastern time zone) | eirik.lohre@hexagongroup.com About Hexagon Composites ASAHexagon delivers safe and innovative solutions for a cleaner energy future. Our solutions enable storage, transportation, and conversion to clean energy in a wide range of mobility and industrial applications. Learn more at www.hexagongroup.com and follow @HexagonASA on LinkedIn. IMPORTANT INFORMATIONThis announcement does not constitute or form a part of any offer of securities for sale or a solicitation of an offer to purchase securities of the Company in the United States or any other jurisdiction. The securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"). The securities of the Company have not been, and will not be, registered under the U.S. Securities Act, and may not be offered or sold in the United States absent registration under the US Securities Act or an available exemption from, or transaction not subject to, the registration requirements of the US Securities Act. There will be no public offering of securities in the United States. Any sale in the United States of the securities mentioned in this communication will be made solely to "qualified institutional buyers" as defined in Rule 144A under the U.S. Securities Act. No public offering of the securities will be made in the United States. The Company has not authorized any offer to the public of securities in any Member State of the European Economic Area nor elsewhere. With respect to any Member State of the European Economic Area (each an "EEA Member State"), no action has been undertaken or will be undertaken to make an offer to the public of securities requiring publication of a prospectus in any EEA Member State. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the EU Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression "EU Prospectus Regulation" means Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (together with any applicable implementing measures in any Member State). In the United Kingdom, these materials are only being communicated to (a) persons who have professional experience, knowledge and expertise in matters relating to investments and qualifying as "investment professionals" for the purposes of article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (all such persons being referred to as "relevant persons") and (b) only in circumstances falling within the circumstances set out in Part 1 of Schedule 1 to The Public Offers and Admissions to Trading Regulations 2024. These materials are directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "anticipate", "believe", "continue", "estimate", "expect", "intend", "may", "should", "will" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date and are subject to change without notice. This announcement is made by and is the responsibility of, the Company. The Manager is acting exclusively for the Company and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, or for advice in relation to the contents of this announcement or any of the matters referred to herein. Neither the Manager nor any of its affiliates make any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein. This announcement is not a prospectus. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. Neither the Manager nor any of its affiliates accepts any liability arising from the use of this announcement. Each of the Company, the Manager and their respective affiliates expressly disclaims any obligation or undertaking to update, review or revise any statement contained in this announcement whether as a result of new information, future developments or otherwise. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

Sinch appoints Jonas Dahlberg as acting CEO to lead next phase of execution and growth

As previously announced on May 7, Laurinda Pang has decided to step down as CEO of Sinch. Following continued discussions between the Board, Laurinda and Jonas, the Board determined that transitioning to an acting CEO is the right step to support Sinch’s next phase of execution and growth. “Over the past several years, Sinch has transformed into a more profitable business, with an integrated customer offering, poised for growth. The Board believes this leadership transition will build on and accelerate that momentum and we are fully aligned with both Laurinda and Jonas on the path forward,” said Erik Fröberg, Chairman of the Board. “Jonas has been deeply involved in the company’s transformation and strategy execution for the past year. He is an accomplished CEO with experience from leading large international organizations in tech enabled services. The Board has great confidence in his ability to lead Sinch during the next phase of development,” Erik Fröberg continued. Jonas Dahlberg joined Sinch as Chief Financial Officer (CFO) Apil 1, 2025. Prior to joining Sinch, he served as CEO and before that as CFO of Transcom, a global customer experience outsourcer. He also served in various executive positions at Sweco, the leading European Engineering Consultancy. Prior to Sweco, he was a consultant at McKinsey & Company. Jonas holds a M.Sc. degree in Applied Physics and B.Sc. in Business Administration. “During the last few years, Sinch has developed into a leading global cloud communications platform under the leadership of Laurinda. We are now well positioned to accelerate growth as the customer communication infrastructure for the AI economy. I’m excited to continue working with our talented teams to execute on our priorities: deliver value to our customers, drive innovation and create value for our shareholders,” said Jonas Dahlberg. “I’m incredibly proud of what we have accomplished as a team. We transformed from acquired stand-alone companies, into a more integrated company, strengthened profitability and reignited growth. Jonas is ideally positioned to lead Sinch into the future. I fully support this transition and the Board’s decision to accelerate the succession timeline as the company enters its next chapter,” said Laurinda Pang As previously communicated, Laurinda Pang will continue to support the company until a permanent successor is appointed, however no later than 31 December 2026. For further information, please contactFredrik HallstanDirector, Corporate CommunicationsMobile: +46761 15 38 30E-mail: fredrik.hallstan@sinch.com Mia NordlanderSVP Investor Relations & SustainabilityMobile: +46 73 511 53 95E-mail: mia.nordlander@sinch.com Note: This information is such that Sinch AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CEST on June 8, 2026 through the agency of the contact person set out above.

Stora Enso’s Shareholders’ Nomination Board composition

The Stora Enso Shareholders’ Nomination Board has been established to exist until otherwise decided. The Shareholders’ Nomination Board consists of the Chair of Stora Enso’s Board of Directors, the Vice Chair of the Board of Directors, and two members appointed by the two largest shareholders (one each) as of 31 May each year.Stora Enso’s two largest shareholders on 31 May 2026 were Solidium Oy and FAM AB.In accordance with the above, the members of the Shareholders’ Nomination Board are:Marcus Wallenberg (Chair of FAM AB’s Board of Directors)Matts Rosenberg (Chief Executive Officer of Solidium)Håkan Buskhe (Chair of Stora Enso’s Board of Directors)Jouko Karvinen (Vice Chair of Stora Enso’s Board of Directors)The Shareholders’ Nomination Board has elected Marcus Wallenberg as its Chair.The Shareholders’ Nomination Board annually prepares proposals for Stora Enso Oyj’s Annual General Meeting concerning the election and remuneration of members of the Stora Enso Board of Directors and Board committees, as well as the appointments of the Chair and the Vice Chair of the Board of DirectorsFor further information, please contact:Jutta MikkolaSVP Investor Relationstel. +358 50 544 6061Stora Enso is a global leader in renewable materials with a strong focus on packaging. Our purpose is to replace non-renewable materials with renewable solutions. Together with our customers, we design and deliver competitive, high-quality packaging materials and solutions, made from fresh and recycled fibers, accelerating the transition to a circular bioeconomy. Stora Enso has approximately 19,000 employees and our sales in 2025 were EUR 9.3 billion. Stora Enso's shares are listed on Nasdaq Helsinki Oy (STEAV, STERV) and Nasdaq Stockholm AB (STE A, STE R). In addition, the shares are traded on OTC Markets (OTCQX) in the USA as ADRs and ordinary shares (SEOAY, SEOFF, SEOJF). storaenso.com/investors STORA ENSO OYJ

Aspia Group acquires Quickinsight to expand advisory offering for business-critical decisions.

The acquisition adds specialist expertise in business-critical situations such as acquisitions, divestments and investments, and reinforces Aspia Group’s ambition to take a leading position in the evolving professional services market. Quickinsight supports investors, entrepreneurs and businesses with financial due diligence, data books, acquisition analysis and vendor assistance. Its services are tailored for SME transactions, where financial information needs to be structured, analysed and translated into clear business insight. By combining Quickinsight’s specialist expertise and tech-enabled ways of working with Aspia Group’s broader advisory platform, the acquisition strengthens Aspia’s ability to turn complexity into clarity for clients facing important business decisions. “Quickinsight brings specialist expertise that strengthens our advisory offering and our ability to support clients in complex business decisions. Together, we can help more clients understand risks, value drivers and opportunities with greater clarity, and move forward with confidence,” says Ola Gunnarsson, CEO of Aspia Group. Quickinsight will operate under the Aspia brand. About Quickinsight Quickinsight is a Swedish specialist firm within financial due diligence and advisory services for SME transactions. The company supports investors, entrepreneurs and businesses with financial due diligence, data books, acquisition analysis and vendor assistance related to acquisitions, divestments and investments. Quickinsight is characterised by senior project management, quality, speed, business acumen and tech-enabled ways of working. About Aspia Group Aspia Group is the premium business partner for tech-enabled business services across Northern Europe. We provide the financial clarity and trust required for over 30,000 customers to lead with confidence. By combining human expertise with smart technology, we help clients manage complexity, make better decisions and focus on their ambition. With 3,000 employees across more than 100 offices and an annual turnover of SEK 3.5 billion, the Group includes the brands Aspia, Accountor and Skeppsbron Skatt. Aspia. Dare to Grow. For further information, please contact:  Ola Gunnarsson CEO, Aspia Group ola.gunnarsson@aspia.se 

Moberg Pharma and Karo Healthcare expand collaboration for MOB-015/Terclara to China

The agreement represents a further expansion of the strategic partnership initiated in November 2025, when Karo Healthcare obtained the rights to market, distribute and sell MOB-015 in 19 European markets with a combined population of approximately 500 million people. In April 2026, the collaboration was expanded to include Australia, New Zealand, South Korea and Taiwan, adding approximately 100 million potential consumers. China represents an attractive market opportunity for MOB-015. Karo Healthcare has an established presence in China's  cross-border channel through its athlete's foot drug under the Lamisil[®] brand and has a proven track record of successful commercialization through this sales model. The athlete's foot drug will, also in this market, complement our drug for nail fungus, as it is common for the same patient to suffer from both conditions which may be caused by the same fungus. The license agreement applies to cross-border sales, providing Moberg Pharma full strategic flexibility to expand into the significantly larger general trade market in the future. Focusing on the smaller but rapidly growing cross-border sales channel enables a fast market entry, and a launch in China is expected to be carried out in parallel with launches in the first European countries under Karo's brand. This launch represents a first step in Moberg Pharma's strategy for establishing a long-term presence in China, where entry into the general trade market would require the generation of additional data. Karo Healthcare is one of several potential partners also for general trade, and possesses the commercial infrastructure, distribution capabilities and local presence required to support it. "This is further proof of the strong partnership we have built with Karo Healthcare. In less than a year, our collaboration has expanded from Europe to several markets in APAC, and now also China. Our ambition is to establish MOB-015 as a leading global treatment for nail fungus, and taking another step into the Chinese market is an important part of that journey," says Anna Ljung, CEO of Moberg Pharma. "China represents an exciting opportunity for MOB-015 and a natural next step in our collaboration with Moberg Pharma. We already have an established presence in the antifungal category through Lamisil[®] and look forward to introducing an innovative treatment for nail fungus to Chinese consumers," says Michael Kaltenborn, Chief Strategy and Corporate Development Officer of Karo. About MOB-015/Terclara[®] and nail fungusNail fungus is a common infection affecting approximately 10% of the general population, with the majority of patients currently untreated. The global market potential is significant, with more than hundred million patients worldwide and a clear demand for improved products. Moberg Pharma estimates the annual worldwide peak sales potential for MOB-015/Terclara[®] to be in the range of USD 250–500 million. MOB-015/Terclara[®], developed by Moberg Pharma, represents the next generation of terbinafine treatment—a novel topical formulation. Oral treatments for nail fungus are associated with risks such as drug interactions and liver damage, which are avoided with topical treatment. Previous attempts at topical terbinafine treatment have failed due to the difficulty of delivering sufficient amounts of active substance through the nail. MOB-015 is the first topical treatment to achieve mycological cure rates comparable to oral therapy; mycological cure (fungal eradication) was achieved in 76% of patients in pivotal studies, and the product has received market approval in 13 EU countries. About this informationMoberg Pharma is releasing this information in accordance with the EU’s Market Abuse Regulation (MAR). The information was released for public distribution through the contact named below at 08.00 a.m. CET on June 8, 2026. For additional information, please contact:Anna Ljung, CEO, Phone: +46 8 522 307 01, e-mail: anna.ljung@mobergpharma.se About Moberg Pharma, www.mobergpharma.comMoberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's drug MOB-015 is a novel topical treatment for onychomycosis (nail fungus) with market approval in 13 EU countries. MOB-015 is sold in Sweden and Norway under the brand name Terclara[®] and is available at all pharmacy chains. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB).

Acquisitions of own shares in Evolution AB (publ)

The repurchase program, which Evolution announced on 18 May 2026, is being implemented in accordance with the EU Market Abuse Regulation No 596/2014 (“MAR”) and the Commission Delegated Regulation No 2016/1052 (“Safe Harbour Regulation”). During the period 01 June 2026 – 05 June 2026, shares in Evolution have been acquired as set out below. Date Aggregated daily Weighted average Transaction volume (number of price per day value per day shares) (SEK) (SEK)2026 158,815 700.0652 111,180,854.74-06-012026 163,612 705.0961 115,362,183.11-06-022026 168,398 701.8671 118,193,015.91-06-032026 172,461 706.0289 121,762,450.12-06-042026 174,885 709.4919 124,079,490.93-06-05 All acquisitions were carried out on Nasdaq Stockholm on behalf of Evolution by Citibank which makes its trading decisions concerning the timing of the purchases of shares independently of Evolution. Following the above acquisitions, Evolution’s holding of own shares amounted to 2,066,158 as of 05 June 2026. The total number of shares in Evolution is 199,226,613. Since 19 May 2026 up to and including 05 June 2026, a total of 2,066,158 shares have been acquired within the scope of the program. A maximum of 19,922,661 shares in total may be acquired. For further information, please contact:Joakim Andersson, CFO, ir@evolution.com. The information was submitted for publication, under the agency of the contact person set out above, on 8 June 2026, at 08:00 CEST.

Share buybacks in Ericsson during the period June 1 - June 5, 2026

+------+-----------------+-------------------+-----------------+|Date |Aggregated daily |Weighted average |Total daily || |volume (number of|share price per day|transaction value|| |shares) |(SEK) |(SEK) |+------+-----------------+-------------------+-----------------+|01/06/|500,000 |122.4013 |61,200,650.00 ||2026 | | | |+------+-----------------+-------------------+-----------------+|02/06/|500,000 |125.9387 |62,969,350.00 ||2026 | | | |+------+-----------------+-------------------+-----------------+|03/06/|500,000 |127.2936 |63,646,800.00 ||2026 | | | |+------+-----------------+-------------------+-----------------+|04/06/|125,000 |123.2703 |15,408,787.50 ||2026 | | | |+------+-----------------+-------------------+-----------------+|05/06/|400,000 |122.5939 |49,037,560.00 ||2026 | | | |+------+-----------------+-------------------+-----------------+|Total |2,025,000 |124.5744 |252,263,147.50 |+------+-----------------+-------------------+-----------------+ The share repurchases are a part of the share buyback program of up to SEK 15,000,000,000 which Ericsson announced on April 16, 2026, and which runs between April 23, 2026, and March 31, 2027, at the latest. The Board of Directors intends to propose to the 2027 Annual General Meeting that the repurchased shares, other than those used to fulfil Ericsson’s obligations under its share-related incentive programs, are cancelled. The share buyback program is executed in accordance with the Regulation (EU) No 596/2014 of the European Parliament and of the Council on market abuse (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 supplementing MAR (the Safe Harbour Regulation). All acquisitions have been carried out on Nasdaq Stockholm by Goldman Sachs Bank Europe SE on behalf of Ericsson. A full breakdown of the transactions is attached to this announcement. Following the repurchases above, Ericsson’s holding of treasury stock amounts to 50,376,778 Class B shares. There are in total 3,371,351,735 shares in Ericsson, 261,755,983 shares of Class A and 3,109,595,752 shares of Class B. NOTES TO EDITORS: FOLLOW US: Subscribe to Ericsson press releases Subscribe to Ericsson blog posts https://x.com/ericssonhttps://www.facebook.com/ericssonhttps://www.linkedin.com/company/ericsson MORE INFORMATION AT:Ericsson Newsroom media.relations@ericsson.com  (+46 10 719 69 92)investor.relations@ericsson.com  (+46 10 719 00 00) FOR FURTHER INFORMATION, PLEASE CONTACT: InvestorsDaniel Morris, Vice President, Head of Investor RelationsPhone: +44 7386 657217E-mail: investor.relations@ericsson.com Lena Häggblom, Director, Investor RelationsPhone: +46 72 593 27 78E-mail: lena.haggblom@ericsson.com Alan Ganson, Director, Investor RelationsPhone: +46 70 267 27 30E-mail: alan.ganson@ericsson.com MediaRalf Bagner, Head of Media RelationsPhone: +46761284789E-mail: ralf.bagner@ericsson.com ABOUT ERICSSON:Ericsson’s high-performing, programmable networks provide connectivity for billions of people every day. For 150 years, we’ve been pioneers in creating technology for communication. We offer mobile communication and connectivity solutions for service providers and enterprises. Together with our customers and partners, we make the digital world of tomorrow a reality. www.ericsson.com

Mölnlycke Health Care strengthens global manufacturing footprint to power future growth in wound care

Building on recent expansion announcements in Brunswick, USA, and Changshu, China, the coordinated investments reflect Mölnlycke’s continued focus on meeting growing demand for advanced wound care solutions and helping to free patients from the burden of wounds, while optimising its manufacturing footprint. Scaling capacity and efficiency in Finland At its Mikkeli site, Mölnlycke is investing in expanded sterilisation and production capabilities. The programme doubles sterilisation capacity and introduces an advanced ‘soft cycle’ process, ensuring gentler product treatment and more sustainable manufacturing processes. This expansion also increases manufacturing capacity by around 100 million units annually, an increase of nearly 50%, supported by a new production line with automated inline packaging and cartoning to improve efficiency and handling. Strengthening resilience in the UK In parallel, Mölnlycke has inaugurated new state-of-the-art clean room and packaging facilities in Oldham, expanding UK manufacturing capacity. Moreover, by bringing sterilisation closer to production, Mölnlycke expects to shorten lead times by around one week while reducing transportation distances and emissions, strengthening supply chain resilience and environmental performance. A connected, future-ready manufacturing network The investments in Mikkeli and Oldham are designed to operate as an integrated system, connecting and optimising how products are manufactured, sterilised and delivered, while strengthening collaboration and knowledge-sharing across sites. “Together, these investments strengthen our global wound care manufacturing network and connect capabilities across sites, enabling us to scale efficiently, improve resilience and deliver sustainable growth,” says David Butler, Global Vice President, Operations Wound Care at Mölnlycke. -Ends- For more information, please contact: Jamie SmithMedia Relations ManagerTel. +46 (0)722-553573E-mail jamie.smith@molnlycke.com About Mölnlycke Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. www.molnlycke.com Mikkeli photo credit: Pihla Liukkonen, Kontrastia

Norse Atlantic with continued strong unit revenue growth and adjusted capacity in May

Arendal, Norway, 8 June 2026 – In May, Norse Atlantic Airways (“Norse” or “the Company”) delivered total unit revenue in its own network (TRASK) of 5.4 US cents per available seat kilometer, an increase of 20% compared to the same month in 2025. Norse has been proactive in reducing loss making routes due to the elevated fuel prices with total available capacity down 29% year-over-year. The Norse product remains attractive with a total load factor of 97%, up nearly 2 percentage points year-over-year. Eivind Roald, the CEO of Norse Atlantic, comments: “May saw another material year-over-year improvement in unit revenues, reflecting continued strong demand for our direct long-haul transatlantic routes and the attractive Norse product. We are filling our adjusted capacity at higher average fares with a load factor above 93% in our own network. Aircraft utilization also remained high across ACMI/charter operations, demonstrating the strength of our balanced business model. Despite ongoing geopolitical uncertainty affecting the aviation industry, we continue to adapt capacity to demand and enter the important summer season with a positive commercial momentum.” (May traffic figures. Comparable figures for year-ago period shown in brackets)  · 97.4% load factor across network and ACMI/Charter operations (95.5%) · Total revenue per available seat kilometer in own network (TRASK) of 5.4 US cents, up 20% from 4.5 US cents · 157 flights in own scheduled network (520) · 256 ACMI/charter flights operated (64) · 104,234 passengers transported (182,854) across network and ACMI/charter operations, down 43% YoY · Norse Atlantic completed 100% of scheduled flights in the Month (100%) · 78% of flights in own network departed within 15 minutes of scheduled departure time (81%) · On-time performance was negatively impacted by continued Air Traffic Control (ATC) delays, airport congestion and travel disruptions as a knock-on effect from the Middle East conflict Investor contact: Anders Hall Jomaas, CFO anders.jomaas@flynorse.comMedia contact: Bård Nordhagen, CCCO baard.nordhagen@flynorse.com About Norse Atlantic ASA Norse Atlantic Airways is an airline committed to offering affordable fares on direct, long-haul flights to popular destinations, along with specialized charter and ACMI services for tailored travel needs and extensive cargo operations. Norse Atlantic operates a modern fleet of 12 fuel-efficient Boeing 787 Dreamliners, serving a network of destinations across North America, Europe, Africa and Asia. This information is subject to disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

DonkeyRepublic Holding A/S: Notification of transactions by persons discharging managerial responsibilities and persons closely associated with them

Company announcement No. 15 - 2026 DonkeyRepublic Holding A/S has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in DonkeyRepublic Holding A/S made by persons discharging managerial responsibilities and/or persons closely related with them. 1.  Details of the person discharging managerial responsibilities/person closely associateda)  Name Badem ApS2.  Reason for the notificationa)  Position/status Related party to Board member Erdem Ovacikb)  Initial notification/ Amendment Initial notification3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)  Name DonkeyRepublic Holding A/Sb)  LEI 9845003RD8BES01DF148 4.  Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type  of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)  Description of the financial  Shares instrument, type of Permanent ISIN code for the instrument Identification code shares: DK0061540770b)  Nature of the transaction Sellingc)  Price(s) and volume(s)  Price(s): 7,70 DKK per share                         Volume(s): 140.000 sharesd)  Aggregated volume: 140.000 · Aggregated information  sharesAggregated price: DKK · Aggregated volume  1.078.000,00Volume-weighted · Price average price: DKK 7,70e)  Date of the transaction 03.06.2026f)  Place of the transaction OTC

Gustav Segerberg appointed new CFO of EQT AB

Gustav Segerberg has been appointed as Chief Financial Officer (“CFO”) of EQT AB and will succeed Kim Henriksson, who has decided to step down following nearly eight years as CFO. The CFO transition is effective as of July 18, 2026. Henriksson will remain with EQT as a Senior Advisor, supporting an orderly transition and continuing to contribute his extensive experience to EQT and its portfolio companies.Segerberg has been instrumental to EQT’s growth, both as a member of the Executive Committee and most recently as Head of the CEO Office. Segerberg has overseen EQT AB’s transformative M&A activities – including the combinations with Baring Private Equity Asia, Exeter Property Group and, most recently, Coller Capital[1] – as well as organic growth initiatives like the expansion into private wealth.CEO Per Franzén said: "Having worked closely with Gustav for many years, I have the utmost confidence in his ability. His deep understanding of EQT's strategy, business model, and stakeholder relationships makes him exceptionally well placed to take on this role. Kim has been a deeply valued partner through one of the most transformative chapters in our firm's history. I want to extend my sincere gratitude to him for his outstanding contributions to EQT to-date and am pleased that he will continue as a Senior Advisor to the benefit of our portfolio companies, clients and shareholders."Commenting on his appointment, Segerberg said: "I am honoured to be appointed CFO of EQT and look forward to working with our exceptional team to continue delivering for our shareholders. EQT is a truly unique firm with a strong culture, a clear strategic vision, and substantial opportunities ahead. I am committed to building on the strong financial foundation Kim has established and driving EQT's continued growth."Under Henriksson’s leadership, EQT has established a highly professional finance function supporting the firm’s development into a leading global and transparent publicly listed private markets platform."It has been a privilege to serve as CFO of EQT since 2018 and to have been part of such an extraordinary growth journey. I am proud of what we have achieved together and confident that Gustav will be an outstanding CFO. I look forward to a smooth handover over the coming months and to thereafter work closely with EQT portfolio company boards, management teams and CFOs as a Senior Advisor, including supporting on IPO preparations and public company financial governance", added Henriksson. ContactOlof Svensson, Head of Shareholder Relations, +46 72 989 09 15EQT Press Office, press@eqtpartners.com, +46 8 506 55 334 [1]The transaction is subject to customary closing conditions, including regulatory approvals and certain Coller Capital fund investor consent approvals, and is expected to close in mid to late Q3 2026.

Elkem ASA – New share capital registered

Oslo, 8 June 2026 Reference is made to the stock exchange announcement made by Elkem ASA (the "Company") on 1 June 2026, informing of the final results of the Company’s subsequent offering (the “Subsequent Offering”), and that in total 11,111,111 new shares (the "Offer Shares") in the Company had been subscribed for and would be issued in the Subsequent Offering. The share capital increase pertaining to the Offer Shares in the Subsequent Offering has now been registered with the Norwegian Register of Business Enterprises. The Company's share capital following such registration is NOK 1,838,847,540, divided into 367,769,508 shares, each with a nominal value of NOK 5. The Offer Shares are tradable on the Oslo Stock Exchange from publication of this stock exchange announcement.  This information is subject to disclosure under section 5-12 of the Norwegian Securities Trading Act. For further information, please contact:Odd-Geir LyngstadVP Finance & Investor Relationstel: +47 976 72 806email: odd-geir.lyngstad@elkem.com About Elkem ASA:Elkem is a global metals and materials company established in 1904. The company holds leading positions in silicon, ferrosilicon, foundry alloys and carbon solutions, supplying materials essential to modern society – from critical infrastructure and manufacturing to digitalisation, mobility and energy solutions. Elkem produces its materials by combining natural raw materials, renewable energy and advanced process technology, creating solutions that enable a more sustainable future. The company employs around 3,000 people, operates in more than 30 locations across Europe, Asia, the Americas and Africa, and is headquartered in Oslo, Norway where it is listed on the Oslo Stock Exchange (ELK). Driven by innovation. Powered by nature. Shaping the future. 

Epiroc Capital Markets Day: Innovation and global presence for profitable growth

The purpose of the event is to give an update on how Epiroc is positioning itself for profitable and resilient growth in an ever-changing world.  “For decades, innovation and global presence have been at the heart of Epiroc,” says Helena Hedblom, Epiroc’s President and CEO. “It is that very same combination that will continue to drive our growth and define our future. We focus on areas where performance matters most. In our industry, downtime is the most expensive thing. Customers do not choose us for the lowest price, they choose us because we improve safety, uptime, productivity, and total cost of ownership. We look forward to demonstrating to the investment community how we are moving from being an equipment supplier to becoming a strong productivity and technology partner for our customers.” Topics that will be covered include: · The strategic areas attractive niches, innovation, aftermarket, operational excellence, and outperformance, built on a foundation of sustainability and a strong corporate culture. · The strong industry trends and Epiroc’s market-leading work within automation, including mixed fleet, as well as digitalization and electrification, · Exploration, including how historically high prices for minerals such as copper and gold are setting the stage for continued exploration growth. The company’s annual exploration orders, rolling 12 months, amounted to SEK 3.1 billion per March 31, 2026, or about 4.7% of Group orders. · How Epiroc combines premium positioning with broader market reach through multi-brand, different value propositions and sales channels as well as R&D synergies. One example of this approach is the successful GIA brand in China. · Insights into how the strategy for the two Business Areas will be executed. Epiroc reconfirms its financial goals as well as its most recent outlook statement, that in the near term it expects mining demand to remain high, while demand from construction customers is expected to increase somewhat from a low level. A three-hour-plus live webcast  of the CMD starts at 14:30 CEST, with presentations from Helena Hedblom, President and CEO; Håkan Folin, CFO; Jess Kindler, Business Area President Equipment & Service; and José Manuel Sanchez, Business Area President Tools & Attachments. The presentation material and link to the webcast will later be available here . Tomorrow, the CMD guests are invited to a deep-dive exhibition with focus on innovation, production and corporate culture.  For more information please contact:Karin Larsson, VP Investor Relations and Media+46 10 755 0106ir@epiroc.comAlexander Apell, Investor Relations Officer+46 72 083 9519ir@epiroc.comOla Kinnander, Media Relations Manager+46 70 347 2455media@epiroc.com Epiroc is a global productivity partner for mining and infrastructure customers, and accelerates the transformation toward a sustainable society. With ground-breaking technology, Epiroc develops and provides innovative and safe equipment, such as drill rigs, rock excavation and construction equipment and tools for surface and underground applications. The company also offers world-class service and other aftermarket support as well as solutions for automation, digitalization and electrification. Epiroc is based in Stockholm, Sweden, had revenues of around SEK 62 billion in 2025, and has around 19 000 passionate employees supporting and collaborating with customers in around 150 countries. Learn more at www.epirocgroup.com.

Recipharm and Fusix Biotech advance novel oncolytic virus platform

Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced a strategic collaboration with Fusix Biotech to support the development and manufacturing of next-generation cancer immunotherapies based on innovative oncolytic virus technology. Fusix Biotech is developing breakthrough cancer treatments using proprietary oncolytic fusion virus technology designed to combine direct tumour cell destruction with modulation of the tumour microenvironment to enhance anti-tumour immune responses. The company’s lead candidate, FUSE102, is a chimeric oncolytic virus encoding a high affinity soluble PD-1 intended to enable immune checkpoint inhibition and strengthen anti-tumour activity. The programme represents a novel approach within the rapidly evolving field of cancer immunotherapy. Under the collaboration, Recipharm will tech transfer the FUSE102 process to support clinical development building on Recipharm’s capabilities in viral vectors and advanced biologics manufacturing. Through its collaboration with iBET, who will do the initial process development, Recipharm will manufacture the Master Virus Seed and GMP clinical material for first in-human trials. Greg Behar, CEO of Recipharm, said: “Oncolytic viruses represent one of the most promising areas in cancer immunotherapy today. We are pleased to collaborate with Fusix Biotech to help advance this innovative platform toward the clinic. This partnership reflects Recipharm’s growing expertise in complex biologics and viral-based therapies, and our ability to support customers from process development through GMP manufacturing as they advance the next generation of oncology treatments.” Jennifer Altomonte, CEO and CSO of Fusix Biotech, added: “Partnering with Recipharm is an important step forward for Fusix Biotech and our InFUSE™ platform. Recipharm’s experience in viral product development and biologics manufacturing makes them a strong partner as we advance our programmes toward the clinic.” This collaboration further demonstrates Recipharm’s capabilities in oncology biologics, where the company supports innovators with integrated development and manufacturing services, spanning viral vectors, oncolytic viruses, nucleic acids, recombinant proteins and sterile fill and finish services. Combined with Recipharm’s analytical development, process optimisation and regulatory support, these capabilities help advance complex programmes from early development through commercial manufacture.   For more information About Fusix Biotech Fusix Biotech is a preclinical-stage biotech company based in Munich, Germany. Fusix is developing next-generation cancer therapies designed to overcome treatment resistance in solid tumors. Leveraging its proprietary InFUSE™ platform, Fusix aims to provide optimized oncolytic viral vector-based immunotherapies that mediate multiple modes of action: direct tumor cell elimination, in situ tumor vaccination, and localized delivery of therapeutic genes to the tumor site. Through broad activity across tumor types and effective systemic application, Fusix is positioning itself to deliver durable responses for patients with aggressive cancers. The company is advancing its lead candidate towards clinical development for treatment of advanced primary liver cancer. About RecipharmRecipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 4,000 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its Recipharm Advanced Bio segment works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Italy, Portugal, Spain, Sweden and the US. For more information about Recipharm, please visit www.recipharm.com and www.recipharm-ab.com  Media contact: Guenaelle Holloway, Head of marketing and communicationsGuenaelle.Holloway@recipharm.com+44 7730 303 708

Inside information: Betolar has been granted €2.1 million in funding under the EU LIFE programme for the MINERVA project

Betolar PlcCompany ReleaseJune 8, 2026 at 1:25 P.M. EEST Inside information: Betolar has been granted €2.1 million in funding under the EU LIFE programme for the MINERVA project Betolar Plc is participating in the MINERVA project (MINeral Efficiency, Recovery and Valorisation in the Arctic), which is funded by the European Union’s LIFE programme. The project aims to develop and pilot new solutions to enhance the recovery of critical raw materials and reduce the amount of mining waste in Arctic conditions. The MINERVA project will be carried out in the Sokli mining area in Eastern Lapland. The project focuses on circular economy-based mining and mineral processing solutions, the development of water use and water management, and the reduction of mining waste and environmental risks. The total estimated cost of the MINERVA project is approximately €8.8 million, of which the EU LIFE programme’s share is approximately €5.3 million. Betolar’s share of the total costs is €3.4 million, of which €2.1 million is funding. The estimated duration of the project is approximately three and a half years. The funding will be drawn down over the course of the project. Betolar’s role in the project is based on the company’s Metal Extraction Technology, which is used to increase the recovery of metals from mining fractions and to utilize the resulting sidestreams in the production of low-carbon circular cement, thereby minimizing waste. "Participation in the MINERVA project strongly supports Betolar’s strategic objective of demonstrating the practical performance of its Metal Extraction Technology. The project also accelerates the advancement of the technology’s proof-of-concept phase and establishes a solid foundation for the development of new circular economy-based business,” says CEO Tuija Kalpala. Betolar participates in the project in the role of a technology supplier. The project does not change Betolar’s previously issued financial guidance. Betolar Plc Further enquiries Tuija Kalpala, President and CEO, Betolar Plc, tel. +358 50 567 6608, tuija.kalpala@betolar.com  Certified Adviser Aktia Alexander Corporate Finance Oy, +358 50 520 4098 About Betolar Betolar is a circular economy and materials technology company. Betolar was founded in 2016 and is domiciled in Kannonkoski, Finland. Betolar is listed on the Nasdaq First North Growth Market (ticker: BETOLAR), and its shares are also traded in the United States on the OTCQX International marketplace (ticker: BTLRF). For more information www.betolar.com.

UPM delivers purpose-built adhesive solutions for demanding label applications

(UPM, Helsinki, June 8, 2026 at 14:00 EEST) – UPM is simplifying adhesive selection with purpose-built solutions designed for demanding label applications. UPM PharmaSure™ for pharmaceuticals, UPM Vetro™ for wine and spirits, and UPM Endurance™ for oil and industrial chemicals help customers choose the right adhesive performance for each end-use. All are part of the UPM Raflatac™ label material offering. Demanding label applications place requirements on adhesives that general-purpose solutions cannot meet. Pharmaceutical packaging must maintain integrity through sterilization cycles, cold-chain storage and small-diameter vials. Wine and spirits labels face humidity, chilled display and ice bucket immersion. Industrial labels must hold on to challenging substrates under chemical exposure, mechanical strain and hot-fill conditions. Each of these environments carries its own technical requirements, regulatory context and consequences when a label fails. UPM’s adhesive formulations are built on decades of experience in these challenging applications and on a global innovation network. UPM PharmaSure, UPM Vetro and UPM Endurance address the range of conditions relevant to each respective industry and are supported by pre-assessed performance data and application documentation. This supports qualification and regulatory processes for converters and brand owners. "With demanding label applications, adhesive selection is a critical decision. Our purpose-built adhesive solutions help our customers choose the right performance for their end-use,” says Christian Szameit, Senior Vice President, Global Markets at UPM Adhesive Materials. Click here to download images.  For more information, please contact:Helena Lamberg, Vice President, Marketing, Sustainability and Communications, UPM Adhesive Materials, helena.lamberg@upm.com, +358 40 5681055 UPM, Media relationsMon-Fri 9:00–16:00 EESTtel. +358 40 588 3284media@upm.com UPM Adhesive MaterialsUPM Adhesive Materials provides high-performance, innovative self-adhesive products, including label materials, graphics solutions, and specialty tapes, as well as reliable services close to customers.We are one of UPM’s fastest-growing global businesses employing around 3,300 professionals. In 2025, our sales reached nearly €1.7 billion ($1.95 billion). Read more:adhesivematerials.upm.com  Follow UPM Adhesive Materials on LinkedIn  | YouTube  | Instagram  UPMUPM is a material solutions company, renewing products and entire value chains with an extensive portfolio of renewable fibres, advanced materials, decarbonization solutions, and communication papers. Our performance in sustainability has been recognized by third parties, including EcoVadis and the Dow Jones Sustainability Indices. We operate globally and employ approximately 15,100 people worldwide, with annual sales of approximately €9.7 billion. Our shares are listed on Nasdaq Helsinki Ltd.UPM – we renew the everydayRead more: upm.com  Follow us onLinkedIn |YouTube |Instagram | #UPM #materialsolutions #WeRenewTheEveryday

Image Systems AB (publ) Appoints New CFO

Image Systems AB (publ) has appointed Mats Franzén as its new Chief Financial Officer (CFO). Mats Franzén will assume the position on 15 June 2026 and will succeed Lotta Öfverström, who previously announced that she will leave the company on 31 July 2026. A handover process will take place during the overlapping period. Mats Franzén brings nearly 30 years of experience from senior finance positions in international technology and industrial companies. Most recently, he served as CFO of Sectra, where he was responsible for the Group’s financial management, financial reporting, financing activities, and the company’s transition to the Nasdaq Stockholm Large Cap segment. Prior to that, he held several senior positions in finance and business control. - We are very pleased to welcome Mats to Image Systems. His extensive experience in financial management, strategic transformation, and international business operations will be a valuable asset to the company’s continued development, says Jan Molin, CEO of Image Systems AB. - Image Systems holds an exciting position in the market, supported by strong technologies and significant growth opportunities. I look forward to working together with the management team and employees to contribute to the company’s continued development and value creation, says Mats Franzén. The Board of Directors and management would also like to express their sincere appreciation to Lotta Öfverström for her valuable contributions during her tenure with the company and wish her every success in her future endeavors.

Composition of Wärtsilä’s Shareholders’ Nomination Board

Composition of Wärtsilä’s Shareholders’ Nomination Board The following members have been appointed to Wärtsilä’s Shareholders’ Nomination Board: · Petra Hedengran, Senior Advisor, Investor AB, appointed by Invaw Invest AB · Markus Aho, Chief Investment Officer & Deputy CEO, Varma Mutual Pension Insurance Company · Rami Vehmas, Head of Equities, Ilmarinen Mutual Pension Insurance Company · Carl Pettersson, CEO, Elo Mutual Pension Insurance Company · Tom Johnstone, Chairman of the Board of Directors of Wärtsilä Wärtsilä’s Shareholders’ Nomination Board consists of five members. Four representatives are nominated by the company’s four largest shareholders, with the fifth member being the Chairman of Wärtsilä’s Board of Directors. The four largest shareholders are determined on the basis of the shareholders’ register maintained by Euroclear Finland Ltd. as of 1 June preceding the Annual General Meeting of shareholders.  The Shareholders’ Nomination Board prepares and presents to the General Meeting proposals relating to the composition and remuneration of the Board of Directors. In addition, the Nomination Board reviews and adjusts the diversity principles of the Board of Directors, as necessary, and does successor planning of the directors. For further information, please contact: Nora Steiner-ForsbergExecutive Vice President, Public Affairs and LegalTel. +358 10 709 0000nora.steiner-forsberg@wartsila.com        For investor information, please contact: Hanna-Maria HeikkinenVice President, Investor RelationsTel. +358 10 709 1461hanna-maria.heikkinen@wartsila.com Wärtsilä in brief Wärtsilä is a global leader in innovative technologies and lifecycle solutions for the marine and energy markets. We emphasise innovation in sustainable technology and services to help our customers continuously improve environmental and economic performance. Our dedicated and passionate team of 17,900 professionals in 199 locations in 78 countries shape the decarbonisation transformation of our industries across the globe. In 2025, Wärtsilä’s net sales totalled EUR 6.9 billion. Wärtsilä is listed on Nasdaq Helsinki. www.wartsila.com

SAS and Garuda Indonesia expand global connectivity through new codeshare partnership

The partnership will offer seamless travel options to and from Jakarta (CGK) and Bali (DPS), as well as Copenhagen, Stockholm and Oslo, with convenient connections via Amsterdam, Tokyo Haneda and, from Winter 2026/2027, Bangkok. The agreement was signed during the IATA Annual General Meeting in Rio de Janeiro by Garuda Indonesia Director of Transformation, Neil Raymond Mills, and SAS President and CEO, Anko van der Werff. “Garuda Indonesia is a key partner for connecting Scandinavia with Indonesia and the wider region. Together, we are making travel simpler and more seamless for the many people, businesses and communities with ties between our countries. By bringing our networks closer together, we are creating more opportunities to connect Scandinavia with one of Asia's most dynamic markets,” said Van der Werff at SAS. The collaboration reflects the shared ambition of both airlines as SkyTeam members to enhance global connectivity and provide broader access between Europe and Southeast Asia. For Garuda Indonesia customers, the partnership opens access to SAS’ Scandinavian gateways, while SAS travelers gain new opportunities to reach Indonesia’s major destinations through Garuda’s network. “As part of Garuda Indonesia’s ongoing transformation journey, we are pleased to deepen our collaboration with Scandinavian Airlines to expand connectivity between Southeast Asia and Northern Europe, leveraging our complementary network strengths to provide customers with broader travel options and a more seamless journey experience. Beyond enhancing market access and presence for both airlines, this partnership will further support tourism, business, and cultural exchange, enabling more travelers from Europe to explore Indonesia’s diverse destinations while offering Indonesian travelers greater access to the unique attractions and cultures of the Scandinavian region,” said Garuda Indonesia’s Deputy CEO, Thomas Oentoro. Frequent flyer members will also benefit from the cooperation, with EuroBonus and GarudaMiles members able to earn and redeem points across the combined network. From 9 June 2026, passengers will be able to purchase itineraries covered by the codeshare agreement through the sales channels of both airlines, while first date of travel will be 15 June.

Inify Laboratories signs agreement with University Hospitals Plymouth NHS Trust to support faster prostate cancer diagnostics

South Oxfordshire, UK, 8th June 2026 – Inify Laboratories, a unique laboratory service that provides diagnostics within pathology, today announced that it has entered into an agreement with University Hospitals Plymouth NHS Trust (UHP) to launch a service evaluation. The evaluation aims to support the consistent delivery of a 7-day histopathology turnaround time and improve performance improvement against the 28-day Faster Diagnosis Standard (FDS). The partnership seeks to ensure patients with suspected prostate cancer receive timely, high-quality diagnostic results. Across the country, cancer waiting times (CWT) remain under significant pressure, with many NHS trusts struggling to meet national targets for timely diagnosis and treatment due to high demand and constrained resources. Prostate cancer diagnostics is one area particularly affected by hugely variable reporting times. NHS targets, including the 28-day FDS, place clear emphasis on delivering timely results to patients. Delays in laboratory processing of tissue and pathology reporting can impact the entire clinical pathway, requiring additional administrative time to track results, rearrange clinics, and manage patient expectations. The collaboration between Inify Laboratories and UHP is designed to support more consistent and predictable histopathology turnaround times, helping the Trust reliably achieve its 7-day histopathology target, and helping clinicians receive high-quality diagnostic reports within agreed timeframes. By combining digital workflows, AI-supported analysis, and streamlined laboratory processes, the service evaluation seeks to reduce variation, improve efficiency, and ultimately enhance patient experience. “Our goal is to provide a reliable, high-quality service,” says Rob Archer and Louise Keers, Laboratory Operations Managers at UHP. “By releasing laboratory capacity in one area, we can enable staff to focus on other clinical priorities and support improved turnaround times across additional indications - helping us meet national cancer targets more sustainably.’’ “We’re very pleased to support this service evaluation in partnership with University Hospitals Plymouth NHS Trust and Inify Laboratories,” says Sunita Berry, Managing Director of the Peninsula Cancer Alliance. “Improving diagnostic timeliness is a key priority across our region, and initiatives that bring greater consistency and efficiency to the prostate cancer pathway are extremely welcome. We’re excited to see the potential impact this collaboration could have for both patients and clinical teams.” “This partnership reflects what can be achieved when clinical expertise, digital innovation and service design come together,” says Kate Bucknall, Managing Director UK at Inify Laboratories. “Inify delivers a dependable, end-to-end service that brings greater efficiency and sustainability to the prostate cancer pathway.” The service evaluation reflects a shared commitment between Inify Laboratories and UHP to improve cancer pathways, reduce patient anxiety associated with waiting for results, and support sustainable cancer diagnostic services for the future. For further information, please contact Kate Bucknall, Managing Director, Inify Laboratories Ltd, kate.bucknall@inify.com, or visit https://www.inify.com  ### This information is considered to be inside information pursuant to the EU Market Abuse Regulation (MAR) and is subject to the disclosure requirements pursuant to MAR article 17 and section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Ann-Charlotte Linderoth, Inify Laboratories AB on the time and date provided. ### The future of diagnostics Inify Laboratories offers diagnostics through specialised laboratory services in histopathology, with a focus on streamlining patient pathways. The company performs clinical diagnostics in prostate cancer and gastroenterology, providing an integrated service that spans from early sample handling to final diagnosis. The laboratory system is scalable both in handling large volumes of patient samples and for replicating in new locations. Quality and response times are optimised in every step - from logistics to tissue preparation and diagnosis - using a fully digital, standardised and AI-assisted workflow. The diagnosis is always performed by a pathologist and is assisted by Inify's proprietary AI, proven to have world-leading precision in clinical evaluations. The entire workflow is supported by a tailor-made system that also enables development to include additional diagnostic areas. Inify Laboratories is an international group headquartered in Solna, Sweden, with local laboratories in Sweden and the UK. The company's share is listed on Euronext Growth Oslo  under the ticker INIFY. 

Volvo Defence to showcase resilient defence solutions at Eurosatory 2026

Volvo Defence to showcase resilient defence solutions at Eurosatory 2026 Paris, June 2026- At Eurosatory 2026, Volvo Defence will showcase how the combined capabilities of the Volvo Group can support modern defence operations with robust, future-ready solutions for demanding and uncertain environments. Drawing on the strengths of Volvo Trucks, Volvo Penta and Volvo Construction Equipment, Volvo Defence will present solutions that support the defence logistics chain from civilian transport and infrastructure capabilities to front-line operations. With a focus on reliability, adaptability and long-term support, Volvo Defence offers solutions tailored to evolving operational requirements. By leveraging the Volvo Group’s global industrial footprint and supply chain strength, customers benefit from proven platforms, secure delivery, high availability and comprehensive lifecycle services. Highlights at Eurosatory 2026, include: · Volvo Logistic Chain SolutionVisualizing the strength of the Volvo portfolio supporting the full logistic chain from the port entry to last mile. · Autonomous capabilities for defence logisticsVolvo Defence will showcase progress in autonomous transport solutions designed to reduce personnel exposure in high threat areas while maintaining efficient movement of supplies and equipment. · Logistical support vehiclesVolvo Defence will present the military-adapted Volvo FMX 6x6 Truck engineered for both on- and off-road performance in the most demanding environments. The military FMX delivers a reliable and scalable solution that meets the requirements of modern defence forces worldwide. Equipped with I-Shift automated manual gearbox with ultra-low crawler gears and automated hook lift it enables optimized traction and mobility across varying terrain conditions. A high degree of commonality with civilian variants ensures real availability, simplified logistics, and economies of scale enabled by Volvo’s global commercial production capabilities. · Off-road engineering vehicles for defence applicationsVolvo Defence will offer a first look at the Volvo Construction Equipment L120, a standard commercial wheel loader adapted with key defence features. These include a fording kit for water depths of up to 1.5 metres, a split cab for reduced transport height, lifting and tie-down points for air freight, and other options relevant to military use. · Counter-drone capabilitiesThe company will also demonstrate how it integrates advanced technologies into its solutions to support safer and more connected operations. These innovations reflect Volvo Defence’s commitment to evolving its offering in line with emerging threats and operational demands. “At Eurosatory, we demonstrate how the strength of Volvo Group products can be combined and integrated with other critical defence technologies to support logistical resilience and real operational capability in the field,” says Andreas Svenungsson, President of Volvo Defence. “Operational readiness depends not only on high-performing equipment, but also on trusted support, reliable supply chains and the ability to sustain operations over time. This is where we create value for our customers.” Volvo Defence will exhibit inHall 6, Swedish Pavilion, Stand H6-J180. For more information about Volvo Defence please visit: volvodefence.com Eurosatory 2026 will take place 15-19 June  at Paris-Nord Villepinte Parc des Expositions More details at eurosatory.com/en/

Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 30/2026 8 June 2026 Reykjavik, Iceland/Copenhagen, Denmark, 8 June 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 1 June to 4 June 2026 Embla Medical has acquired 58,784 shares under the Program at the average price of DKK 26.98. Following the transactions below, the Company holds 1,743,095 shares, corresponding to 0.41% of the Company’s total share capital. Transaction No. of Avg. purchase price in DKK Transaction value in DKKdate shares1 June 2026 20,000 27.12 542,3612 June 2026 5,784 26.84 155,2613 June 2026 30,000 26.90 807,0004 June 2026 3,000 27.12 81,359Total 58,784 26.98 1,585,981 The purpose of the Program is to reduce the Company’s share capital and adjust the capital structure by distributing capital to shareholders in line with the Company’s Capital Structure and Capital Allocation Policy. The Program will end no later than 31 December 2026, but the Company is entitled to discontinue the Program at any time.   The Company may purchase up to 2,000,000 shares under the Program, corresponding to 0.46% of the current share capital. The total consideration for shares purchased under the Program shall not exceed USD 10 million. The Program on Nasdaq Copenhagen is carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission’s delegated regulation 2016/1052. Further information Klaus Sindahl, Head of Investor Relations, KSindahl@emblamedical.com, +45 5363 0134 Embla Medical press releases by e-mail If you wish to receive Embla Medical press releases by e-mail, please register at http://www.emblamedical.com/investors About Embla Medical Embla Medical (Nasdaq Copenhagen: EMBLA) is a leading global provider of innovative mobility solutions that help people live a Life Without Limitations[®]. Embla Medical is home to several leading brands renowned for positively impacting people's health and well-being. They include Össur, a leading global provider of prosthetics and bracing solutions; Fior & Gentz, an innovative developer of neuro orthotics; College Park, a provider of lower limb prosthetics; and ForMotion, a global network of Orthotic and Prosthetic (O&P) patient care facilities. Embla Medical is committed to sustainable business practices, is a signatory to the UN Global Compact and UN Women’s Empowerment Principles and contributes to the UN Sustainable Development Goals. The company's climate targets have been verified by the Science Based Targets initiative. Embla Medical operates globally and has around 4,500 employees. www.emblamedical.com

Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer

As healthcare systems increasingly embrace precision medicine, the demand for advanced precision diagnostics in uro-oncology continues to grow. Photocure, already recognized for its proven leadership in bladder cancer diagnostics where accuracy is critical, is well positioned to meet this need. This research initiative with Artera underscores Photocure’s commitment to grow an array of complementary diagnostic solutions to address the evolving needs of patients, physicians, and the broader healthcare community, towards more personalized, data-driven care in uro-oncology, enabling better clinical outcomes and supporting the shift toward precision medicine. The research collaboration will provide Artera with access to high-quality data from the Photocure U.S. BLC registry to further validate the ArteraAI Bladder Test. Together, the companies will utilize real world evidence to help urologists more effectively identify bladder cancer and manage its treatment. Unlike many other cancers, there are fewer well-established biomarkers in bladder cancer, which currently limits clinicians from personalizing treatment options. The partnership between Photocure and Artera is dedicated to advancing research that guides smarter treatment decisions and helps patients receive therapies best suited to their disease. The objectives of using the BLC registry’s long-term clinical practice data are to develop, evaluate, and optimize the performance of Artera’s multimodal AI (MMAI) histopathology biomarkers in patients with non-muscle invasive bladder cancer (NMIBC). The joint research aims to validate the prognostic and predictive capabilities of the ArteraAI Bladder by addressing critical clinical questions. “With this collaboration, we are exploring additional ways to enter scientific collaborations that may utilize Photocure’s BLC registry to advance the field of precision diagnostics. When urologists use BLC, they often perform biopsies and resection to achieve a more accurate diagnosis and a more complete procedural outcome. By pairing the BLC captured specimen with the ArteraAI Bladder Test, we aim to accurately determine the grade and stage of disease while also providing a readout on whether these patients are optimal candidates for specific follow-up drug therapy. BLC and Artera’s AI-powered biomarkers have the promise to set patients on the right course of bladder cancer management, streamlining the decision-making for pathologists and urologists,” said Anders Neijber, Chief Medical Officer of Photocure. “Artera is excited to be working with Photocure to expand the application of our MMAI algorithms into other genitourinary cancers. Given the impact we’ve made to date in the prostate cancer realm, we hope to make a similar impact in bladder cancer and deliver personalized prognostic and predictive insights to patients and physicians,” said Andre Esteva, co-founder and CEO of Artera. “Building on the success of BLC, Photocure is expanding its vision to develop a complementary suite of precision diagnostic solutions. With established expertise, relationships and a track record in bladder cancer, we are uniquely placed to drive progress and set new standards in the future of uro-oncology precision diagnostics. Today we are seeking to accelerate the advancement of personalized care in a manner that has not previously been achieved. Along with Artera, we are truly excited about what we can do for urologists, their staff and their patients,” said Dan Schneider, President and CEO of Photocure. For more information, please contact: Photocure: Dan SchneiderPresident and CEOPhotocure ASAEmail: ds@photocure.com Priyam ShahVice President Investor RelationsTel: +17176815072Email: priyam.shah@photocure.com Media and IR enquiries:Geir BjørloCorporate Communications (Norway)Tel: +47 91540000Email: geir.bjorlo@corpcom.no Artera: Media Contact: Vanessa DonohueEmail: artera@antennagroup.com Note to editors: All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA, except for Artera.  This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that Photocure does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. About Bladder CancerBladder cancer ranks as the 8[th] most common cancer worldwide – the 5[th] most common in men – with 1 949 000 prevalent cases (5-year prevalence rate)[1a], 614 000 new cases and more than 220 000 deaths in 2022.[1b]Approx. 75% of all bladder cancer cases occur in men.[1] It has a high recurrence rate with up to 61% in year one and up to 78% over five years.[2] Bladder cancer has the highest lifetime treatment costs per patient of all cancers.[3]Bladder cancer is a costly, potentially progressive disease for which patients have to undergo multiple cystoscopies due to the high risk of recurrence. There is an urgent need to improve both the diagnosis and the management of bladder cancer for the benefit of patients and healthcare systems alike.Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall. NMIBC remains in the inner layer of cells lining the bladder. These cancers are the most common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has grown into deeper layers of the bladder wall. These cancers, including subtypes T2, T3 and T4, are more likely to spread and are harder to treat.[4] [1 ]Globocan. a) 5-year prevalence / b) incidence/mortality by population.  Available at: https://gco.iarc.fr/today, accessed [February 2024].[2 ]Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657[3 ]Sievert KD et al. World J Urol 2009;27:295–300[4 ]Bladder Cancer. American Cancer Society. https://www.cancer.org/cancer/bladder-cancer.html About BLC[®] with Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves the detection of tumors and leads to more complete resection, fewer residual tumors, and better management decisions.Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all other markets. Photocure is commercializing Cysview/Hexvix directly in the U.S. and Europe and has strategic partnerships for the commercialization of Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer to https://photocure.com/partners/our-partners for further information on our commercial partners.The following safety information is solely included to comply with U.S. regulatory requirements: Important Risk & Safety Information for Cysview [®] (hexaminolevulinate HCl)  About Photocure ASAPhotocure is a commercial diagnostic company with global reach, committed to driving progress in uro-oncology precision diagnostics, delivering meaningful advances for patients with urological cancers. Our unique core technology has led to better health outcomes for patients worldwide. The company aims to provide an array of transformative solutions that help physicians with timely diagnostic information, to inform more personalized decisions on how best to manage each individual patient. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit www.photocure.com/news About ArteraArtera is a global leader in precision medicine, leveraging multimodal artificial intelligence (MMAI) to personalize cancer care. Artera’s MMAI platform leverages a patient’s digitized histopathology images along with the patient’s clinical data to determine cancer aggressiveness and predict therapy benefit. Artera’s flagship product, the ArteraAI Prostate Test, is commercially available as a laboratory-developed test in the US and internationally through its distribution partners. The ArteraAI Prostate Test is the first of its kind to deliver both prognostic and predictive insights for patients with prostate cancer, empowering clinicians and patients to make more informed treatment decisions.

Repurchase of shares in Synsam during June 1, 2026 – June 5, 2026 (week 23)

The repurchases form part of the share buy-back program of maximum MSEK 200 announced by Synsam on May 28, 2026, and which runs during the period from June 1, 2026, until February 26, 2027. The share buy-back program is being carried out in accordance with the EU Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation"). The purpose of the share buy-back program is to adjust the Company's capital structure by reducing its share capital. Shares in Synsam have been repurchased in accordance with the following: Date Aggregated daily Weighted average Total daily volume (number of share price per day transaction value shares) (SEK) (SEK)2026 25 000 56,666764             1 416-06 669-012026 25 000 55,602680             1 390-06 067-022026 25 000 54,813500             1 370-06 338-032026 25 000 55,528316             1 388-06 208-042026 25 000 56,125728             1 403-06 143-05 All repurchases have been carried out on Nasdaq Stockholm by DNB Carnegie Investment Bank AB (publ) on behalf of Synsam. Following the above listed repurchases, Synsam's holding of own shares as per June 5, 2026, amounts to 3,476,252 shares. The total number of outstanding shares in Synsam is 145,313,746. A full breakdown of the transactions pursuant to article 5.3 of MAR and article 2.3 of the Safe Harbour Regulation is attached to this announcement. For further information, please contact: Per Hedblom, CFO Synsam GroupE-mail: per.hedblom@synsam.comTelephone: +46 (0)8-619 28 60Website: www.synsamgroup.com  Synsam Group is a leading optician group in the Nordic region, with a differentiated and affordable subscription offering. Synsam Group offers a wide range of products and services for eye health and eye fashion, catering to the customer’s different lifestyles and needs. The group has approximately 5,400 employees, net sales of approximately SEK 7.1 billion (rolling twelve months until March 2026) and approximately 600 stores in the Nordics, operating under the brands Synsam, Synsam Outlet and Profil Optik in Denmark. Through digitalization, subscription services and other innovative concepts, Synsam Group is at the forefront of innovation in the Nordic optical retail market across multiple dimensions including customer journey, product offering and ESG. Synsam Group’s share is traded on Nasdaq Stockholm (SYNSAM). www.synsamgroup.com 

Composition of Konecranes Plc’s Shareholders’ Nomination Board

KONECRANES PLC STOCK EXCHANGE RELEASE June 8, 2026 at 7:15 PM EEST Composition of Konecranes Plc’s Shareholders’ Nomination Board Konecranes has a Shareholders' Nomination Board which prepares proposals to the Annual General Meeting, and, if necessary, to an Extraordinary General Meeting, for the election and remuneration of the members of the Board of Directors and to identify potential Board member candidates. The Shareholders' Nomination Board is comprised of one member appointed by each of the four largest shareholders of Konecranes Plc. The shareholders entitled to appoint a member are determined on the basis of the shareholders' register of the Company maintained by Euroclear Finland Ltd. on May 31 each year. The following members have been appointed to Konecranes’ Shareholders Nomination Board: · Petter Söderström, Chief Financial Officer of Solidium, appointed by Solidium Oy with 26,379,369 shares, · Annika Paasikivi, Executive Chair of Oras Invest, appointed by Oras Invest Oy with 10,715,000 shares, · Esko Torsti, Head of Alternative Investments of Ilmarinen, appointed by Ilmarinen Mutual Pension Insurance Company with 7,891,560 shares, · Markus Aho, Deputy CEO, Chief Investment Officer of Varma, appointed by Varma Mutual Pension Insurance Company with 7,614,003 shares. Pasi Laine, the Chair of the Konecranes’ Board of Directors, serves as an expert in the Nomination Board without being a member. The now appointed Nomination Board will forward its proposals for the 2027 Annual General Meeting to the Board of Directors by January 31, 2027. KONECRANES PLCLinda HäkkiläVice President, Investor Relations FURTHER INFORMATIONLinda Häkkilä,Vice President, Investor Relations,tel. +358 (0) 20 427 2050 Konecranes is a global leader in material handling solutions, serving a broad range of customers across multiple industries. We consistently set the industry benchmark, from everyday improvements to the breakthroughs at moments that matter most, because we know we can always find a safer, more productive and sustainable way. That's why, with around 16,500 professionals in over 50 countries, Konecranes is trusted every day to lift, handle and move what the world needs. In 2025, Group sales totalled EUR 4.2 billion. Konecranes shares are listed on Nasdaq Helsinki (symbol: KCR). DISTRIBUTIONNasdaq HelsinkiMajor mediawww.konecranes.com

Granarium Technologies raises EUR 1 million to commercialise the world’s first renewable, affordable supercapacitors for grid stability and industrial reliability

Granarium Technologies  (Granarium), a deep-tech energy startup originating from VTT, has raised over EUR 1 million in total funding, comprising a pre-seed round led by BSV Ventures joint by Beamline, with participation from FiBAN (Finnish Business Angels Network), EstBAN and LatBAN. VTT has transferred the underlying technology and IP to the newly established company. Granarium will use the funding to industrialise its patented renewable supercapacitor technology for grid stabilisation and industrial applications, both increasingly challenged by electrification, renewable integration, and power quality demands. Grid volatility is increasing across Europe, while EU requirements, including grid codes and resilience frameworks, are tightening. The transition to renewable energy and electrification is creating structural demand for fast-response power storage, with UBS forecasting global energy storage demand to grow by approximately 40% year over year in 2026 . Granarium’s renewable energy storage technology is built on a nanocellulose-based material platform that binds biocarbon structures for power storage, enabling up to 80% lower production capital expenditure in safe, scalable, and locally producible systems. “A key structural shift is that storage is no longer just ‘backup power’ – it is becoming core grid infrastructure. Granarium is the perfect addition to our portfolio because the company is solving a massive global challenge in a safe and scalable way. We were also impressed with the company’s technology and experience, as well as the capacity to use local raw materials to make the production process sustainable and inexpensive,” says Jana Budkovskaja, Partner at BSV Ventures. The company has secured pilot customers and key value chain partners and is preparing to launch its first pilots within six months of funding, focusing on process industries and continuously running production operations. Initial commercial production will begin at a small industrial scale, with capacity to deliver up to 50 units per year, forming the basis for rapid scale-up through industrial partnerships and international market expansion. “Our approach supports Europe’s strategic goals of reducing dependency on critical raw materials and building local, resilient energy infrastructure. The new technology offers an easily scalable, self-sufficient solution that removes complex logistics chains and enables simple production using locally sourced materials. Deployment is as simple as installing a battery,” says Granarium CEO Paula Viinamäki. Granarium’s first-of-its-kind technology can upcycle waste materials to create 100% renewable supercapacitors that store electricity. The system acts as a fast-response layer within energy systems, complementing batteries and addressing short-duration power needs such as grid balancing, frequency response, and industrial power quality. The devices help manage peak loads, improve power quality, and manage distributed power generation. “”Granarium demonstrates how successful technology transfer can turn advanced bio-based materials into real industrial solutions for secure and resilient energy storage,” says Atte Virtanen, Vice President, Advanced bio-based materials at VTT. “We are not just improving existing solutions but redefining how power storage can be built and utilized. Compared to lithium-based energy storage devices that utilise finite resources, our devices are far more environmentally sustainable as they derive from local and self-sufficient renewable carbon sources, and lower in cost to produce compared to battery gigafactory investments,” says Otto-Ville Kaukoniemi, CTO at Granarium. Granarium originated from VTT with strong, granted patents and validated technology (TRL5). The team combines expertise in materials science, energy systems, industrial scale-up, and commercialisation. In the future, the innovation will enable new concepts, including the use of the device’s design freedom to replace the passive elements of EVs to increase battery life. For additional information: Media kit with pictures  In the group photo of the Granarium Technologies team: Vesa Kunnari, Paula Viinamäki and Otto-Ville Kaukoniemi.  [Granarium_Vesa-Kunnari_Paula-Viinamaki_Otto-Ville-Kaukoniemi-1.jpg] Granarium Technologies OyPaula Viinamäki, CEO +358 40 708 0513, paula.viinamaki@granariumtech.comwww.granariumtech.com VTT Technical Research Centre of FinlandAtte Virtanen, Vice President+358 50 577 9770, atte.virtanen@vtt.fi Further information on VTT:Paula Bergqvist, Communications Manager+358 20 722 5161, paula.bergqvist@vtt.fiwww.vttresearch.com Granarium Technologies OyGranarium Technologies Oy develops supercapacitors made from renewable materials for fast power stabilization in industrial and energy systems. The company utilizes forest industry side streams and high-consistency nanocellulose to create scalable, low-emission energy storage materials and devices. Granarium Technologies’ technology supports peak power management, power quality, renewable integration, and 24/7 industrial reliability while enabling local, resource-efficient production. For more information, visit www.granariumtech.com 

Saab to divest its Public Safety Solutions operations

Saab Public Safety Solutions is a leading provider of situational awareness for mission critical organisations including police, fire, airport and transport, to enable faster, more informed decision-making and support a more coordinated response. The divestment is in line with Saab’s strategy to increase its focus on core areas of its business and, upon closing, Saab will divest its product unit Public Safety Solutions, including software solutions, customer base, and 75 employees transferring to Omda. “As we strategically prioritize addressing the evolving needs of our defense customers, we anticipate that Public Safety Solutions will find even greater opportunities for growth and success within Omda. This decision is in line with our strategic objectives and aims to provide Public Safety Solutions with the optimal conditions to advance,” says Carl-Johan Bergholm, head of Saab’s business area Surveillance. “Integrating Saab’s advanced Situational Awareness technologies into our Emergency product portfolio strengthens our offering and market position,” says Omda’s CEO Sverre Flatby. “Current and new customers will gain access to a unique, integrated software suite that supports the entire value chain across healthcare, police, and fire services,” Flatby continues.Based in Hull, United Kingdom, and Gothenburg, Sweden, Public Safety Solutions is renowned for its high-quality, accurate products that perform reliably in the most challenging conditions. Saab is a leading defence and security company with an enduring purpose, to help nations keep their people and society safe. Empowered by its 28,000 talented people, Saab constantly pushes the boundaries of technology to create a safer and more sustainable world. Saab designs, manufactures and maintains advanced systems in aeronautics, weapons, command and control, sensors and underwater systems. Saab is headquartered in Sweden. It has major operations all over the world and is part of the domestic defence capability of several nations. Saab AB (publ)SE-581 88 LinköpingSweden 

ALL.SPACE Awards $8.2M Production Order to Sivers Semiconductors for Ka-Band Beamforming ICs

Kista, Sweden –June 9,2026–Sivers Semiconductors  AB (STO:SIVE), a global leader in photonics and wireless technologies,today announcedan $8.2M production order for 2027 from ALL.SPACE , the world's leading multi-orbit satellite communications company, for Sivers’ multi-beam Ka-band beamforming integrated circuits (BFICs). This purchase order underscores Sivers' growing momentum in the defense and commercial satellite communications market, as its BFICs play a critical role as a key enabler of next-generation multi-orbit satellite communications platforms. ALL.SPACE has recently demonstrated strong portfolio and pipeline momentum supporting U.S. Army and U.S. Navy customers, conducting trials with the Royal Canadian Navy, and rapidly adding support for a variety of satellite networks such as Telesat, SES, and Viasat. York Space Systems  (NYSE: YSS) has also entered into a definitive agreement (DA) to acquire ALL.SPACE, further cementing its position in the U.S. defense ecosystem. “This production order represents an important milestone in our partnership with ALL.SPACE as we move from development and initial production to scaled multi-year deployment,” said Vickram Vathulya, CEO of Sivers Semiconductors. “The successful market adoption validates both the differentiated performance of Sivers’ beamforming platform and the importance of ALL.SPACE next-generation terminals for future satellite communications infrastructure.” “Our continued partnership with Sivers Semiconductors has been instrumental in bringing our next-generation multi-orbit communications capabilities to market,” said Paul McCarter, CEO of ALL.SPACE. "This production order reflects the strong performance of the jointly developed Ka-band beamforming technology and supports growing demand from our customers worldwide.” Demand for multi-orbit satellite communications is accelerating as defense organizations and commercial operators increasingly seek resilient, always-on connectivity across LEO, MEO, and GEO satellite networks. As a result, advanced beamforming semiconductors and electronically steered antenna technologies are becoming critical enablers, helping deliver the flexibility, performance, and reliability required to seamlessly operate across multiple orbital constellations. For more information, please visit https://www.sivers-semiconductors.com/.  About Sivers Semiconductors Sivers Semiconductors is a critical enabler of a greener data economy with energy-efficient photonics & wireless solutions. Our differentiated high-precision laser and RF beamformer technologies help our customers in key markets such as AI Datacenters, SATCOM, Defense and Telecom solve essential performance challenges while enabling a much greener footprint. For additional information, please visit us at:www.sivers-semiconductors.com. (SIVE.ST) About All.Space All.Space was founded in 2013 with a vision to provide the solution to the challenges of multi-orbit communications. As the providers of the most advanced platforms for total communications convergence, ALL.SPACE is shaping the very future of defense operations with the world's first fully capable multi-link terminal, which connects seamlessly and simultaneously to all satellite and cellular networks. For more information, please visit: https://www.all.space/. ###

Paratus Energy Services Ltd. – Full redemption of Senior Secured Notes due 2026

Hamilton, Bermuda, June 9, 2026 – Reference is made to the two announcements on May 7, 2026 made by Paratus Energy Services Ltd. (the "Company" or "Paratus") (ticker code: PLSV), available on the Company's website (www.paratus-energy.com) regarding (i) the successful placement of USD 250 million new senior secured bonds (the "2031 Bonds" or "2031 Bond Issue") and (ii) the conditional redemption notification to holders of notes (the "Notes") issued under the amended and restated indenture dated January 20, 2022. The Company is pleased to announce that the proceeds from the 2031 Bond Issue have now been released from escrow and approximately USD 201 million thereof has been used to redeem Notes in full (including accrued and unpaid interest). The residual balance on the escrow account has been released to the Company. For further information, please contact:Baton Haxhimehmedi, CFO and Interim CEOBaton.Haxhimehmedi@paratus-energy.com+47 4063 9083 About ParatusParatus Energy Services Ltd. (ticker: PLSV) is an investment holding company of a group of leading energy services companies. The Paratus Group is primarily comprised of its ownership of Fontis Energy (held for sale) and a 50/50 JV interest in Seagems. Fontis Energy is an offshore drilling company with a fleet of five high-specification jack-up rigs in Mexico. Seagems is a leading subsea services company, with a fleet of six multi-purpose pipe-laying support vessels in Brazil.

Inside information: Sitowise signs an agreement to sell its Swedish subsidiary

Sitowise Group Plc 9 June 2026   Inside Information   8.30 a.m. EEST Sitowise Group Plc has signed an agreement to sell the entire shareholding of its Swedish subsidiary Sitowise Sverige AB (the Sweden business area) to Sweco. The business to be divested, Sitowise Sverige AB, offers technical consulting services in Sweden with a focus on structural engineering and building services for commercial and residential buildings, infrastructure design, and project management. It generated net sales of EUR 26.3 million in 2025, employs about 265 people and was loss-making. The management has decisively executed a restructuring of the Swedish operations, delivering a material operational improvement that ultimately created the conditions for a divestment. The divestment allows Sitowise to focus on the highest impact for solid growth and strengthened profitability. Sitowise’s Swedish subsidiary Sitowise Digital Solutions AB (previously Infracontrol AB) continues to be a part of Sitowise's Digital Solutions business area. The parties have agreed on an enterprise value (EV) of approximately EUR 3.0 million. The parties have also agreed on an earn-out of up to approximately EUR 2.0 million related to long-term lease liabilities, which will be recognized in profit or loss in 2027–2029 if realized. “We are pleased that our Swedish business has attracted interest and we have reached this agreement with Sweco. We are confident that Sweco will be a good new home for our current Swedish experts,” says Jannis Mikkola, acting CEO of Sitowise Group Plc. “The transaction marks a new phase for Sitowise. Our three continuing businesses – Infra, Buildings and Digital Solutions – stand on solid foundations. We will focus on strengthening our competitiveness and market position, leveraging technological transformation, AI and automation to remain at the forefront of the industry. The transaction will improve Sitowise Group’s profitability and cash flows,” Mikkola continues. From here on, the priority is to grow ahead of the market across all three business areas. This will be driven by expansion in Sitowise’s strong client segments and selected growth areas, supported by deploying the best talent across the organization. In the medium term, growth will be complemented by selective M&A. Sitowise continues to move forward as a company built for sustainable growth and long-term value creation. Sitowise will classify the business to be divested as assets held for sale until completion of the transaction and present it as discontinued operations starting from the second quarter interim report of 2026. The assets and liabilities of the divestment are measured at fair value less costs to sell. Any resulting impairment is recognized as part of the result from discontinued operations. Sitowise will, therefore, publish restated Group financial information for 2025 and for January–March 2026 prior to the publication of the second quarter interim report on 12 August 2026. The financial impacts of the transaction are still to be confirmed, but for illustrative purposes, had the transaction taken place in 2025, it would have reduced the Group's net sales by EUR 26.3 million, while clearly improving the Group's adjusted EBITA margin. Sitowise expects to record a sales loss on the remaining book value of its shares in Sitowise Sverige AB in the Group parent company. The completion of the transaction is subject to customary closing conditions and regulatory approvals. The transaction is expected to be completed during the third quarter of 2026.   Further information:Jannis Mikkola, acting CEO, tel. +358 40 747 9670Sanna Sormaala, CFO, tel. +358 50 452 5498Media desk, mediadesk@sitowise.com, tel. +358 400 158 637 Distribution:Nasdaq Helsinki LtdKey mediawww.sitowise.com Sitowise in brief Sitowise is a Nordic expert in technical consulting and digital solutions. Our mission is to engineer the foundation of Nordic resilience. We design infrastructure, buildings and cities that stand the test of time and change. We enhance society’s operational reliability by developing critical infrastructure and ensure the sustainable use of the environment and natural resources. We operate in three business areas that are Infra, Buildings and Digital Solutions. The Group’s net sales in 2025 were EUR 189 million, and the company employs approximately 1,900 experts. Sitowise Group Plc is listed on the Nasdaq Helsinki stock exchange under the trading symbol SITOWS.

Sweco acquires building and infrastructure company in Sweden with approximately 250 experts

Sitowise Sverige AB is a subsidiary of the Finnish engineering and consulting group Sitowise Group Oyj  and delivers consulting services within structural engineering, building service systems, project management and transport infrastructure to the Swedish market, including in the pharma and life science segment. The company reported a turnover of approximately SEK 296 million in 2025. Sweco has 7 600 employees in Sweden and delivered a strong first quarter  in 2026. “I am excited to welcome the experts from Sitowise Sverige AB to join Sweco in Sweden. With this important addition, we strengthen our leading position as a technology advisor in buildings and infrastructure and increase our strong geographical footprint across Sweden. Together with our new colleagues from Sitowise, we will now focus on delivering client value and on continued profitable growth, says Fredrik Wallner, Business Area President for Sweco Sweden.The acquisition will be subject to approval by the Swedish Competition Authority (Konkurrensverket) and the Inspectorate of Strategic Products (ISP). Once that is completed, approximately 250 experts will be integrated into Sweco in Sweden as soon as possible. Press photos: · Sweco Sweden consultants, free use, please credit: Måns Berg · Sweco Sweden's Fredrik Wallner, free use, please credit: Anna W Thorbjörnsson About Sweco’s acquisition agenda This acquisition aligns with Sweco’s acquisition strategy to grow the business by adding key skills that complement Sweco’s 23,000 experts and expands the Group’s market position as Europe’s leading architecture and engineering consultancy. Sweco’s strategy is to grow through a combination of acquisitions and organic growth. The Group has completed close to 170 acquisitions over the past 20 years. In total, Sweco completed 13 acquisitions in 2025, adding approximately SEK 2.1 billion in annual net sales and more than 1,500 experts to Sweco. 

Nimlas Group launches 4-40-4: from SEK 10 to SEK 40 billion – and from the Nordics to Europe

“Nimlas was never built for a SEK 10 billion finish line. Since 2021, we've built the fastest growing and most profitable installations group in the Nordics, in the toughest market conditions in decades. As we now take our operational engine into Germany and Poland, we see it as going from the domestic league to the Champions League: higher ambitions, faster growth and bigger wins,” says Christoffer Järkeborn, CEO of Nimlas Group.  Nimlas was founded to become the most successful company in the technical installations industry. Since its founding, it has gone from a handful of companies to close to 150. From a few hundred professionals to 5,000 – and from SEK 1.5 billion to SEK 10 billion in net sales. Behind the rapid growth is an engine, and the way it works is simple: each local company keeps its brand, its people, and full ownership of results. Nimlas sets the direction and contributes operational expertise, tools, systems and purchasing power.  That engine now powers the next phase. In Sweden, Finland and Norway, Nimlas is pushing to double its size and become the region's largest installations group by 2031 through accelerated acquisitions and continued organic growth.  “The technical installations market in the Nordics is fragmented and there are still many great companies suited to be part of Nimlas Group. With our engine, these companies become even better, which in turn enables us to strengthen our tools for growth and continue our race to be number one in the region," says Christoffer Järkeborn, CEO of Nimlas Group.  Beyond the Nordics, Nimlas is taking its engine into new European markets, starting with Poland and Germany. Poland is one of Europe's fastest-growing economies, with significant investment in infrastructure, digitalisation, defence and building modernisation. Germany is Europe's largest economy and is expected to become Nimlas' biggest market over time. In both markets, Nimlas will build strong local groups through a combination of greenfield investments and acquisitions. 

Ebbot targets next growth phase with strengthened board

From left: Jeanette Jäger, Kristofer Hillhammar, and Tibor Rathonyi. Stockholm, June 9, 2026: Ebbot is strengthening its board with Jeanette Jäger as its new Chair of the Board, alongside Kristofer Hillhammar and Tibor Rathonyi as new board members. The reinforcement comes as the company enters its next growth phase and sees growing demand for secure, concrete, and scalable AI solutions for service organizations. “We are in the middle of a shift where AI is rapidly changing how service organizations work and create value. For Ebbot, this represents a major opportunity. We have built a strong position through our combination of AI expertise, service understanding, and practical implementation, and we are now entering a phase where we can take the next step in how AI is used in service for real. The new board gives us even stronger conditions to scale, develop our position, and take the next step in the market that is now emerging,” says Johan Ekberg, CEO of Ebbot. Jeanette Jäger joins as Chair of the Board and brings extensive experience from leading roles in Nordic business. Her background includes CEO and board assignments in listed, data-driven, and socially critical organizations, with particular experience in innovation, growth, security, resilience, and regulatory complex environments. “What makes Ebbot particularly interesting is the combination of innovative strength, clear customer value, and a platform built to scale with control. The company has the potential to grow rapidly in a market where AI is becoming an increasingly central part of how companies organize and deliver service. My experience from growth, security-critical infrastructure, and heavily regulated environments is fundamentally about building organizations that can scale long-term, responsibly, and with customers’ trust. I look forward to contributing to Ebbot’s continued growth together with the board, management, and team,” says Jeanette Jäger, Chair of the Board at Ebbot. Kristofer Hillhammar brings experience from SaaS, product strategy, technology leadership, and profitable growth. He has held senior roles in product and technology at fast-growing software companies and has experience as an investor and board member in entrepreneur-led growth companies. He also has a previous connection to Ebbot through Dialogtrail, where he was an early investor and board member before the company was acquired by Ebbot. “Ebbot has a strong foundation to build on in a market where AI is rapidly moving from experimentation to business-critical infrastructure. The next phase is about continuing to develop the company’s technology, product, and business with a focus on scalability, customer value, and profitable growth. I look forward to contributing my experience from product, technology, and company building to that development,” says Kristofer Hillhammar, board member at Ebbot. Tibor Rathonyi brings extensive experience from entrepreneurship, telecom, software, and advanced analytics. As founder and CEO, he has built a data-driven technology company from idea to international establishment and a successful acquisition by a global player. His background is particularly relevant in markets where large volumes of data, complex infrastructure, and high operational reliability are central. “Ebbot operates in a market where reliability, data-driven ways of working, and the ability to handle complex environments are becoming increasingly important. My experience is that strong technology only creates real value when it works at scale, in everyday operations, and in critical flows. That gives Ebbot a very interesting position to build from,” says Tibor Rathonyi, board member at Ebbot. About Ebbot Ebbot is an AI platform that enables organizations to automate and scale support and service processes reliably with the help of AI. The platform works as an independent AI engine on top of existing systems and helps organizations deploy AI agents across multiple channels and workflows. Today, Ebbot’s platform is used by organizations in more than 20 countries to improve efficiency, service quality, and operational insight. Press contact:Axel Hellström, CMO+46705454101axel@ebbot.ai

Nokian Tyres plc: Shareholders' Nomination Board 2026-2027

Nokian Tyres plcStock Exchange Release June 9, 2026 at 9:00 a.m. EEST The following members have been appointed to Nokian Tyres’ Shareholders' Nomination Board: · Mr. Petter Söderström (Chief Financial Officer, Solidium Oy), appointed by Solidium Oy (10.1% of shares and votes) · Mr. Timo Sallinen (Director, Head of Listed Securities, Varma Mutual Pension Insurance Company), appointed by Varma Mutual Pension Insurance Company (4.84% of shares and votes) · Mr. Mikko Mursula (President and CEO, Ilmarinen Mutual Pension Insurance Company), appointed by Ilmarinen Mutual Pension Insurance Company (3.2% of shares and votes) · Ms. Marie Karlsson (Head of Nordic, Finnish and Swedish Equities at Nordea Asset Management) appointed by Nordea funds (2.97% of shares and votes) · Mr. Jouko Pölönen, Chair of the Board of Directors, Nokian Tyres plc Shareholders’ Nomination Board prepares proposals for the Annual General Meeting concerning the election and remuneration of the Board of Directors. The proposals will be submitted to Nokian Tyres' Board of Directors latest on January 31, 2027. Shareholders’ Nomination Board consists of four members representing the company’s largest shareholders the Chair of the Board of Directors and. The composition of the Shareholders’ Nomination Board was determined based on the holdings registered on June 1, 2026 in the shareholders’ register maintained by Euroclear Finland Ltd. and the information received. Further information:Elisa Erkkilä, General Counsel, SVP Legal & ComplianceTel. +358 10401 7050ir@nokiantyres.com Nokian Tyres' purpose is to make the world safer by reinventing tires, and how they are made, over and over again - a safer place to drive, work and live now and for generations to come. Inspired by our northern heritage, we develop and manufacture premium tires for passenger cars, trucks and heavy machinery with sustainability at the heart of all our operations. Our Vianor chain provides tire and car services. We are some 4,000 people with net sales of EUR 1.4 billion in 2025, and together we lead the journey to smarter driving for people and for businesses. Nokian Tyres is listed on Nasdaq Helsinki.Further information:company.nokiantyres.com,www.nokiantyres.com

Four leading Canadian healthcare providers unite on Sectra’s cloud solution to enhance city-wide radiology collaboration and patient care

"With Sectra One Cloud, our regional teams gain faster and more reliable access to images whenever and wherever they are needed. Its high availability will make a real difference in our ability to provide timely, world-class care," says Dr. John Donnellan, Chief, Diagnostic Services, Hamilton Health Sciences. The hospitals are located in southwestern Ontario and serve a population of over 2 million citizens. Previously, they used two separate radiology solutions. Following this transition, all imaging will be consolidated into a single, unified cloud instance, enabling these organizations to deliver high-quality patient care more efficiently and collaboratively. "Sharing a common cloud-based imaging system allows for enhanced collaboration across St. Joe's and partner hospitals. It improves clinician access to real-time imaging information which is invaluable when making critical decisions. Sectra's advanced system supports better continuity of care and an improved experience for both patients and care teams," says Rick Badzioch, Vice President, Renal, Ambulatory Services and Clinical Support Programs, St. Joseph's Healthcare Hamilton. As Sectra manages the operations, monitoring, optimization, and continuous upgrades of the cloud service, it will ease the pressure on the hospitals' IT teams. The solution also strengthens security around system operations and patient privacy, and provides the scalability required for growing imaging volumes or new imaging specialties. “Implementing Sectra One Cloud marks an important step forward for our organizations. It enables our teams at Norfolk General Hospital and West Haldimand General Hospital to access diagnostic images seamlessly and collaborate more effectively with regional partners. By moving to a unified, cloud-based solution, we are strengthening our ability to provide timely, high-quality care to the communities we serve, both now and into the future,” says Erin McNeice, Integrated Director of Diagnostic Services, West Haldimand General Hospital and Norfolk General Hospital. The five-year Sectra One Cloud contract was signed in the fourth quarter of Sectra's 2025/2026 fiscal year, and the healthcare providers will primarily utilize the modules for radiology and breast imaging. The agreement represents an estimated volume of more than 3.6 million imaging exams over the five years. "Moving to a unified, cloud-based imaging solution is not just a technology shift, it is a strategic move that empowers care teams to work smarter and closer together. It lays the groundwork for scalable, data-driven diagnostics that can evolve with future healthcare needs. We are proud to support them on this journey toward more coordinated care across the region," says Nader Soltani, President of Sectra in Canada. Sectra One Cloud is a fully managed service for enterprise imaging that enables Sectra to continuously monitor, optimize, and upgrade the solution, as well as provide 24/7 support. The enterprise imaging solution provides a unified strategy for all imaging needs in a single system, thereby improving outcomes and reducing operational costs. The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from one ology to another and from one enterprise to another without acquiring a new back end. Visit Sectra's website to read more about Sectra and why it's top-ranked in "Best in KLAS" .

Extraordinary places to stay in Bremen: City adventures including a house boat, the harbour and a nature reserve

Staying on the water: from a houseboat to a historic hotel ship The houseboats and hotel ships along the Weser are a perfect invitation to get to know Bremen from a different perspective. On the strip of land between Neustädter Hafen and the Weser, the Hausboote am Lankenauer Höft  offer a relaxed break in a luxury holiday home, just a stone’s throw from restaurants and the beach. There is also some very special floating accommodation in the historic city centre. The traditional green-sailed ‘Alexander von Humboldt ’ on the famous Schlachte-Ufer is a chance to experience the maritime history of Bremen close up. The cosy cabins on the hotel ship are the perfect retreat for all those looking for a special alternative to a traditional hotel room. Innovative concept hotels reflect Bremen’s creative side At the same time, Bremen is showing off its creative side with concepts that reinterpret the character of converted marine and industrial spaces. In a novel twist, the HafenTraum IndoorHostelCamp  brings camping inside in the dry: indoor tiny houses and vintage caravans combine urban design with a feeling of adventure. Accommodation like Camp 28  also feeds the desire for freedom. The unspoilt lakeside campsite on the Stadtwaldsee is well connected to the city centre via cycle routes and public transport, so a relaxed camping holiday in the countryside can be combined with a city break. The Land of Green  is also evidence of how well sustainability and eco-conscious tourism can be combined with modern comfort and experiences on a trip to Bremen. To the south of the artists’ community of Worpswede, travellers can stay in unspoilt tiny houses or tree-houses, and enjoy the Teufelsmoor nature conservation area at any time of year. The forest resort also offers a range of wellness amenities and foodie treats. Perfect combination of countryside and city break The variety of accommodation makes Bremen ideal for all kinds of breaks, from a spontaneous weekend trip to a longer holiday with the family. With short connections and an excellent network of cycle paths and public transport, countryside bases also make the perfect starting point for exploring the city. The different accommodation options  in Bremen and the surrounding area reflect the maritime, creative, natural and relaxed character of the city. This is what makes it such a charming destination for those seeking a city full of atmosphere and charm.

Scania launches modular protected cab and showcases hybrid defence capabilities at Eurosatory

At Eurosatory in Paris, Scania will demonstrate how its modular system, broad powertrain portfolio and global support network can help defence customers meet operational requirements, in peace, crisis or conflict. With the message “Designed to perform, built to deliver”, Scania will showcase protected mobility, battlefield power, modular logistics solutions, Power Solutions and Integrated Logistic Support. Scania’s display at Eurosatory includes: Indoor display Hall 6 – J244 · Heavy equipment tractor with CrewCab, 8x4/4 · Power Solutions display including next-generation 13-litre inline engine, 16-litre V8 engine and e-machine for hybrid or fully electric propulsion  · Integrated Logistic Support experience table, presenting Scania’s defence service portfolio Outdoor display ExtPe6a – D194 · Scania protected cab / modular protected cab concept · 4x4 vehicle with air defence system · 4x4 hybrid vehicle with military equipment powering capabilities · Multi-role 8x8 logistics truck Press activities · Press event at 09:30 on Tuesday 16 June · Handover of hybrid vehicle at 11:00 on Tuesday 16 June “Defence customers need solutions that perform in demanding operations and continue to deliver over time. At Eurosatory, we are showing how Scania’s modular system, powertrain expertise and global support capability come together to support operational availability, flexibility and resilience,” says Stefano Fedel, Head of Commercial, Scania. Since 1967, Eurosatory has established itself as a benchmark global trade show for Defence and Security, bringing together key players from across the international ecosystem. For Scania, the event is a platform to show how proven commercial technology, modularity and support can be adapted to meet defence requirements.One of Scania’s key launches at Eurosatory is the new modular protected cab, developed to combine crew protection, mobility and operational performance in demanding defence environments. The modular protected cab represents a new step in Scania’s defence offering and demonstrates how the company adapts its proven modular vehicle platform to meet evolving operational requirements.The protected cab is developed for demanding defence operations where crew protection, mobility, ergonomics and operational availability are critical. The solution combines protection with visibility, driver control and performance in challenging terrain, harsh weather and around-the-clock operations. A central part of this year’s display is Scania’s hybrid truck, which adds a new dimension to operational flexibility and battlefield power capability. The hybrid solution demonstrates how electrified capability can support both mobility and local power supply in the field.The vehicle can provide silent power generation for external equipment, reducing the need for conventional diesel generators while supporting operational flexibility in environments where infrastructure is limited or unavailable. “Hybrid technology can bring important operational benefits in defence applications. It can enable silent operation, reduce the need for idling and support battlefield power capability for external systems in the field,” says Sara Forsberg, CTO and Head of Scania R&D.The hybrid vehicle is connected to a research project and will be part of a formal handover ceremony during Eurosatory. For defence customers, performance is measured throughout the lifecycle of the system. Scania’s Integrated Logistic Support is designed to secure operational availability, reduce lifecycle costs and provide products and services across the entire lifecycle. This includes supply support, technical documentation, training, support and test equipment, technical support, repair and maintenance services, obsolescence management and configuration management. At Eurosatory, visitors can explore Scania’s ILS defence service portfolio at the Integrated Logistic Support experience table. “We combine robust products with a global support structure. For defence customers, that means not only receiving the right vehicle, but having the service, parts, training and technical support needed to keep it operational over time. Scania is the preferred partner for many defence organisations across the globe, as we have delivered more than 10,000 of trucks and engines for generations, including the needed support functions,” says Fedel. Scania welcomes media representatives to its Eurosatory press event at 09:30 on Tuesday 16 June at Hall 6 J244 where the company will present its defence offering and key news, including the protected cab. At 11:00 on Tuesday 16 June, Scania will host the handover of the hybrid vehicle at Hall 6 J244 The handover will highlight the vehicle’s battlefield power capability and its role in a research project exploring how hybrid solutions can support military operations. Scania will be present at Hall 6 J244 and ExtPe6a D194 throughout Eurosatory. Learn more about Scania’s defence solutions .

Valmet’s solution boosts Gren Tartu’s district heating capacity in Estonia with flue gas heat recovery

Valmet has received an order from Gren Tartu for the delivery of a flue gas condenser and heat pumps to the Tartu biomass heat and power plant in Estonia. The solution will increase the amount of heat supplied to the local district heating network. The new equipment recovers heat from the plant’s flue gas and upgrades it with heat pumps for district heating use. The solution will add more than 10 MW of additional heat supply to the district heating network. This enables the production of more district heat, using less fuel and reducing emissions. “To satisfy the needs of our customers, increasing our heat production capacity is a key priority for us, and environmentally sustainable solutions that utilize waste heat are the most effective way to achieve the increase. We have had a long and successful cooperation with Valmet, and their experience and expertise make them a reliable partner to support us on this journey,” says Margus Raud, Head of Technical Development, Gren Tartu. “This project is a good example of how flue gas heat recovery and heat pumps can significantly improve energy efficiency of a plant and strengthen the security of heat supply. We are pleased to support Gren Tartu with an engineered solution that captures low‑temperature heat and upgrades it for district heating use,” says Lari‑Matti Kuvaja, Director, Environmental Solutions, Valmet. The order is included in Valmet’s orders received for the second quarter of 2026. The value of the order will not be disclosed. Valmet’s efficient flue gas heat recovery solution boosts Gren Tartu’s district heating capacity in Estonia. (Photo Gren Tartu) Improved plant efficiency and reduced fuel consumption The delivery consists of a flue gas condenser and heat pumps  for improved heat recovery at Gren Tartu’s CHP plant in Tartu, Estonia. The solution enables efficient recovery of low‑temperature heat from flue gases and upgrades it to a temperature level suitable for district heating. This improves overall plant efficiency, reduces fuel consumption, and supports lower emissions. About the customer Gren and Gren Tartu Gren is a leading Northern European energy solutions infrastructure company providing district heating and cooling, renewable energy solutions, and industrial energy services. Gren operates in the Baltics and the UK with 1,500 MW of production capacity and 3.0 TWh of annual energy sales. More than 95 percent of the energy is produced from renewable and recovered fuels. In Estonia, the company focuses on developing sustainable energy solutions that meet local community needs. Gren Tartu supplies clean, reliable and comfortable district heating to offices, public buildings, industrial businesses, hospitals, housing associations, and individual homes. Additionally, the company offers district cooling mainly to business customers. VALMET Corporate Communications For further information, please contact: Lari-Matti Kuvaja, Director, Environmental Systems, Pulp, Energy and Circularity, Valmet, tel.+358 40525 6674 Jonas Wallén, Senior Sales Manager, Projects, Energy and Circularity, Valmet, tel. +358 50385 1818 Valmet has a global customer base across various process industries. We are a leading global developer and supplier of process technologies, automation, and services for the pulp, paper, and energy industries. With our automation and flow control solutions, we serve an even broader base of process industries. Our more than 19,000 professionals worldwide work close to our customers and are committed to moving our customers’ performance forward – every day. The company has over 225 years of industrial history and a strong track record in continuous improvement, sustainability, and renewal. Valmet’s net sales in 2024 were approximately EUR 5.4 billion. Valmet’s shares are listed on the Nasdaq Helsinki, and the head office is in Espoo, Finland. Follow us on valmet.com  | X  | X (IR)  | LinkedIn  | Facebook  | YouTube  | Instagram  | Processing of personal data 

New smart air valve integrates operational reliability and hygiene in drinking water networks

As demands for operational safety and drinking water quality in modern drinking water networks continue to rise, the role of traditional valves is undergoing a fundamental shift. Today, addressing individual functions in isolation is no longer sufficient. What is required are integrated solutions that combine hygiene safety and network monitoring into a single, holistic approach. To meet this need, the VAG DUOJET® @ON Smart Air Valve was developed and introduced as a production-ready solution at the IFAT trade fair in Munich in May 2026. It marks the next step in the evolution of a proven valve into an enhanced system component. The core approach is to combine hygiene protection and network monitoring in a single valve. The traditional venting and air-release function is combined with an automated, hygienically effective flushing strategy. This ensures that areas within the drinking water system that are prone to stagnation are regularly flushed, thereby maintaining drinking water quality at a defined level at all times. The flushing function is designed to run automatically at user-defined intervals – for example, every three months – and can be adapted to the specific system conditions. This helps ensure compliance with the hygiene requirements of DVGW W392-2 without requiring on-site service personnel to intervene. The manual flushing cycles that were previously required are no longer necessary. The process is repeatable and significantly reduces operational effort for work assignments. Timo Bugert, Product Manager for Global Engineering at VAG, explains from a technical perspective: “The automatic flushing system integrates seamlessly into the system and offers not only hygienic benefits but also advantages in terms of maintenance and network operation. This integration establishes a reliable foundation for consistently reliable hygiene safety throughout the entire network.” In addition to its integrated flushing function, the valve fulfills its core purpose as a single-chamber high-performance valve for the controlled venting and filling of piping systems. It combines three essential functions: venting during discharge, air release during filling, and continuous operational venting. The design enables the stable and efficient removal of both large volumes of air during dynamic operating phases and small amounts of air during continuous operation – even at air velocities approaching the speed of sound. In addition, the smart valve enables continuous monitoring of relevant operating conditions. The integrated sensors and system controls measure pressure conditions and valve positions. This data is not collected in isolation but rather enables a reliable assessment of the system’s condition. Upon request, operators receive both regular status updates and real-time alerts in the event of deviations from normal operation. The information gathered enables continuous monitoring of the condition of the pipelines and the manhole infrastructure. Pressure deviations, unusual operating conditions, or unauthorized access to the valve or the installation shaft can be detected early and transmitted to the network operator as status or warning messages. This advancement allows early detection of potential incidents, such as pipe breaks or critical operating conditions. The valve thus assumes a significantly enhanced role within the supply network. Security is also a top priority when it comes to data transmission. Communication is unidirectional and encrypted. Only status and warning messages are transmitted from the field to the operator; external access to the valve is prevented. This ensures a high level of IT security. The combination of a low-maintenance design – with operating periods designed for a minimum of three years without requiring on-site service – and integrated data capabilities supports compliance with the requirements of DVGW W392-2 and enables seamless integration into existing and future network structures. At the same time, it lays the groundwork for advanced applications such as condition-based maintenance or higher-level network analyses. This approach demonstrates that the future of water supply does not depend on the isolated digitization of individual components, but rather on the intelligent integration of function and information. Only when the valve itself becomes an active information carrier does measurable added value emerge – both in technical and economic terms. In this way, the valve becomes an integral part of a resilient and sustainable water supply network. To learn more about the VAG DUOJET® @ON Smart Air Valve and how it can enhance hygiene safety and operational efficiency in your network, visit vag-group.com  or contact our experts for a personalized consultation.

Norse Atlantic Airways appoints Frans Leenaars as Chief Commercial Officer

Arendal, Norway, 9 June – Norse Atlantic Airways today announced the appointment of Frans Leenaars as Chief Commercial Officer (CCO), effective immediately. Frans joins Norse with more than two decades of international leadership experience across aviation, travel and customer-focused businesses. Throughout his career, he has held senior commercial positions within Air France-KLM and Disney Parks & Resorts, as well as a range of executive leadership roles at TUI Group, one of the world's leading travel companies. As CCO, he will be responsible for leading Norse's global commercial strategy and technology developments, including continued network development, partnerships, customer experience, revenue management, sales, marketing and IT. "Frans brings a unique combination of aviation expertise, commercial leadership and customer-centric thinking," said Eivind Roald, Chief Executive Officer of Norse Atlantic Airways. "His extensive experience from both airlines and the broader travel industry will be highly valuable as we continue to evolve our commercial platform, strengthen strategic partnerships and optimize the deployment of our fleet across scheduled, charter and ACMI operations. Frans will play an important role in further enhancing the customer experience while supporting Norse's focus on profitability and value creation as an airline on demand." Commenting on his appointment, Frans Leenaars said: "Norse has established itself as a modern and innovative airline. I am impressed by what the team has accomplished in a relatively short period of time and look forward to working alongside colleagues across the company to further strengthen our commercial proposition, expand partnerships and deliver value to customers and owners". The appointment comes as Norse continues to build on its commercial and operational progress, supported by a balanced business model, a growing customer base and a strengthened financial foundation. Investor contact: Anders Hall Jomaas, CFO anders.jomaas@flynorse.com  About Norse Atlantic ASA Norse Atlantic Airways is an airline committed to offering affordable fares on direct, long-haul flights to popular destinations, along with specialized charter and ACMI services for tailored travel needs and extensive cargo operations. Norse Atlantic operates a modern fleet of 12 fuel-efficient Boeing 787 Dreamliners, serving a network of destinations across North America, Europe, Africa and Asia

New SAS–Aerolíneas Argentinas codeshare expands travel options

Under the agreement, Aerolíneas Argentinas will place its AR code on SAS‑operated flights between Madrid and Rome and the Scandinavian capitals of Copenhagen, Stockholm and Oslo. In turn, SAS will place its SK code on Aerolíneas Argentinas’ transatlantic services between Buenos Aires, Madrid and Rome, giving travelers in Northern Europe new one‑stop access to Argentina. The cooperation also enables unique long‑range itineraries across the SkyTeam network — including the possibility to travel from the world’s southernmost commercial airport in Ushuaia to the northernmost in Longyearbyen on a single, integrated journey. “This partnership marks an exciting step forward for SAS as we continue strengthening our global reach together with trusted SkyTeam partners. Aerolíneas Argentinas is a natural fit for us, and by linking our networks we are opening new and genuinely compelling opportunities for customers travelling between Scandinavia and South America. This cooperation not only creates smoother journeys and stronger connectivity — it also brings two regions with deep cultural and economic ties closer together. We are thrilled to offer our passengers an even broader world of destinations and look forward to welcoming more travelers onboard across our joint network,” said Paul Verhagen, Executive Vice President & Chief Commercial Officer, SAS. The agreement allows passengers to travel on a single ticket, complete one check‑in process and check baggage through to their final destination, significantly improving the travel experience and expanding connection options between Scandinavia and Argentina. "This agreement allows us to continue expanding our international connectivity network and offer our passengers new travel alternatives to Northern Europe through a strategic partner such as SAS,” said Fabián Lombardo, President of Aerolíneas Argentinas. As SkyTeam members, both airlines will also offer eligible customers access to SkyPriority services, while members of EuroBonus and Aerolíneas Plus will be able to earn and redeem points across the combined network. Implementation of the codeshare agreement is planned for the third quarter of 2026, subject to regulatory approvals.

Bittium puts unmanned systems on the tactical network

Bittium CorporationPress Release Bittium puts unmanned systems on the tactical network Bittium Corporation press release on 9 June 2026, at 3.00 pm (CEST +1) Purpose built radio module brings unmanned land, air and sea systems into a single, jam resistant IP network, giving defence forces real-time command, control and situational awareness across contested environments. Bittium Corporation today launched Bittium Tough SDR Unmanned™, a dedicated radio solution that integrates unmanned land, air and sea systems directly into a resilient tactical communications network. For the first time, drones, unmanned ground vehicles and other autonomous platforms can operate not just as remote tools but as active, connected nodes within the same battlefield IP network used by soldiers and commanders. It is also fully European sovereign solution. The operational significance is substantial. Unmanned systems are now central to modern military operations for reconnaissance, logistics, force protection and strike support. Yet their communications have often been their weakest point: dependent on fragile point-to-point links, vulnerable to jamming and disconnected from the broader tactical network. Bittium Tough SDR Unmanned™ eliminates that vulnerability as it integrates unmanned systems into the common operational picture. This allows the commander to view drone sensor feeds within the same situational awareness display as the positions of infantry units. A networked command chain from the air to the ground Bittium Tough SDR Unmanned™ enables remote command and control, real-time sensor data transmission and the use of unmanned platforms as relay nodes extending connectivity between dispersed units. In complex terrain or electronically contested environments where line-of-sight communications fail, unmanned systems equipped with Bittium Tough SDR Unmanned™ can bridge gaps in the network automatically, keeping the force connected when it matters most. The solution is built on advanced MANET routing technology, forming a self-organising and self-healing network that does not rely on any single node. If one link is lost or jammed, the network reroutes. Communications remain uninterrupted across combat arms and service branches, and the force remains unified. Military grade performance built for contested airspace and ground operations Bittium Tough SDR Unmanned™ is a compact radio module designed for integration into unmanned platforms. It delivers the same performance as Bittium's Tough SDR Handheld™ radios, is compatible with all Bittium offered waveforms, and operates across a wide frequency range, including low frequencies specifically suited to long-range remote control of unmanned platforms operating beyond visual line of sight. The solution is engineered for jam resistance and mission-critical reliability in high-threat environments where electronic warfare is a constant operational factor, not an edge case. "Unmanned systems are playing an increasingly critical role in modern military operations. Bittium Tough SDR Unmanned™ brings them into the same resilient network and enables reliable communications even under electronic warfare conditions. The solution supports our objective of a unified, IP-based network that enables seamless information exchange across different domains," says Tommi Kangas, Senior Vice President of Bittium's Defence and Security Business Segment. Bittium at Eurosatory 2026 at Bittium's stand G146, Hall 6. For more information, visit: https://www.bittium.com/defence-security/bittium-tough-sdr-unmanned  Further information: Tommi KangasSenior Vice President, Bittium Defence & SecurityTel. +358 40 344 2789 (group communications)Email: defence(a)bittium.com Distribution:Main media Bittium Defence & Security As a trusted supplier in the Defence & Security market with 40 years of experience in advanced radio communication technologies, we provide next-generation resilient and mobile tactical communications systems for defence forces and secure communication solutions for governments and authorities. Our products and systems for tactical communications bring broadband data and voice seamlessly to all troops across multi-domain operations. The offering is completed by mobile devices and cyber security solutions certified up to CONFIDENTIAL and NATO Restricted levels. In addition to the products and systems supplied to the Defence & Security market, Bittium offers solutions focused on measuring and processing of biosignals as well as R&D services and wireless embedded solutions. Bittium’s net sales in 2025 were EUR 119.3 million and operating profit EUR 19.4 million. Bittium is listed on Nasdaq Helsinki. www.bittium.com Follow us on social mediaLinkedIn  X  Instagram  Facebook  YouTube 

Borr Drilling Limited – Early Tender Results for its Previously Announced Consent Solicitation and Tender Offer and Early Settlement Date

Hamilton, Bermuda, June 9, 2026 – Borr Drilling Limited (NYSE and OSE: BORR) (“Borr Drilling” or the “Company”) today announced the early tender results, as of 5:00 p.m., New York City time, on June 8, 2026 (the “Early Tender/Consent Deadline”), in respect of the previously announced offer by Borr IHC Limited, its wholly-owned subsidiary (the “Issuer”), to purchase for cash (the “Tender Offer”) (i) any and all of its outstanding 10.000% Senior Secured Notes due 2028 (the “2028 Notes”) and (ii) any and all of its outstanding 10.375% Senior Secured Notes Due 2030 (the “2030 Notes” and, together with the 2028 Notes, the “Notes”), and the related solicitation of consents (the “Consent Solicitation”) from Holders to vote in favor of certain proposed amendments (the “Proposed Amendments”) to the indenture dated November 7, 2023 (as amended or supplemented from time to time, the “Existing Indenture”), in each case pursuant to the terms and subject to the conditions set forth in the offer to purchase and consent solicitation statement dated May 26, 2026 (as amended or supplemented from time to time, the “Statement”). Capitalized terms used in this release but not otherwise defined have the meaning given in the Statement. On May 27, 2026, the Issuer priced an offering of $1,100,000,000 8.750% Senior Secured Notes due 2032 and $935,000,000 9.000% Senior Secured Notes due 2034 (together, the “New Notes Offering”) in connection with satisfaction of the Financing Condition. The closing of the New Notes Offering is expected to occur on June 10, 2026 and is subject to customary closing conditions. Early Tender ResultsThe Withdrawal/Revocation Time and the Early Tender/Consent Deadline passed at 5:00 p.m., New York City time, on June 8, 2026. The following table sets forth certain information regarding the Notes and the Tender Offer, including the aggregate principal amount of Notes (and related Consents) that were validly tendered and not validly withdrawn as of the Early Tender Time according to Global Bondholder Services Corporation, the Tender Agent and Information Agent for the Tender Offer: []Notes CUSIP / ISIN Original Outstanding Aggregate Numbers Principal Amount Principal Amount Original Issued Principal Amount Tendered [(1)]10.000% Rule 144A: 100018 AA8 $1,380,696,000.00 $1,128,129,659.88 $1,324,402,000Senior /US100018AA89RegulationSecured Notes S: G1467F AA1 Due / USG1467FAA15 202810.375% Rule 144A: 100018 AB6 $877,094,000.00 $770,650,554.20 $794,306,000Senior / US100018AB62Secured Regulation S: G1467F Notes AB9 / Due USG1467FAB97 2030 1. 1. As of May 22, 2026. For the 2030 Notes, this reflects the initial aggregate original principal amount of 2030 Notes adjusted to reflect amortization in respect thereof. For the 2028 Notes, this reflects the initial aggregate original principal amount of 2028 Notes adjusted to reflect amortization in respect thereof. The Company has received valid and unrevoked tenders (and related Consents) of Notes representing 95.92% of the aggregate original principal amount of the 2028 Notes outstanding and 90.56% of the aggregate original principal amount of the 2030 Notes outstanding, representing 93.84% of the aggregate original principal amount of the Notes outstanding. Holders can no longer validly withdraw tenders of Notes (and revoke related delivered Consents) as the Withdrawal/Revocation Time has passed. In addition, pursuant to the terms of the Existing Indenture, as Holders of more than 90% of the aggregate original principal amount of the outstanding 2028 Notes and Holders of more than 90% of the aggregate original principal amount of the outstanding 2030 Notes have validly tendered and not withdrawn Notes in the Tender Offer, the Issuer intends to redeem all remaining Notes of each such series that remain outstanding (after giving effect to the purchase of tendered Notes on the Early Settlement Date) at a redemption price equal to the price offered to each tendering Holder (excluding any early tender or incentive fee) plus, to the extent not included in the payment to tendering Holders, accrued and unpaid interest, if any, to, but excluding, the date of such redemption. The Issuer intends to issue a notice of redemption promptly on or after the Early Settlement Date with an anticipated redemption date of such remaining Notes on or promptly after the Final Settlement Date. However, there can be no assurance that any Notes will be so redeemed. Nothing contained herein shall constitute a notice of redemption for the Notes. Because the Company received consents of Holders representing 93.84% of the outstanding aggregate principal amount of the Notes, such Notes having been validly tendered (and not validly withdrawn), on June 8, 2026, the Issuer and BNY Mellon Corporate Trustee Services Limited, as trustee, and Wilmington Trust (London) Limited, as security agent, among others, executed supplemental indentures to the Existing Indenture (the “Supplemental Indentures”), which implement the Increased Offer Proposed Amendments. The Increased Offer Proposed Amendments will (i) remove substantially all of the covenants and other obligations under the Indenture that can be removed with the consent of Holders of a majority of the aggregate principal amount of the Notes then outstanding and (ii) release all Liens in the Collateral securing the Notes and disapply certain covenants relating to the Collateral. The Supplemental Indentures will only become operative upon the Early Settlement Date (as defined below) if the relevant settlement conditions (as described under the caption “Conditions to Consummation of the Tender Offer and the Consent Solicitation” contained in the Statement) are satisfied or waived. On the Early Settlement Date (as defined below), Holders who validly tendered their Notes (and related Consents) before the Early Tender/Consent Deadline are eligible to receive: i. for each $1,000 original principal amount of the 2028 Notes, an amount determined in the manner described in the Statement by reference to the Fixed Spread for the 2028 Notes specified on the front cover of the Statement over the applicable Reference Yield based on the bid-side price of the applicable Reference Security specified on the front cover of the Statement, andii. for each $1,000 original principal amount of the 2030 Notes, $1,060.00. Holders may continue to tender their Notes (and thereby deliver Consents) until 5:00 p.m., New York City time, on June 24, 2026, in respect of the Tender Offer and Consent Solicitation, unless extended or earlier terminated by the Issuer in its sole discretion, subject to applicable law (the “Expiration Time”). Holders who validly tender their Notes (and related Consents) after the Early Tender/Consent Deadline but at or prior to the Expiration Time will not be eligible to receive the Total Consideration, but will be eligible to receive the Tender Offer Consideration on the Final Settlement Date (as defined in the Statement). The Tender Offer Consideration or the Total Consideration, as applicable, will be multiplied by the applicable Factor (as defined in the Statement), which reflects the partial amortization of the Notes. Holders whose Notes are accepted for purchase pursuant to the Tender Offer will also receive accrued and unpaid interest, multiplied by the applicable Factor from the last interest payment date on such purchased Notes up to, but not including, the applicable Settlement Date. Important Dates and TimesPursuant to the terms and conditions of the Statement, the Issuer has elected to settle on June 10, 2026 the Notes tendered at or prior to the Early Tender/Consent Deadline (the “Early Settlement Date”). The final settlement date will occur promptly following the Expiration Time and is expected to be the second business day after the date on which the Expiration Time occurs (the “Final Settlement Date”). The Issuer reserves the right in its sole discretion, subject to applicable law, to (i) waive prior to the Expiration Time any and all conditions to the Tender Offer; (ii) extend the Expiration Time; (iii) amend the terms of the Tender Offer and Consent Solicitation in any respect; or (iv) terminate, withdraw or otherwise decide not to proceed with the Tender Offer and Consent Solicitation at any time prior to or at the Expiration Time and not accept for purchase or payment any Notes not theretofore accepted for purchase or payment. The Issuer’s obligations to accept for purchase and pay for Notes pursuant to the Tender Offer and the Consent Solicitation is subject to the satisfaction of, or where applicable, the Issuer’s waiver of, the conditions set forth under “Conditions to Consummation of the Tender Offer and the Consent Solicitation,” including the Financing Condition, the Supplemental Indenture Condition, and the General Conditions as described in the Statement. Information Relating to the Tender Offer and the Consent SolicitationThe Company has engaged Citigroup Global Markets Inc is acting as the dealer manager and solicitation agent for the Tender Offer and the Consent Solicitation (“Dealer Manager and Solicitation Agent”). Questions regarding the terms of the Tender Offers and Consent Solicitations may be directed to Citigroup Global Markets Inc. at +1 (212) 723-6106 (banks and brokers) or +1 (800) 558-3745 (toll-free) or via email at ny.liabilitymanagement@citi.com. Global Bondholder Services Corporation is acting as (i) the Information Agent for the Tender Offer and the Consent Solicitation, (ii) the Tender Agent for the Tender Offer and (iii) the Tabulation Agent for the Consent Solicitation. Requests for copies of the Statement should be directed to Global bondholder Services Corporation at +1 (212) 430- 3774 (banks and brokers) or +1 (855) 654-2014 (toll-free) or via email at contact@gbsc-usa.com. This press release is for information purposes only and does not constitute or form part of an offer to sell or the solicitation of an offer to purchase or subscribe for securities, nor will there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities referred to herein have not been and will not be registered under the Securities Act of 1933 or applicable state securities laws, and may not be offered or sold in the United States or to U.S. persons (other than distributors) unless such securities are registered under the Securities Act of 1933, or an exemption from the registration requirements of that act is available. About Borr Drilling LimitedBorr Drilling Limited is an international drilling contractor incorporated in Bermuda in 2016 and listed on the New York Stock Exchange since July 31, 2019 and on Euronext Oslo Børs since May 21, 2026 under the ticker “BORR.” The Company owns and operates jack-up rigs of modern and high specification designs and provides services focused on the shallow-water segment to the offshore oil and gas industry worldwide. Please visit our website at www.borrdrilling.com. Forward-Looking StatementsThis press release and related discussions include forward-looking statements made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements do not reflect historical facts and may be identified by words such as “anticipate”, “believe”, “continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will”, “ensure”, “likely”, “aim”, “plan”, “guidance” and similar expressions and include statements regarding the Tender Offer and Consent Solicitation, including expected Early Settlement Date, the Financing Transaction and other non-historical statements. Such forward-looking statements are subject to risks, uncertainties, contingencies and other factors that could cause actual events to differ materially from the expectations expressed or implied by the forward-looking statements included herein, including risks related to the Tender Offer and Consent Solicitation including risks relating to the terms and conditions of the Tender Offer and the Financing Transaction and other risks and uncertainties, including those described in our most recent annual report on Form 20-F for the year ended December 31, 2025 and our other filings with the Securities and Exchange Commission. Such risks, uncertainties, contingencies and other factors could cause actual events to differ materially from the expectations expressed or implied by the forward-looking statements included herein. These forward-looking statements are made only as of the date of this release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act. The Board of DirectorsBorr Drilling LimitedHamilton, Bermuda

Absolicon acquires SavoSolar to strengthen position in European renewable heat market

The acquired business includes the SavoSolar trademark, project references, customer relationships, technical documentation, CRM systems, intellectual property rights, sales pipeline, selected personnel and a stock of solar thermal collectors and materials with a book value exceeding EUR 200,000. SavoSolar Summa Energy Oy is a supplier of large solar thermal plants, the company designs and delivers clean energy production systems for industry and district heating production as complete deliveries. In 2025, the company's turnover was EUR 8.6 million (EUR 9.7 million in 2024) and company employed an average of 23 people in 2025. Business scope The business acquired by Absolicon consists of three main areas. The first area is long-term cooperation with existing customers. While historical project liabilities and warranty obligations remain with Summa, Absolicon takes over the operational business connected to the installed base of solar thermal plants. This includes service agreements, technical support, spare parts sales and replacement collector deliveries to existing SavoSolar plants across Europe. The second area is consultancy and project development. SavoSolar has built extensive know-how in helping utilities, industrial companies and project developers evaluate and design large solar thermal plants. The acquired business includes engineering tools, simulation software, technical documentation and a substantial database of ongoing project opportunities and customer relationships developed over many years. The third area is the delivery of new solar thermal plants. Large solar thermal projects in Europe are typically developed through competitive public tenders where project developers and utilities procure turnkey or EPC solutions. The projects are then executed using specialized material suppliers and local subcontractors for civil works, piping, installation and commissioning. SavoSolar has developed extensive experience in this project model with large reference projects in Germany, France, Denmark and other European markets. SavoSolar’s former collector manufacturing plant in Mikkeli, Finland, was decommissioned during 2025 and Absolicon does not currently plan to restart in-house manufacturing of flat plate collectors. The business model is primarily focused on project development, engineering, EPC deliveries and service, with collector manufacturing sourced from qualified partners. Future SavoSolar projects are expected to use collectors sourced from established external manufacturers of large-scale flat plate solar collectors and Absolicon’s concentrating collectors. At the same time, the acquisition includes all intellectual property rights, patents, production documentation and manufacturing know-how required to restart collector production in the future if market conditions motivate such a decision. The transaction includes agreed compensation mechanisms related to any future restart of the unique SavoSolar flat plate collector manufacturing. In addition, potential future proceeds from sales or licensing of the SavoSolar intellectual property portfolio will be shared equally between Absolicon and Summa. Solar thermal market The European market for renewable heat is currently undergoing expansion driven by EU climate policy, district heating investments and industrial decarbonization. The implementation of the EU’s Fit for 55 package and the upcoming Heating & Cooling Strategy are expected to further strengthen the market for large-scale solar thermal. For Absolicon, the acquisition strengthens two important market segments. Within the industrial process heat segment, Absolicon already has a strong position in concentrating solar thermal for high-temperature applications. The current draft of the EU Heat Auction proposes lowering the eligible temperature threshold to approximately 80°C, allowing flat plate solar collectors to qualify for industrial projects financed by the EU Innovation Fund. This makes the large-scale flat plate solar thermal systems, where SavoSolar has strong expertise, attractive for a much wider range of industrial heat applications. Within solar district heating, the acquisition gives Absolicon immediate access to one of Europe’s strongest brands and reference portfolios in large-scale solar district heating. While Absolicon has primarily focused on industrial process heat, SavoSolar has built deep expertise in large district heating solar fields, seasonal thermal storage integration and public tender-based utility projects across several European markets. Transaction The acquisition was completed through a Business Purchase Agreement entered into between Absolicon and Summa Energy Ltd and the payment of the cash consideration on 9 June 2026. The total consideration amounts to EUR 393,000. The consideration consists of a cash payment of EUR 175,000 and newly issued shares in Absolicon corresponding to EUR 218,000. Directed share issue As part of the consideration for the acquisition, the Board of Directors of Absolicon has on 9 June 2026 resolved, pursuant to the authorization registered with the Swedish Companies Registration Office (Bolagsverket) on 23 June 2025, to issue 355,723 new Class B shares in a directed share issue to Summa Energy Oy. The reason for deviating from the shareholders’ preferential rights is that the new shares constitute part of the consideration payable under the Business Purchase Agreement relating to the acquisition of the SavoSolar business. The Board of Directors considers that the directed share issue is an integral and necessary part of the transaction and is beneficial to Absolicon and its shareholders. The subscription price amounts to SEK 6.66 per share, corresponding to a total issue value of approximately SEK 2.37 million (EUR 218,000). The subscription price has been determined through negotiations between the parties and reflects the Board of Directors’ assessment of the market value of the Absolicon share. Payment for the shares is made through set-off against part of the seller’s claim for the purchase price. Following the issue, the number of shares in Absolicon will increase from 13,594,648 to 13,950,371 shares and the share capital will increase by SEK 355,723 from SEK 13,594,648 to SEK 13,950,371. The issue results in a dilution of approximately 2.5 percent for existing shareholders. For the purpose of calculating dilution, the current number of shares is assumed to be 13,594,648, including 1,500,000 shares relating to the over-allotment option in Absolicon’s recent rights issue. The issuance of these shares remains subject to approval by an Extraordinary General Meeting on 12 June 2026. Following completion of the share issue, Summa Energy Oy will hold approximately 2.6 percent of the shares and votes in Absolicon. – The renewable heat market in Europe is entering a new phase. Utilities and district heating companies across Europe are planning major investments in fossil-free heat production. SavoSolar has built a strong brand and reference portfolio in European district heating solar projects, and together with Absolicon’s position in industrial solar heat we create a stronger platform for future growth. Lower temperature thresholds in the 1 billion Euro Heat Auction open new opportunities for large-scale flat plate solar thermal in industry, says Joakim Byström, CEO of Absolicon.

Inside information: The business of Summa Defence’s subsidiary Summa Energy is sold

Summa Defence Plc       Company announcement, inside information        9 June 2026 at 6:00 p.m. EEST Summa Energy Oy has signed an agreement with Absolicon Solar Collector AB on the sale of its business. The transaction is part of Summa Defence's goal announced on 6 March 2026 to clarify the Group's structure and allocate resources to the company's focus areas. Summa Energy Oy is a supplier of large solar thermal plants. The company designs and delivers clean energy production systems for industry and district heating production as complete deliveries. In 2025, the company's net sales was EUR 8.6 million (EUR 9.7 million in 2024). Absolicon Solar Collector AB is a Swedish company that develops, manufactures and sells solar energy systems that generate renewable energy. Absolicon’s share is traded on the Spotlight marketplace (XSAT). “The divestment of Summa Energy’s business is part of the strategic review and evaluation of strategic alternatives for some of our subsidiaries. The objective of this review is to support Summa Defence’s long-term strategy, strengthen our capital structure and accelerate growth in our core businesses in the defence sector,” says Robert Blumberg, CEO of Summa Defence. Summa Energy's sales price is EUR 393,000, of which EUR 175,000 is cash and EUR 218,000 is Absolicon Solar Collector AB’s shares. The transaction will be recorded in the first half of 2026. The review and evaluation of strategic alternatives regarding the other subsidiaries is ongoing. The evaluation is part of Summa Defence’s normal strategic development work and may not necessarily result in any arrangements or transactions. SUMMA DEFENCE PLC More information:Robert Blumberg, CEOPhone: +358 40 839 7408E-mail: robert.blumberg@summadefence.com Summa Defence in brief Summa Defence Plc is a Finnish defence and security technology group whose mission is to create a strong industrial foundation of innovative defence and dual use SMEs for strengthening the comprehensive security of society. Summa Defence aims for both organic and inorganic growth across three focus areas: maritime technologies, land technologies and new technologies. The company’s vision is to be a forerunner in comprehensive security industry. The shares of Summa Defence Plc are listed on the Nasdaq First North Growth Market in Sweden (SUMMAS) and Finland (SUMMA).www.summadefence.fi/en/ The company’s Certified Adviser is Augment Partners AB, info@augment.se, tel. +46 8 604 22 55.

Borr Drilling Limited – Pricing Terms for its Previously Announced Consent Solicitation and Tender Offer for its Senior Secured Notes due 2028

Hamilton, Bermuda, June 9, 2026 – Borr Drilling Limited (NYSE and OSE: BORR) (“Borr Drilling” or the “Company”) today announced the pricing terms of its previously announced offer by Borr IHC Limited, its wholly-owned subsidiary (the “Issuer”), to purchase for cash (the “Tender Offer”) (i) any and all of its outstanding 10.000% Senior Secured Notes due 2028 (the “2028 Notes”) and (ii) any and all of its outstanding 10.375% Senior Secured Notes Due 2030 (together with the 2028 Notes, the “Notes”), and the related solicitation of consents (the “Consent Solicitation”), in each case pursuant to the terms and subject to the conditions set forth in the offer to purchase and consent solicitation statement dated May 26, 2026 (as amended or supplemented from time to time, the “Statement”). Capitalized terms used in this release but not otherwise defined have the meaning given in the Statement.  The table below indicates, among other things, the Total Consideration for each $1,000 original principal amount of the 2028 Notes validly tendered at or prior to 5:00 p.m., New York City time, on June 8, 2026, as calculated at 10:00 a.m. (New York City time) today, June 9, 2026 (the “Price Determination Date”) in accordance with the terms of the Statement: [][][][]Notes CUSIP / ISIN Original Outstanding Factor U.S. Blomberg Fixed Total Numbers Principal Amount Principal Amount Treasury Reference Spread Consideration Issued Reference Page Security [(1)] [(2)] [(2)(3)(4)]10.000% Rule 144A: 100018 AA8 $1,380,696,000.00 $1,128,129,659.88 0.81707317 2.000% FIT3 +50 $1,048.36[(5)] Senior / UST dueSecured US100018AA89Regulation NovemberNotesDue S: G1467F AA1 15, 2028 / USG1467FAA15 2026 1. As of May 22, 2026. This reflects an aggregate original principal amount of 2028 Notes adjusted to reflect amortization in respect thereof. 2. The factor is a number that represents a fraction (expressed as a decimal rounded to 8 decimal digits) the numerator of which represents the unpaid principal amount of such series of securities and the denominator which represents the initial principal amount outstanding of such series of securities (the “Factor”). The Total Consideration will be the amount set forth in the table above multiplied by the applicable Factor, which reflects the partial amortization of the 2028 Notes. 3. For each $1,000 original principal amount of 2028 Notes validly tendered and accepted for purchase and with respect to which the applicable Holder has provided its Consent. The Early Tender Payment includes a Consent Payment of $2.50 for each $1,000 original principal amount of 2028 Notes. Holders that validly tender their 2028 Notes and thereby deliver their Consents at or prior to the Early Tender/Consent Deadline (and do not validly withdraw such 2028 Notes and therefore do not validly revoke the related Consents) will be eligible to receive the Consent Payment of $2.50 per $1,000 original principal amount of 2028 Notes in respect of such 2028 Notes. 4. Excludes Accrued Interest, which will be paid in addition to the Total Consideration. 5. The Total Consideration for the 2028 Notes validly tendered has been determined in the manner described in the Statement by reference to the fixed spread (the “Fixed Spread”) specified above plus the yield (the “Reference Yield”) based on the bid-side price of the U.S. Treasury Reference Security specified above (the “Reference Security”) as quoted on the Bloomberg Bond Trader FIT3 series of pages (the “Reference Page”) as of the Price Determination Date, which includes the Early Tender Payment (including the Consent Payment). Holders may continue to tender their Notes (and thereby deliver Consents) until 5:00 p.m., New York City time, on June 24, 2026, in respect of the Tender Offer and Consent Solicitation, unless extended or earlier terminated by the Issuer in its sole discretion, subject to applicable law (the “Expiration Time”). The Issuer reserves the right in its sole discretion, subject to applicable law, to (i) waive prior to the Expiration Time any and all conditions to the Tender Offer; (ii) extend the Expiration Time; (iii) amend the terms of the Tender Offer and Consent Solicitation in any respect; or (iv) terminate, withdraw or otherwise decide not to proceed with the Tender Offer and Consent Solicitation at any time prior to or at the Expiration Time and not accept for purchase or payment any Notes not theretofore accepted for purchase or payment. The Issuer’s obligations to accept for purchase and pay for Notes pursuant to the Tender Offer and the Consent Solicitation is subject to the satisfaction of, or where applicable, the Issuer’s waiver of, the conditions set forth under “Conditions to Consummation of the Tender Offer and the Consent Solicitation,” including the Financing Condition, the Supplemental Indenture Condition, and the General Conditions as described in the Statement. Information Relating to the Tender Offer and the Consent SolicitationThe Company has engaged Citigroup Global Markets Inc is acting as the dealer manager and solicitation agent for the Tender Offer and the Consent Solicitation (“Dealer Manager and Solicitation Agent”). Questions regarding the terms of the Tender Offers and Consent Solicitations may be directed to Citigroup Global Markets Inc. at +1 (212) 723-6106 (banks and brokers) or +1 (800) 558-3745 (toll-free) or via email at ny.liabilitymanagement@citi.com. Global Bondholder Services Corporation is acting as (i) the Information Agent for the Tender Offer and the Consent Solicitation, (ii) the Tender Agent for the Tender Offer and (iii) the Tabulation Agent for the Consent Solicitation. Requests for copies of the Statement should be directed to Global bondholder Services Corporation at +1 (212) 430- 3774 (banks and brokers) or +1 (855) 654-2014 (toll-free) or via email at contact@gbsc-usa.com. This press release is for information purposes only and does not constitute or form part of an offer to sell or the solicitation of an offer to purchase or subscribe for securities, nor will there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities referred to herein have not been and will not be registered under the Securities Act of 1933 or applicable state securities laws, and may not be offered or sold in the United States or to U.S. persons (other than distributors) unless such securities are registered under the Securities Act of 1933, or an exemption from the registration requirements of that act is available. About Borr Drilling LimitedBorr Drilling Limited is an international drilling contractor incorporated in Bermuda in 2016 and listed on the New York Stock Exchange since July 31, 2019 and on Euronext Oslo Børs since May 21, 2026 under the ticker “BORR.” The Company owns and operates jack-up rigs of modern and high specification designs and provides services focused on the shallow-water segment to the offshore oil and gas industry worldwide. Please visit our website at www.borrdrilling.com. Forward-Looking StatementsThis press release and related discussions include forward-looking statements made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements do not reflect historical facts and may be identified by words such as “anticipate”, “believe”, “continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will”, “ensure”, “likely”, “aim”, “plan”, “guidance” and similar expressions and include statements regarding the Tender Offer and Consent Solicitation, including expected settlement dates, the Financing Transaction and other non-historical statements. Such forward-looking statements are subject to risks, uncertainties, contingencies and other factors that could cause actual events to differ materially from the expectations expressed or implied by the forward-looking statements included herein, including risks related to the Tender Offer and Consent Solicitation and other risks and uncertainties, including those described in our most recent annual report on Form 20-F for the year ended December 31, 2025 and our other filings with the Securities and Exchange Commission. Such risks, uncertainties, contingencies and other factors could cause actual events to differ materially from the expectations expressed or implied by the forward-looking statements included herein. These forward-looking statements are made only as of the date of this release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act. The Board of DirectorsBorr Drilling LimitedHamilton, Bermuda

Nimlas Norway signs agreement to acquire Miljø Elektro AS

The acquisition marks another step in Nimlas’ expansion in the region, following its entry into Region West in 2025, through the acquisitions of Teca and TekniskBureau. With Miljø Elektro, Nimlas continues to build its presence in an important Norwegian market. Founded in 1991, Miljø Elektro has established a strong position within electrical installations for the project segment, serving commercial, construction and public sector clients. The company combines solid technical expertise with strong project execution and long-standing customer relationships. “Miljø Elektro is a well-run company with a clear market position and skilled employees. The company is a strong strategic and cultural fit for Nimlas”, says Terje Myhre, CEO of Nimlas Norway. Miljø Elektro is headquartered in Sandnes, close to Stavanger, and has approximately 30 employees. Its operations are primarily project-driven, with a strong local presence and focus on quality delivery. “Joining Nimlas gives us access to a broader professional environment and enables further development of the company. At the same time, it is important for us to maintain our local identity and culture”, says Andreas Lundh, Managing Director of Miljø Elektro AS. Following completion, Miljø Elektro will continue to operate under its existing brand, management and organization. The transaction supports Nimlas’ continued growth and strengthens the overall capacity and capabilities in the region. Completion of the transaction is subject to approval from the Norwegian Competition Authority.

Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026

· Upcoming presentations at ENDO 2026 highlight Lundbeck’s Focused Innovator strategy and continued expansion into rare neuroendocrine diseases with high unmet medical needs · The scientific program showcases Lundbeck’s investigational neurohormonal and neuroimmunological targeted therapeutic candidates, asedebart and Lu AG22515, respectively   · Preliminary Phase II data for asedebart, an investigational anti-adrenocorticotropic hormone (ACTH) monoclonal antibody in Cushing’s disease (CD), demonstrate Lundbeck’s biomarker-supported approach to evaluating novel therapeutic mechanisms in rare endocrine disorders · Preclinical characterization of the CD40L blocker Lu AG22515 will be shared as well as data from a patient study in thyroid eye disease (TED,) reflecting exploratory studies of CD40L modulation in autoimmune disease biology, with potential relevance to neuroinflammation implicated in several neurological and endocrine diseases Valby, Denmark, Wednesday 10 June 2026 – H. Lundbeck A/S (Lundbeck) today announced that new data will be presented at the 2026 Endocrine Society’s Annual Meeting (ENDO), taking place June 13–16 in Chicago, Illinois, U.S. Lundbeck will present preliminary Phase II data for asedebart (Lu AG13909) in CD, reflecting Lundbeck’s expansion into neuroendocrine diseases.  In addition, preclinical and Phase Ib clinical exploratory findings on Lu AG22515 in patients with TED will be shared, providing insights into the broader therapeutic potential of CD40L pathway modulation across inflammatory and immunological disorders. “Lundbeck’s presence at ENDO 2026 reflects how we have expanded upon our neuroscience heritage in recent years. This involves pursuing biological drug targets within hormonal and immunological signaling pathways that offer the potential to deliver highly differentiated therapeutics for neurological and neuroendocrinology indications with high medical unmet need,” said Johan Luthman, EVP and Head of Research & Development at Lundbeck. “Through this approach, we have made significant progress across our rare disease programs, enabling decisive, biomarker-supported patient studies that facilitate early development decisions, as exemplified by our ENDO 2026 scientific program.” Asedebart data provide insight into ACTH neutralization in Cushing’s disease Among the highlights are preliminary Phase II data for asedebart, an investigational anti-adrenocorticotropic hormone (ACTH) monoclonal antibody, being evaluated in adults with CD. CD is a rare neuroendocrine disorder typically caused by an ACTH-secreting pituitary adenoma, leading to chronic excess cortisol production and substantial physical and neuropsychiatric burden.[1,2] While surgery is the standard first-line treatment, many patients experience persistent or recurrent disease despite available pharmacologic options, and significant unmet need remains. The Phase II data being presented include impact on urinary free cortisol (UFC) levels following individualized dose titration of asedebart, alongside safety and tolerability assessments, supporting further understanding of direct ACTH neutralization in CD. The CD study builds on earlier Phase I findings in classic congenital adrenal hyperplasia (CAH) (ClinicalTrials.gov: NCT05669950 ), which showed pharmacodynamic effects on key adrenal steroid biomarkers. The CD data presented at ENDO add to Lundbeck’s evaluation of targeting ACTH-driven endocrine conditions with links to brain function — using early clinical and pharmacodynamic evidence to assess therapeutic potential in areas of significant unmet need. Asedebart has received Orphan Drug Designation (ODD) for CAH in the European Union and the United States as well as ODD in Japan for the treatment of patients with CD and CAH. Lu AG22515 data provide insight into CD40L pathway biology At ENDO, Lundbeck will also present preclinical characterization findings for the investigational CD40L blocker Lu AG22515. CD40L is a key immune signaling molecule heavily implicated in a wide range of immune disorders, neurology and potentially endocrine conditions.[3] The presentation will describe the inhibitory effect and PK/PD profile of Lu AG22515, including effects on membrane-bound and soluble CD40L, B-cell activation and differentiation, proinflammatory cytokine production and in vivo antibody responses. Additionally, clinical findings will be presented from an exploratory Phase Ib open label study on AG22515 in TED patients. TED is an autoimmune disorder that can cause proptosis, diplopia, pain, disfigurement and, in severe cases, visual impairment or vision loss.[4  ]The presentation will cover three areas: pharmacodynamic assessments designed to evaluate CD40L pathway engagement, safety and tolerability, and preliminary clinical efficacy in TED, including effects on proptosis and other measures of disease activity. The data further enhance the understanding of CD40L pathway modulation in TED and other CD40L-mediated immune disorders. Asedebart and Lu AG22515 are investigational drugs not approved for marketing by any regulatory authority worldwide, and the efficacy and safety of both molecules have not been established. Details of Lundbeck presentations at ENDO 2026 Therapeutic Presentation Presentation Type ReferenceArea contentCushing’s A Phase II, Open Oral presentation Sun 14 Junedisease -label, Dose 14:45-15:00 CTAsedebart -titration Trial Room W183BCLu AG13909 to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Novel Anti -ACTH Antibody Asedebart in Adults with Cushing’s DiseaseThyroid eye Results From a Oral presentation Mon 15 Junedisease Phase 1b Trial 14:15-14:30 CT(TED) Evaluating CD40 W184ABCLu AG22515 -Ligand Blocker Lu AG22515 in Patients with Moderate-to -Severe Thyroid Eye DiseaseThyroid eye Preclinical Rapid-fire Sun 14 Junedisease Pharmacokinetic presentation and 09:00- 16:00 CT(TED) and poster ENDOExpo;Lu AG22515 Pharmacodynamic Poster floor Profile of Lu AG22515, a CD40 -Ligand Blocker in Development for Thyroid Eye Disease About Cushing’s disease Cushing’s disease is a rare neuro-endocrine disorder caused by a pituitary adenoma that secretes excess ACTH, leading to chronic overproduction of cortisol.[1]  The condition is associated with significant morbidity and increased mortality, and patients may experience a wide range of physical and neuropsychiatric symptoms.[2] First-line treatment is surgical removal of the tumor; however, not all patients are eligible, achieve sustained remission, or benefit fully from current available treatment options, highlighting an ongoing unmet need for effective and well-tolerated therapies. About asedebart (Lu AG13909) Asedebart is a humanized anti-ACTH monoclonal antibody designed specifically to recognize ACTH with high affinity. It blocks the binding of ACTH to the melanocortin 2 receptor in the adrenal glands and thereby inhibits the neurohormonal signalling of ACTH. This inhibition causes a decreased secretion of glucocorticoids, mineralocorticoids and androgens from the adrenal glands. [5,6 ]ACTH plays a key role in the biosynthesis of adrenal steroids[7] and is therefore considered a promising therapeutic target in conditions characterized by elevated ACTH levels.[6]   About thyroid eye disease (TED) Thyroid eye disease (TED) is a rare autoimmune condition associated with thyroid dysfunction, characterized by inflammation and expansion of retro-orbital tissues. Clinical manifestations include proptosis, double-vision, pain, swelling, and disfigurement, and in severe cases may lead to visual impairment or loss of vision. TED can have a substantial impact on daily functioning, quality of life and psychological wellbeing.[4] Current treatments are not optimal for all patients and may be associated with significant adverse effects, highlighting the need for additional therapeutic approaches that target underlying autoimmune disease biology.[ 4]  About Lu AG22515 Lu AG22515 is an investigational CD40L blocker being evaluated in CD40L mediated autoimmune diseases. Lu AG22515 is a recombinant fusion protein that binds CD40 ligand (CD40L) and human serum albumin (HSA) to extend half-life. By blocking the interaction between CD40L and the CD40 receptor, Lu AG22515 is designed to modulate a key immune co-stimulatory pathway involved in B-cell activation, antibody responses and inflammatory signaling. Contacts Anders Crillesen Jens HøyerSenior Director, Vice President, Head of Investor RelationsExternal & InternalRelationsAECE@lundbeck.com JSHR@lundbeck.com+45 27 79 12 86 +45 30 83 45 01   About H. Lundbeck A/S Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases. Brain disorders affect a large part of the world’s population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments. As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology. We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families, and society as a whole. Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com  and connect with us via LinkedIn .  References: 1. Lacroix A, Feelders RA, Stratakis CA, et al. Lancet. 2015;386(9996):913–927 2. Sharma ST, Nieman LK, Feelders RA. Pituitary. 2015;18(2):188–194 3. Ots HD, Tracz JA, Vinokuroff KE, et al. Int J Mol Sci. 2022;23(8):4115 4. Dhaliwal NK, Razzaq L. Cureus. 2025;17(6):e86483. 5. Lundbeck. Data on file 6. Feldhaus AL, et al. Endocrinology 2017;158(1):1-8 7. Xing Y, et al. J Endocrinol 2011;209(3):327-35 

Crunchfish CEO Joachim Samuelsson to Deliver Keynote at Payments Conference in Madrid

Joachim Samuelsson will deliver a keynote presentation titled “Offline Architecture: The Missing Strategic Layer in A2A Payments.” The presentation will explore how payment systems can be designed to remain operational when connectivity or central infrastructure is unavailable, and why offline capabilities are becoming a strategic requirement for resilient payment ecosystems. The keynote will discuss three key topics: · Offline Payments Within a Payment System – How can an instant payment system continue to operate without network connectivity or system availability?  · Offline Interoperability Across Payment Systems – How can users pay offline across different payment systems?  · Beyond Offline Payments – What other use cases benefit from portable user authorization? By introducing an architectural approach that enables offline functionality both within and across payment systems, the presentation will highlight new opportunities to strengthen resilience, interoperability, and user autonomy in digital payments. For more information about the event, visit Leadership Pulse Series . For more information, please contact: Joachim Samuelsson, CEO of Crunchfish AB +46708 46 47 88 joachim.samuelsson@crunchfish.com This information was provided by the above for publication on June 10th, 2026, at 08:30 CEST. Västra Hamnen Corporate Finance AB is the Certified Adviser. Email: ca@vhcorp.se. Telephone +46 40 200250. About Crunchfish –crunchfish.com  Crunchfish is a deep fintech company developing governed offline payments technology for payment systems, banks, and payment applications. The company enables offline payments as a Layer-2 solution on top of existing payment systems, allowing transactions to be executed without connectivity while ledger authority and settlement remain unchanged. Through a reservation-based model, resilience is achieved without creating parallel forms of money or unmanaged credit risk. Crunchfish’s architecture is patented and enables interoperability across multiple payment systems and markets. The solution strengthens system stability while also supporting economic incentives by ensuring that liquidity backing offline payments remains within the regulated financial system.

Volvo Group Capital Markets Day – Built for Resilience and Growth

“In a world shaped by geopolitical uncertainty, increasing regionalization, and rapid technological change, demand for transport and infrastructure solutions will continue to grow. We are well positioned to capture the opportunities created in this evolving landscape, leveraging our strong assets. We have strong brands, retail excellence, deep segment and application expertise, and robust regional value chains,” says Martin Lundstedt. Over the last decade, the Volvo Group has been on a journey characterized by improved financial performance, product innovation and a strong commitment to shaping the future of transport and infrastructure. The Group is focused on delivering the sustainable and profitable growth that defines its strategy. At the Capital Markets Day, Martin Lundstedt outlines how earnings resilience is strengthened by empowering decentralized decision-making, enabling faster, customer-focused actions across the Group. Earnings resilience is further enhanced through flexibility tools, disciplined pricing, and consistent cost control. At the same time, growing the service business increases recurring revenues and supports earnings over the business cycle. In addition to long-term growth in global transport demand, there are substantial opportunities for the Volvo Group to grow by increasing content and service value through total offers, driving market share gains, and targeting selected regions and growth segments across business areas. Among the levers driving growth, the Trucks segment and Volvo Construction Equipment are expected to outperform their historical growth rates. Renault Trucks aims to double its light-duty business, while Volvo Penta plans to double its revenue in the coming years. Volvo Autonomous Solutions is targeting driverless on-highway operations by the first quarter of 2027 and has the ambition to approach approximately USD 3 billion in revenues within five years, accretive to the Group’s operating margin. The Group’s investments in R&D and CAPEX have laid the foundation for continued technology leadership, building platforms and industrial capacity to drive future growth and support a more resilient earnings profile, while maintaining a high return on capital employed and strong shareholder returns. In a current trading update, Mats Backman, Volvo Group CFO, notes that business activity remains solid. In Europe, customer demand and deliveries are stable at good levels across business areas. In North America, demand remains strong, with production gradually increasing. Cost inflation is trending upward, while at the same time, high utilization of customers’ trucks and machines supports service activity. “Our strategy has served us, our customers and our owners well, and we are committed to continuing this journey. We have built the Volvo Group for both resilience and growth across the business cycle,” says Martin Lundstedt. The Capital Markets Day is webcast on www.volvogroup.com.  A recording of the presentation and the presentation material will be made available after the event.           June 10, 2026          Journalists wanting further information, please contact:Claes Eliasson, Head of Media Relations+46 76 553 7229press@volvo.com     For more information, please visit volvogroup.com For frequent updates, follow us on LinkedIn  The Volvo Group drives prosperity through transport and infrastructure solutions, offering trucks, buses, construction equipment, power solutions for marine and industrial applications, financing and services that increase our customers’ uptime and productivity. Founded in 1927, the Volvo Group is committed to shaping the future landscape of sustainable transport and infrastructure solutions. The Volvo Group is headquartered in Gothenburg, Sweden, employs almost 100,000 people and serves customers in almost 180 markets. In 2025, net sales amounted to SEK 479 billion (EUR 43 billion). Volvo shares are listed on Nasdaq Stockholm.

Polymer Factory Enters Material Transfer Agreement with Thermo Fisher Scientific

The agreement establishes a framework for evaluating materials and potential calibration products based on Polymer Factory’s proprietary SpheriCal® technology platform. Under the agreement, the parties will explore selected product concepts and application areas within analytical instrumentation and mass spectrometry. SpheriCal® is Polymer Factory’s patented dendritic polymer technology developed to provide highly defined calibration standards for advanced analytical workflows. The platform has been designed to address challenges associated with calibration accuracy, reproducibility, and instrument performance in modern analytical applications. The agreement reflects growing industry interest in advanced calibration solutions and provides an opportunity to evaluate how SpheriCal® can address emerging analytical needs. “Collaborations with leading industrial companies are an important part of our strategy to broaden the commercial reach of our technology platforms,” said Mats Wallnér, CEO of Polymer Factory. “Thermo Fisher Scientific is a highly respected organization within analytical sciences, and we are pleased to establish this framework for evaluating SpheriCal® in new application areas. We look forward to exploring the possibilities that this collaboration may create.” Polymer Factory continues to focus on expanding the application base for its proprietary technologies through collaborations with industry, academia, and commercial partners. The Company believes that strategic partnerships play an important role in identifying new opportunities and accelerating the adoption of innovative analytical solutions. The agreement does not include any immediate commercial commitments or guaranteed revenues but provides a structured basis for evaluation and potential future discussions between the parties.

Gasum secures long-term LNG capacity at Klaipeda terminal for 2033–2040

Gasum has secured LNG terminal capacity at the Klaipeda LNG terminal in Lithuania for the period 2033–2040. The long-term capacity reservation supports Gasum’s ability to supply the Northwestern European market with liquefied natural gas (LNG) and liquefied biomethane (bio-LNG) over the coming decade. The Klaipeda terminal has been a part of Gasum’s supply chain for some time already. Gasum uses the Klaipeda terminal primarily as a reloading point for its own carrier and bunker vessels, but also to support the company’s natural gas operations in Finland and the Baltic countries. Klaipeda is well located regarding the company’s own LNG terminal network in Finland, Sweden, and Norway. Gasum will also utilize the capacity to serve its maritime customers directly in and around the Danish straits. “Securing capacity at Klaipeda supports Gasum’s strategic long-term supply capability and gives us flexibility in optimizing deliveries to our terminal network and maritime customers. It also underpins our commitment to being a dependable partner in the energy transition”, says Anders Malm, Senior Vice President, Supply & Trading, Gasum. Demand for LNG and bio-LNG is set to grow Demand for LNG is expected to grow especially in the maritime market, as the number of LNG-powered vessels is set to increase notably in coming years. The maritime industry faces increased pressure to transition to low-emission fuels. The UN's maritime organization IMO and the EU have set goals and targets for reducing greenhouse gas emissions, but also customers are demanding more sustainable transportation to meet their emission reduction goals.  The capacity at Klaipeda can additionally be used for virtual liquefaction of pipeline fed biomethane into bio-LNG, through mass balancing and biomethane certificates. Gasum believes this to be an important capability going forward, as a growing number of the company’s customers are seeking to reduce the lifecycle emissions of fuel further than what LNG alone can offer. Read more about Gasum's LNG bunkering services  Read more about Gasum's LNG terminal network  Photo: Gasum's container vessel Coral Energy at Klaipeda LNG terminal. Courtesy of KN Enenergies.

Akobo Minerals – Operational Update for May 2026

Oslo, Norway, 10 June 2026 – Akobo Minerals AB (publ) (“Akobo” or the “Company”) (Euronext Growth Oslo: AKOBO), the Scandinavian-based gold producer operating in Ethiopia, provides an operational update for May 2026. Following the fuel supply disruptions that temporarily impacted operations during April, key activities progressively resumed during May as diesel availability improved. This enabled a phased restart of mining, processing and development activities. By the end of May, operations had largely returned to normal levels, and the Company entered June on a business-as-usual basis. The Company currently maintains sufficient fuel inventories on site, with additional deliveries in transit to support ongoing operations. While fuel availability has stabilised, regional supply constraints may still affect future deliveries, and the Company continues to monitor the situation closely. Key highlights · Gold production in May: 0 kg (processing of newly mined ore will commence in June) · Cumulative doré production to date: approx. 124 kg · Stockpile of lower-grade material available for processing: approx. 300 tonnes Mining restart and vertical shaft development update Mining activities resumed towards the end of May following successful dewatering of the underground workings. Development of the vertical shaft continued in parallel. Following completion of the remaining collar works and advancement of the shaft into competent hard rock, blasting activities resumed during May. Shaft sinking is expected to accelerate as development now progresses below the collar section. The operational disruption in April and early May resulted in a temporary loss of momentum. However, the site team managed the situation effectively, maintaining control of critical activities and minimising the overall impact on production and development. With all core activities now fully resumed, the Company entered June under normal operating conditions. Prospect drive 4 before blasting and after continued blasting, with visible build-up of blasted material in the drive. Shama village water project A small inauguration ceremony was held for the Shama village water project, providing access to clean and reliable freshwater for the nearest local village and surrounding community. The project is expected to improve access to safe drinking water, reduce reliance on bottled water, and contribute to a reduction in associated plastic waste, with positive health and broader community benefits. For more information, contact Jørgen Evjen, CEO, Akobo Minerals Mob: (+47) 92 80 40 14 Mail: jorgen@akobominerals.com LinkedIn: www.linkedin.com/company/akobominerals  Web: www.akobominerals.com  About Akobo Minerals Akobo Minerals is a Scandinavian-based gold producer and explorer with more than 15 years of active operations in Ethiopia. The Company holds an exploration licence covering 182 km² and a mining licence covering 16 km² in the Gambela region, Dima Woreda. The Segele mine hosts an Indicated and Inferred Mineral Resource of approximately 69,000 ounces at an average grade of 22.7 g/t gold. The mineralised system remains open at depth, supporting further resource growth and potential mine life extension. In addition, the Company’s exploration licence hosts multiple high-quality targets with significant resource potential. Akobo Minerals places ESG principles at the core of its operations and maintains strong relationships with local communities and government authorities. The Company is committed to sound ethics, transparency and responsible mining practices. Akobo Minerals is headquartered in Oslo and listed on Euronext Growth Oslo and the Frankfurt Stock Exchange under the ticker AKOBO. In the United States, the Company’s shares trade on the OTC Pink Market under the symbol AKOBF. The Company complies with the JORC Code (2012) and places strong emphasis on internationally recognised industry standards.

Horse Powertrain wins prestigious Autocar Sturmey Award for innovation

London, UK (10 June 2026) – Horse Powertrain, a global leader in innovative and low-emission powertrain systems, has been awarded the prestigious Sturmey Award at the 2026 Autocar awards. First awarded in 2014, the Sturmey Award is one of Autocar’s biggest and most prestigious prizes, recognizing outstanding people, companies, or technologies that represent the most significant innovations and achievement for the automotive industry. Horse Powertrain was selected for the prize, with judges praising the impressive engineering and innovation behind the company and its products and services. The company’s technical innovation includes its pioneering series of X-Range powertrains, which enable automakers to convert BEV-native platforms into HEVs, PHEVs, and REEVs. Furthermore, it was recognized for its breakthroughs in increasing powertrain thermal efficiency and reducing the carbon intensity of combustion and hybrid vehicles. Matias Giannini, the CEO of Horse Powertrain, received the trophy from Autocar editor-at-large, Matt Prior, at the annual event taking place at Armoury House, London. On accepting the award, Matias Giannini said: “It is a great honour to receive this prestigious award from Autocar and a fantastic recognition of the talented global teams that make up Horse Powertrain. Together, they are delivering the innovations driving the industry towards net zero. As a powertrain solutions partner to numerous OEMs, we remain committed to a culture of innovation that, through our products and systems integration expertise, enables continuous reductions in mobility emissions - whether through electrification, alternative fuels or highly efficient hybrids.” Mark Tisshaw, Autocar editor, commented: “Horse Powertrain’s rule-breaking approach is challenging almost every established way of thinking in the automotive game. This unique strategy that focuses on reimagining and advancing the combustion engine is as technically innovative as it is commercially disruptive. In winning this award, we are pleased to recognize the foresight and courage of a company that continues to push forward and champion the combustion engine, even in the face of the wider industry trend towards all-out electrification.” Named after Henry Sturmey, the founder of Autocar magazine, previous Sturmey Award winners include Tesla, Aston Martin's Marek Reichman, Dacia's Denis le Vot, Polestar's Thomas Ingenlath and JLR's Gerry McGovern. ENDS About Horse Powertrain Horse Powertrain is a global leader in innovative, low-emission hybrid and combustion powertrain solutions, supporting automotive OEMs with a range of systems including engines, transmissions, power electronics, range extenders, and integrated hybrid platforms. Horse Powertrain has operations in Europe, China, and South America, and employs over 19,000 people across 18 plants and five R&D centers. Its 25 customers include Renault Group, Geely Auto, Volvo Cars, Proton, Nissan, and Mitsubishi Motors Corporation. Horse Powertrain is headquartered in London, UK. For more information, please contact: · Kate Saxton:kate.saxton@horse-powertrain.com; +34 679 07 20 87 · Performance Communications: horse@performancecomms.com

Annual General Meeting held in OssDsign AB

The annual general meeting resolved: · to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2025; · that the company’s result shall be carried forward in new account and that no dividend shall be paid for the financial year 2025; · to grant the board members and the CEO discharge from liability for the financial year 2025; · that the board of directors shall consist of five ordinary members without deputy members, to re-elect Christer Fåhraeus, Jill Schiaparelli, David Jern and Tomas Blomquist as ordinary board members, election of Per Aniansson as new ordinary board member, and to elect Per Aniansson as new chairman of the board; · that a registered accounting firm shall be elected as auditor and to re-elect Ernst & Young AB as the company’s auditor; · that fees payable to the board members until the end of the next annual general meeting shall amount to a total of SEK 1,300,000 out of which SEK 400,000 shall be paid to the chairman and SEK 300,000 to each of the other board members except for Christer Fåhraeus to whom no board fee is to be paid. In addition, it was resolved that fees shall be paid to the board members serving on the audit committee for the period until the end of the next annual general meeting in a total amount of SEK 120,000, of which SEK 80,000 shall be paid to the chairman of the audit committee and SEK 40,000 to the other member of the audit committee; · that the auditor is to be paid in accordance with approved invoices; · on an authorization for the board of directors to increase the share capital through issuance of new shares, warrants and/or convertible debentures through which the company’s share capital may be increased by an amount corresponding to not more than twelve (12) per cent of the share capital after such issue(s); · to adopt the board's proposed resolution on (i) implementation of a long-term incentive program for employees and contractors (Warrant Programme 2026/2029:1) through a directed issue of no more than 3,100,000 warrants of series 2026/2029:1 to the company and/or any of its subsidiaries and approval of the subsequent transfer of the issued warrants to certain employees and contractorswithin the group against payment of the market value of the option right or, provided that it does not entail negative tax consequences for the group, free-of-charge, and (ii) cancellation of Warrant Programme 2025/2028:1 which has not been utilised. Each warrant entitles the holder to subscribe for one (1) new share in the company, as adjusted downwards by application of the mandatory so-called quotient exercise model set forth in the proposed resolution, during the period from and including 1 July 2029 until and including 31 December 2029, against payment of a subscription price per new share corresponding to 160 percent of the volume weighted average trading price for the company’s share on Nasdaq First North Growth Market during a period of five (5) trading days before the annual general meeting. The warrants are governed by customary terms and conditions, including any adjustments to the subscription price and the number of new shares that each warrant entitles the holder to subscribe for in the event of certain events affecting the company.

Finnair starts flights from Turku and Tampere, connecting customers to Finnair's international network

Finnair will reintroduce Tampere and Turku to its flight network in October 2026. The new flights will seamlessly connect Tampere and Turku to Finnair's extensive international network via its Helsinki hub. Finnair flies from Helsinki to approximately 90 destinations in Europe, 11 destinations in Asia, 7 destinations in North America and one destination in Australia. "Tampere and Turku are rapidly growing cities, and we have conducted a continuous dialogue with the regions about the possibilities of providing smoother connections to the world. The flights, which will start in October, will smoothly connect Tampere and Turku to Finnair's extensive network," says Finnair's President and CEO Turkka Kuusisto. "The morning flight brings customers to flights to European destinations, and the evening flight takes customers home for the evening. Midday flights, on the other hand, bring customers from Tampere and Turku smoothly to our afternoon bank." Starting in October, Finnair will fly one daily overnight flight to both Tampere and Turku, connecting customers with Finnair's European flights departing in the morning and with flights returning to Helsinki in the evening. In addition to overnight flights, Finnair brings customers from Turku and Tampere to Helsinki in the afternoon, so that a flight from Oulu to Helsinki stops in Tampere and a flight from Stockholm to Helsinki stops in Turku and then continues to Helsinki. The flights will be operated with ATR aircraft with 68–70 seats. Finnair replaced flights to Tampere and Turku with bus connections in 2022–2023. When flights are resumed in October 2026, the bus service will continue during the day, but the late-night service will be removed and replaced by an overnight flight. The new flights are on sale at https://www.finnair.com/fi-fi and through travel agencies. The flight schedules are: Tampere: AY 269 HEL-TMP daily 23:50-0:20 (+1) AY270 TMP-HEL daily 06:00-06:35 AY644 TMP-HEL daily 12:20-12:50 Turku: AY229 HEL-TKU daily 23:50-0:20 (+1) AY 230 TKU-HEL daily 06:00-06:35 AY 654 TKU-HEL daily 11:55-12:30

KONE spins out VAELLA, an AI operator for buildings to help the world’s busiest public spaces run more safely and efficiently in real time

As cities face increasing pressure on critical infrastructure due to rising footfall and shrinking resources, VAELLA supports building operators and facility managers by serving as an extended, AI-powered operational brain for their expert teams. The privacy-first platform delivers the real-time situational awareness and predictive intelligence needed to create safer, more efficient, and more people-friendly experiences in the most complex and crowded spaces. ESPOO, Finland (June 10, 2026), VAELLA , a new technology company developing an AI operator for buildings and public infrastructure, has launched as an independent spinout from KONE , a global leader in the elevator and escalator industry. The newly founded company VAELLA is focused on helping operators of densely populated, high-footfall environments, including transport hubs, airports, stadiums, and large commercial buildings, anticipate and manage disruption, maintain flow, and strengthen resilience. The platform acts as an AI operator that can help teams shift from reactive monitoring toward real-time situational awareness and predictive operational response. Originally created within the technology and innovation unit at KONE, VAELLA addresses a growing challenge facing cities and infrastructure operators: public environments are becoming more interconnected, more dynamic, and more vulnerable to disruption, while the systems used to manage them remain fragmented and reactive. At the same time, safety and security threats continue to rise, and facility operators are being asked to do more with fewer on-site personnel, as public sector resources remain constrained. “The world’s busiest public environments are becoming exponentially more complex, but most operational systems are still designed to react after problems emerge,” says Fabien Fédy, CEO and co-founder of VAELLA. “VAELLA was created around a simple idea: if operators can understand what is happening now, and what is likely to happen next, they can make faster, better-informed decisions that keep facilities running smoothly and absorb pressure before it becomes a crisis. This enables operators to keep people safe, and make even the most crowded public spaces easier to navigate for millions every day.” Today’s control rooms often rely on disconnected inputs from cameras, sensors, access systems, equipment monitoring, and building infrastructure. Although operators have access to more data than ever, they frequently lack a unified operational picture that helps teams understand where pressure is building, how disruption may propagate, and what decisions are needed in real time. Rather than functioning as another standalone software tool, VAELLA is designed to operate more like an extended, AI-powered operational team working alongside existing staff, across all functions of the facility. The platform combines sensor data, operational systems, and predictive intelligence into a unified real-time operational view designed to support faster decision-making, improve continuity of operations, and help teams manage increasingly complex environments under pressure. Unlike many conventional systems, which rely on invasive, camera-centric monitoring, VAELLA is designed as a privacy-first operational platform that connects the existing infrastructure rather than replacing it. “Facility operators are not short of data. The challenge is that it’s scattered across too many systems and still requires people to interpret what matters in real time,” says Ulla Tikkanen, CCO and co-founder at VAELLA. “VAELLA isn’t replacing these people; it’s levelling up every aspect of the existing operational team’s capabilities by turning fragmented information into intelligence. Consider it like having an additional equivalent of your best facility manager, your most experienced security supervisor, your smartest energy analyst, and your most reliable accessibility coordinator, and having all of them working together, in real time, around the clock, on every floor and in every corridor of your facility at once.” Initial pilots and validation work have already been conducted in real operational environments, including Helsinki and Brussels, where VAELLA has tested how real-time situational awareness and predictive operational insights could improve the management of complex public transport hubs. Tested applications included crowd build-up detection, passenger incident response, accessibility disruption management, demand-aware station operations, and adaptive energy management. Additionally, the technology has identified ways to save energy at the station and reduce unnecessary visits by security teams by using real-time data. “Transport hubs and metro stations, for example, can experience sudden surges in passenger volumes following concerts, sporting events, or service disruptions, creating safety risks in busy transit areas,” Fédy explains. “According to one pilot customer, overcrowding contributes to nearly 30 percent of operational incidents. By identifying congestion patterns in real time, operators can respond earlier, increase train frequency, redirect passenger flows, or adjust escalator directions before situations worsen. Real-time occupancy insights can also help optimise lighting, ventilation, and other building systems dynamically, with some pilot environments identifying potential energy savings of up to 20 percent.” For KONE, the decision to back VAELLA as a spinout is a deliberate initiative to give the venture the independence and autonomy to move quickly while connecting it to KONE’s global expertise in urban mobility and extensive worldwide customer relationships. “KONE has spent decades understanding how people move through buildings and cities. The natural extension of that is understanding how equipment and the spaces around it behave as living systems: observing patterns, seeing where pressure accumulates, and anticipating and responding in the moments before something goes wrong,” says Amy Chen, Chief Innovation Officer at KONE. “VAELLA, our first ever spinout, is addressing that challenge with a completely new approach designed for the operational realities of crowded public environments. The way VAELLA has been designed to work reinforces KONE’s purpose to shape the future of cities, and by giving this innovation its own structure, we can solve our customers’ most pressing challenges directly, with breakthrough solutions.” Urban infrastructure investment cycles are often measured in decades, yet the pressure on existing public environments is already intensifying right now. Cities and operators cannot expand transport networks, airports, and other critical infrastructure quickly enough to keep pace with rising demand, increasing passenger volumes, and growing operational complexity. As a result, attention is increasingly shifting toward how existing environments can be operated more intelligently, efficiently, and adaptively in real time. This is the operational challenge VAELLA was created to address. Applicable anywhere people move fast and with scale, like airports, stadiums, shopping centres, university campuses, and civic spaces, which all face growing expectations for safer, smoother, and more resilient operations, creating a clear market for AI-assisted systems to support better real-time decisions. ### For additional information:Media kit with pictures  Fabien Fédy, CEOVAELLA+358 50 366 5211fabien.fedy@vaella.com Gia Forsman-Härkönen,Global Head of Media RelationsKONE Corporation+358 50 324 30 78media@kone.com VAELLA is a Finnish technology company developing an AI operator for buildings and other crowded public infrastructure. Originating within KONE, a global leader in urban mobility, and launched as an independent venture, VAELLA builds on decades of expertise in understanding how people move through buildings and cities. The AI-powered platform helps facility operators gain real-time situational awareness and anticipate operational challenges before they occur, without intrusive surveillance, creating safer, more resilient, and more people-friendly spaces.  The name is inspired by the Finnish word vaeltaa: to journey, to move through, to navigate. It reflects VAELLA's core belief that seamless, safe people movement is built on intelligent infrastructure operation that serves people. VAELLA’s applications span transport hubs, airports, metro systems, sports and concert stadiums, shopping centres, university campuses, and other high-footfall environments. www.vaella.com  At KONE, our purpose is to shape the future of cities. As a global leader in the elevator and escalator industry, we move two billion people every day, making their journeys safe, convenient, and reliable with smart and sustainable People Flow®. In 2025, KONE had annual sales of EUR 11.2 billion, and at the end of the year over 60,000 employees in close to 70 countries. KONE class B shares are listed on the Nasdaq Helsinki Ltd. in Finland. www.kone.com

Episurf Medical acquires Kuststaden Invest with a property portfolio at an agreed property value of SEK 647 mn

The acquisition in brief Episurf has entered into an agreement to acquire all shares in Kuststaden Invest AB, corp. reg. no. 559419-5231, including the company’s wholly owned property-owning subsidiaries. The sellers are the company’s current owners: NEEL Capital Partners AB (corp. reg. no. 559015-7706), Virbo Invest AB (corp. reg. no. 559015-7698), Polberga AB (corp. reg. no. 556338-7538), Magnus Johansson and Robert Pejic (jointly the “Sellers”). The property portfolio comprises twenty properties with a total lettable area of approximately 52,000 sqm, primarily located in Oskarshamn with additional properties in Västervik, Mönsterås and Hultsfred. The portfolio is mixed-use and comprises retail, grocery, light industry and logistics, office and residential, with tenants such as Scania, Coop, Region Kalmar län, Oskarshamn Municipality and Swedbank. The total agreed property value amounts to SEK 647 mn. Payment of the purchase price The purchase price is financed through an issue of B-shares of SEK 184 mn at a price of SEK 0.10 per B-share, together with financing from banks and credit institutions. The acquisition is conditional upon the buyer obtaining the requisite financing. Dilution The issue of B-shares may result in dilution for existing shareholders of approximately 30.1 percent based on the current number of registered shares. Calculated on all issued and contracted shares prior to the acquisition (fully diluted basis), the dilution amounts to approximately 4.23 percent. Background and rationale On 30 December 2025, Episurf’s board of directors announced that the company had decided to acquire property companies in order to broaden its operations and strengthen its financial position. Episurf has since entered into agreements to acquire, among others, Frusipe Intressenter Target 1 AB, KlaraBo Empire Holding AB, Mofast Invest II AB, a property portfolio from Botrygg AB, a property portfolio from Lilium, two smaller properties from HanssonGruppen and a property portfolio from Setune Assets AB in Uppsala. With the acquisition of Kuststaden Invest, Episurf continues to build its Nordic property platform with a focus on cash flow and returns. Based on property acquisitions already signed, the annual rental income of Episurf’s property segment is, on a pro forma basis following the acquisition, expected to increase from approximately SEK 439 mn to approximately SEK 496 mn, and total property assets from approximately SEK 5,264 mn to approximately SEK 5,911 mn. Key figures for the property portfolio The property portfolio has an agreed property value of SEK 647 mn, a lettable area of approximately 52,000 sqm, a rental income of approximately SEK 56.9 mn and an occupancy rate of approximately 95 percent. The yield amounts to approximately 7.2 percent and the weighted average unexpired lease term (WAULT) to approximately 8.2 years. Advisers CMS Wistrand is legal adviser to Episurf. Bergman & Eek Advokat AB is legal adviser to the Sellers and Bolton Advisors, through Michael Wilton, is financial adviser to the Sellers. For more information, please contact: Jens Andersson, CEO, Episurf Medical Tel: +46 (0) 768 55 67 02 Email: jens.andersson@episurf.com Magnus Johansson, CEO, Kuststaden Invest Tel: +46 (0) 70-699 01 39 Email: magnus@kuststaden.se About Episurf Medical Episurf Medical is a property company with exposure to a diversified portfolio of property assets. The company’s objective is to create value growth through the acquisition and management of Nordic properties. The company also has a medical technology business based on the individualised implant Episealer® and associated surgical instruments, which are used to treat cartilage injuries in joints. Episurf Medical’s head office is located in Stockholm, Sweden. About Kuststaden Kuststaden is a property company operating in south-eastern Sweden with a focus on high-yielding assets. Through a market-driven and creative approach, the group focuses on creating long-term value and sustainable cash flows, with strong roots in the local region. The company has long experience of the property industry and a well-established network, where value-creating transactions, refinement of holdings and growth have always been at the forefront over the years. This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact person set out above, at 13:34 on 10 june 2026. THIS PRESS RELEASE HAS BEEN PUBLISHED IN SWEDISH AND ENGLISH. IN THE EVENT OF ANY DISCREPANCY BETWEEN THE LANGUAGE VERSIONS, THE SWEDISH VERSION SHALL PREVAIL.

Inside Information: Profit warning – Kemira downgrades its profitability outlook for 2026

Kemira downgrades its profitability outlook for 2026 due to the raw material and logistics cost increases caused by the prolonged war in Iran, which have had a larger negative impact on Kemira’s financial performance during the second quarter than previously expected. Kemira has mitigated the impact of the increased costs by implementing price increases, but the impact comes with a delay and has so far been less than previously estimated due to demand weakness in Kemira’s key customer industries. Kemira now expects the revenue to be between EUR 2,600 and 3,000 million, and the operative EBITDA to be between EUR 400 and 500 million in 2026. Earlier, Kemira expected the revenue to be between EUR 2,600 million and EUR 3,000 million, and the operative EBITDA to be between EUR 470 and EUR 570 million. The assumptions behind Kemira’s outlook have also been updated. Kemira’s updated outlookfor 2026Revenue: Kemira's revenue is expected to be between EUR 2,600 and EUR 3,000 million in 2026 (2025 revenue: EUR 2,753.5 million).Operative EBITDA: Kemira's operative EBITDA is expected to be between EUR 400 and EUR 500 million in 2026 (2025 operative EBITDA: EUR 524.6 million) Assumptions behind outlook (updated)The demand in Kemira's end-markets remains weak due to continued global economic uncertainty and geopolitical tensions. The outlook assumes no significant further increases in raw material costs, including oil derivatives, and logistics costs. The outlook assumes no major disruptions to Kemira’s manufacturing operations or the supply chain and the US dollar to remain steady. Kemira’s previous outlook for 2026 (reiterated April 24, 2026)Revenue: Kemira's revenue is expected to be between EUR 2,600 and EUR 3,000 million in 2026 (2025 revenue: EUR 2,753.5 million).Operative EBITDA: Kemira's operative EBITDA is expected to be between EUR 470 and EUR 570 million in 2026 (2025 operative EBITDA: EUR 524.6 million) Previous assumptions behind outlook (specified April 24, 2026)The demand in Kemira's end-markets remains weak due to continued global economic uncertainty and increased geopolitical tensions. In particular, the packaging and pulp market continues to be impacted by this uncertainty. The urban water treatment market is expected to grow modestly, but there is demand volatility within Kemira's industrial customer segment. The outlook assumes that Kemira can largely mitigate raw material and logistics cost increases caused by the war in Iran. The outlook assumes no major disruptions to Kemira’s manufacturing operations or the supply chain and for the US dollar to weaken slightly from the end of 2025. The acquisitions which Kemira announced before the Financial Statements Bulletin 2025 was published are included in the outlook. For more information, please contact Kemira OyjKiira Fröberg, Vice President, Investor RelationsTel. +358 40 760 4258kiira.froberg@kemira.com Kemira is a global leader in sustainable chemistry for water-intensive industries. We operate globally and serve a wide range of customers including municipal and industrial water treatment companies and the fiber industry. Our solutions and services help secure clean water for millions of people every day and support our customers in advancing circularity and responsible resource use throughout their value chains. In 2025, Kemira’s revenue totaled EUR 2.8 billion, and we employed approximately 4,900 people. Kemira’s shares are listed on Nasdaq Helsinki (symbol: KEMIRA) www.kemira.com

Wallenstam sells its wind farms

Wallenstam invested in its first wind turbine in 2007 and thereby began its commitment to renewable energy based on its social engagement and an ambition to contribute to the green transition. In 2013, Wallenstam became the first listed property company to be self-sufficient in renewable electricity on a monthly basis through its own wind power generation. When the investment began, wind power accounted for just under one percent of Sweden’s electricity production. Today, this share amounts to approximately 25 percent. In connection with the sale, Wallenstam is securing renewable electricity for its properties through an agreement with Locus Energy for the supply of renewable energy. “It feels good to have contributed to the green transition of electricity generation in Sweden. We invested early in wind power and have been on a journey where a lot has happened. Now, repowering and other investments are required to further develop the wind turbines, something that a larger and more specialized operator like Locus Energy is better equipped to do. The timing feels right. Meanwhile, it is important to me that we can also ensure a continued supply of renewable energy for our properties,” says Hans Wallenstam, CEO. The sale is being carried out through a company transaction, where the wind turbines have a value of SEK 830 million. The buyer Locus Energy will take over the company once the Swedish Inspectorate of Strategic Products (ISP) has given its approval for the transaction. “Together with Locus Energy, we are now also entering into a joint development project with the goal of using modern technology to develop a dynamic tool for creating electricity price agreements for the real estate market. The ambition is to create a solution that also works for property companies with different and more varied consumption profiles than those traditionally covered by this type of agreement,” says Hans Wallenstam, CEO. “It is exciting to take over the baton and continue developing the wind power assets to meet future conditions. With our existing portfolio of different asset classes, we look forward to working together with Wallenstam and our partners to create a electricity price agreement tailored to the needs of real estate companies,” says Niklas Sörensen, CEO of Locus Energy. Locus Energy is a long-term owner and developer of renewable energy in the Nordic region. The company is owned by the Article 9 fund SEB Nordic Energy and invests capital from the fund. Its portfolio consists of hydropower, wind power and battery storage, with a focus on developing existing assets. The Locus Energy platform is part of the long-term partnership between SEB Asset Management and Locus Infra for investments in renewable energy and infrastructure.

Continued success for the new anti-infective therapies developed by Hamlet BioPharma

The Journal of Infectious Diseases publishes the paper “Targeting the disease response with NlpD and LytM for effective non-antibiotic treatment of urinary tract infections.” This study demonstrates that inhibiting the disease response of the host offers an efficient alternative to antibiotics for the treatment of bacterial infections. By inhibiting the disease response to infection and accelerating bacterial clearance, the drug candidates protect infected tissues from disease, with similar efficacy as antibiotics. doi.org/10.1093/infdis/jiag243. The paper reveals a promising non-antibiotic approach to treating bacterial infections, by  targeting the host’s disease response rather than the bacteria themselves. This is shown for urinary tract infections (UTIs), one of the most common bacterial infections worldwide. Researchers from Lund University, in collaboration with Hamlet BioPharma, have demonstrated that bacterial infections can be effectively treated using the bacterial protein NlpD or its peptide LytM - including those caused by antibiotic-resistant bacteria. This study introduces drug candidates that inhibit the chaotic and excessive immune response that causes the symptoms of disease in infected patients. NlpD and LytM inhibit the disease response by targeting RNA Polymerase II (Pol II), a critical enzyme in the host’s transcriptional machinery. By disrupting Pol II’s function, these drug candidates suppress excessive responses such as cytokine storms, that drive tissue damage during infection. NlpD or LytM treatment each reduced disease severity and accelerated bacterial clearance, including infections caused by antibiotic resistant bacteria. The importance of this non-antibiotic treatment approach was recently demonstrated in a groundbreaking clinical study of the IL-1 receptor antagonist anakinra . The new publication in the Journal of Infectious Diseases now adds further drug candidates discovered by the scientists at Lund University that are being developed for clinical use. ‘’This study is based on extensive infection studies where NlpD and LytM show potent therapeutic effects against disease in mice. The animal models are crucial for the pre-clinical development, to select the right molecules for future use in patients, says Hien Tran, PhD, Lund University. "Our findings challenge the view that bacterial infections must be treated by killing the bacteria with antibiotics. By identifying the disease mechanism, we can treat infections by targeting the disease, including antibiotic resistant strains", says Ines Ambite, PhD, Lund University. Links to the publication: Targeting the disease response with NlpD and LytM for effective non-antibiotic treatment of urinary tract infections. The Journal of Infectious Diseases, doi.org/10.1093/infdis/jiag243. For more information please contact: Ines Ambite, Senior Scientist, Lund University, +46-762 08 89 58 ines.ambite@med.lu.se (ines.ambite@med.lu.sem) Catharina Svanborg, Chair of the Board, Hamlet BioPharma, +46-709 42 65 49 catharina.svanborg@hamletpharma.com www.hamletbiopharma.com

EQT Real Estate acquires 2.4 million square foot logistics portfolio in key markets across the Southeast U.S.

EQT Real Estate is pleased to announce that the EQT Real Estate Industrial Value Fund VI (“EQT Real Estate”) has acquired a 2.4 million square foot logistics portfolio across three fast-growing markets in the U.S. Southeast, comprising Savannah, Georgia, Jacksonville, and Lakeland, Florida.  The portfolio consists of three Class A industrial buildings with strong access to critical transportation infrastructure. The Savannah asset is located approximately five miles from the Port of Savannah, one of the busiest container ports in the U.S., while the Jacksonville building benefits from proximity to JAXPORT and regional road networks. The Lakeland asset sits along the I-4 corridor between Tampa and Orlando, a key location for serving Florida’s large and growing consumer base. The Port of Savannah handled 5.7 million TEUs in 2025, its second-busiest year on record, while JAXPORT moved more than 10 million tons of cargo over the same period.   The assets are fully leased to a range of blue-chip tenants, and were built to modern logistics specifications, including cross-dock layouts, large building footprints, and clear heights that support efficient movement of goods. EQT Real Estate plans to deploy its hands-on approach to active management supporting long-term performance, operational quality, and resilience for current and future occupiers.  Matthew Brodnik, Global Chief Investment Officer at EQT Real Estate, said: “The Southeast continues to stand out as one of the most important logistics corridors in the U.S., driven by population growth, expanding port activity, and the ongoing modernization of supply chains. This portfolio combines scale, modern functionality, and strategic access to critical transportation infrastructure across three markets that we believe will continue to see strong demand from businesses serving the region’s growing economy.  EQT Real Estate would like to thank John Huguenard, Trent Agnew, and Will McCormack of JLL who advised the seller, a Brookfield affiliate, in the transaction.  ContactEQT Press Office, press@eqtpartners.com

FairWind strengthens Americas presence with acquisition of US-based Rope Partner

Colorado-based Rope Partner is a leading provider of at-height maintenance, inspection and performance enhancement services. The company specialises in blade repair, turbine cleaning and inspection and warranty verification services that support asset life extension and operational safety. Rope Partner's WindCorps technicians are the driving force behind the company's relationships with more than 40 blue chip wind energy asset owners and OEMs, and have built an unparalleled quality and safety record across more than two decades of operations. With more than 20 years’ experience, Rope Partner also delivers comprehensive rope access technician training at its purpose-built facility in Denver, Colorado. All courses are certified by the US-based Society of Professional Rope Access Technicians (SPRAT). The company currently employs 135 people. The acquisition significantly expands FairWind’s service offering in the Americas, enabling the delivery of integrated installation and maintenance solutions while leveraging Rope Partner’s established local client base, regional expertise, training capabilities, and its dedicated highly specialised technicians. Stewart Mitchell, CEO at FairWind commented: “The US wind sector has seen rapid growth in recent years, and Rope Partner brings highly specialised expertise in blade repair and at-height services that directly complement our core capabilities. By combining our global experience in turbine installation and service with Rope Partner’s technical strengths, we are in a strong position to scale our presence and further support customers with high-quality solutions across the full lifecycle of assets. “Rope Partner’s established training programmes will also enable us to further invest in developing a highly skilled, safety-driven workforce in the United States. As demand for wind energy continues to grow, access to qualified technicians will be critical to maintaining high standards across the industry and we look forward to driving this activity.” Eric Stanfield, CEO at Rope Partner, said: "Joining FairWind not only strengthens our position in the North American renewables market but opens up exciting opportunities for growth as part of a world-leading wind energy company. We are looking forward to reaching new markets, bringing greater capability to our clients, and playing a bigger role in the global transition to sustainable energy, all while upholding the excellent safety and quality reputation that both companies have built over the years.” FairWind has a workforce of more than 2,000 people in more than 40 countries across Europe, North America, South America, Asia, and Oceania. The business provides complete lifecycle solutions for the installation and maintenance of onshore and offshore wind turbines around the world. 

World’s first large-scale 100% hydrogen engine tested at Wärtsilä’s Bermeo laboratory to support the Spanish grid

· Wärtsilä Energy has successfully operated a new 100% hydrogen engine supplying power to Spain’s national electricity grid in Bermeo, Spain. This is the world’s first demonstration of a large-scale hydrogen engine running on 100% pure hydrogen. · The demonstration marks a significant step beyond hydrogen-ready technologies, proving that engine-based power generation can run entirely on hydrogen in real grid conditions – paving the way for this capability to become a reality at scale in the future. · Hydrogen-fuelled Wärtsilä 31 engines can also support energy-intensive sectors, such as AI data centres and industry in the future. Technology group Wärtsilä has started validation of a new 100% hydrogen engine to power Spain’s national electricity grid in Bermeo, northern Spain – the world’s first demonstration of a large-scale, 100% hydrogen engine. The trial marks a major step forward in proving that engine technology can operate on 100% sustainable fuels such as hydrogen, building on Wärtsilä’s earlier launch of the world’s first large-scale 100% hydrogen-ready engine power plant  and opening a clear pathway towards fully renewable power systems. With global renewable energy generation set to grow by almost 4,600 GW by 2030 , flexible technologies capable of balancing grids during periods of low wind and solar output are becoming increasingly critical. Green hydrogen produces no carbon emissions, enabling clean power generation while supporting the decarbonisation of renewable-heavy grids. It can store excess renewable electricity and provide reliable power when wind or solar generation drops, helping to stabilise the system and improve energy reliability. The Wärtsilä 31H2 engine, part of the Wärtsilä 31 platform, one of the world’s most efficient multi-fuel 4-stroke engines, shows that hydrogen can move beyond theory into real-world energy infrastructure. The Wärtsilä 31H2 engine is the world’s largest pure hydrogen engine, with performance currently being verified in Bermeo. Rasmus Teir, Director of Technology Strategy & Decarbonisation at Wärtsilä, says: “This is a trial for the future of renewable power. As countries rapidly scale wind and solar energy, one of the biggest challenges facing the energy transition is how to maintain reliable electricity supplies sustainably during periods of low renewable generation or spikes in demand. Today, our Wärtsilä 31H2 hydrogen engine is operating on 100% hydrogen and supplying power to Spain’s national grid, demonstrating that large-scale hydrogen engines can provide the flexible, dispatchable sustainable power needed to support future renewable energy systems.” “We have proven the technology is ready. Now, the focus must be on creating the right environment to scale it, underpinned by decisive regulation, investment clarity, and the infrastructure needed to accelerate the growth of renewable energy and sustainable fuels like hydrogen. The technology is here – now it’s time to scale it.”  The Wärtsilä 31 based power plant is designed to support rapidly growing, energy-intensive industries – including data centres, manufacturing facilities and industry – with flexible, sustainable power generation, and off-grid environments. Spain, as one of the forerunners in renewable energy adaption, provided an ideal location for the trial thanks to its efforts to reduce exposure to fossil fuel volatility, making it a strong test bed for demonstrating the future potential of hydrogen technologies. In June 2026, Wärtsilä’s customers from around the world witnessed the operation of the engine, marking a significant milestone in its commercial validation. Media contact: Katri Pehkonen Communications Manager Wärtsilä Energy Mob: +358 50 591 6180 katri.pehkonen@wartsila.com Contact for product related inquiries:  Christian HultholmProduct Manager, W31 Power PlantsWärtsilä EnergyMob: +358 40 194 9579 christian.hultholm@wartsila.com Media kit including key materials  Image caption: Wärtsilä has started validation of a new 100% hydrogen engine to power Spain’s national electricity grid in Bermeo, northern Spain – the world’s first demonstration of a large-scale, 100% hydrogen engine. © Wärtsilä Corporation All Wärtsilä releases are available at www.wartsila.com/media/news-releases and at news.cision.com/wartsila-corporation where also the images can be downloaded. Use of the image(s) is allowed only in connection with the contents of this press release. Wärtsilä images are available at www.wartsila.com/media/image-bank. About Wärtsilä Energy Wärtsilä Energy is at the forefront of the transition towards a 100% renewable energy future. We help our customers and the power sector to accelerate their decarbonisation journeys through our market-leading technologies and power system expertise. Our solutions include flexible engine power plants, energy storage and optimisation technology, and services for the whole lifecycle of our installations. Our engines are future-proof and can run on sustainable fuels. Our track record comprises 81 GW of power plant capacity and over 130 energy storage installations in 180 countries around the world. About 35% of our operating installed base is under service agreements. www.wartsila.com/energy Wärtsilä in brief Wärtsilä is a global leader in innovative technologies and lifecycle solutions for the marine and energy industries. We emphasise innovation in sustainable technology and services to help our customers continuously improve environmental and economic performance. Our dedicated and passionate team of 17,900 professionals in 199 locations in 78 countries shape the decarbonisation transformation of our industries across the globe. In 2025, Wärtsilä’s net sales totalled EUR 6.9 billion. Wärtsilä is listed on Nasdaq Helsinki. www.wartsila.com  

RUFF Golf expands in the UK through the consolidation of Bunker Indoor Golf

RUFF Golf has signed a new ten-year Master Franchise agreement for the Midlands in the UK. The agreement will see the existing Bunker Indoor Golf venues in Nottingham and Heanor gradually converted into RUFF venues and integrated into RUFF’s international concept, brand, and operating platform. The businesses are operated by Ultima Enterprise Ltd, led by entrepreneurs Adam Grace, Luke Robinson, Adam Dixon, and Mel Parker, who will now become RUFF’s Master Franchise partner for the Midlands region. Alex Bengtsson, CEO and founder of RUFF Golf, says: “We are very happy and proud to welcome the new team to the RUFF family. This partnership shows that more established operators see the value of joining a larger network, where we can build stronger brands, better customer experiences, and more profitable venues together.” The two existing Bunker Indoor Golf venues in Nottingham and Heanor will be integrated into RUFF’s brand, systems, operating model, and future product development. At the same time, Ultima Enterprise Ltd will be responsible for operating and developing the RUFF concept across the Midlands, with Nottingham and Heanor as the first step. For RUFF, the agreement marks another step in the company’s international growth strategy, combining experienced local entrepreneurs with RUFF’s scalable concept, brand, and platform. Alex Bengtsson continues: “This is exactly the type of partnership we believe in. When driven entrepreneurs with strong local market knowledge join forces with RUFF’s concept, brand, and platform, we create something stronger than either of us could have built on our own.” Established Indoor golf operators join the RUFF network RUFF is seeing growing interest from existing indoor golf operators who want to become part of a larger international network. The integration of already established venues into the RUFF network reflects a broader development in the indoor golf market, where operators are looking for stronger brands, more efficient operations, and scalable business models. Adam Grace, Director at Ultima Enterprise Ltd: “Over the past few years, we have built Bunker Indoor Golf into a strong local business focused on customer experience, technology, and community. Partnering with RUFF gives us access to a proven concept, operational expertise, and an international network that will help us take the next step. Our ambition is to make England a leading market for indoor golf in Europe,” Today, RUFF has 21 open venues across Europe. The company combines golf, technology, food, drinks, and social experiences in a modern indoor golf format designed for both experienced golfers and new audiences.

Metso strengthens mineralogy capabilities with new investment to accelerate customer project development

Metso is reinforcing its mineralogy capabilities at its Research Center in Pori, Finland, with a new investment designed to help customers move faster and make better-informed decisions across the full lifecycle of their minerals processing projects from early phase project design through to operational optimization. The enhanced capabilities strengthen Metso's ability to deliver high-quality mineralogical data more rapidly, enabling faster execution and better-informed flowsheet development.   The investment includes the installation of a TESCAN TIMA™ automated mineralogy analyzer. This advanced equipment integrates high-resolution field emission scanning electron microscopy (FE-SEM) imaging with multidetector elemental analysis into a single, fully automated system. The new equipment complements Metso’s long-established expertise in mineralogical analysis and significantly increases analysis speed while enabling higher sample capacity. This enables Metso's specialists to generate quantitative data on ore characteristics, mineral associations, and metallurgical behavior across a higher volume of samples.   Detailed mineralogical insight to support decision-making  “In minerals processing and metals refining, the mineralogy of the feed material dictates the outcome of the entire process. By applying detailed mineralogical analysis to feed, concentrates, tailings, and other process products across mineral processing, hydrometallurgy, and pyrometallurgy, the foundation for selecting the appropriate metallurgical route at an early stage can be provided," says Tero Kravtsov, Senior Mineralogist at Metso.   "This investment strengthens the mineralogy expertise we have applied for decades. By expanding our analytical capacity and shortening turnaround times, the experts at the Pori Research Center can deliver clear, actionable mineralogical data for a greater number of cases.  Such clarity directly reduces project risk and improves resource efficiency across the entire process," explains Matthew Hicks, Director, Minerals Processing at Metso.   Leading research capabilities for the benefit of the mining industry  Metso’s unique capabilities, spanning advanced mineralogy, laboratory testing, pilot work and flowsheet development, allow mining customers to improve recoveries, optimize resource efficiency and develop more robust and sustainable processing routes across the full lifecycle of operations.   Metso Research Center in Pori is one of Metso's hubs for research and product development and is focused on mineral processing, hydrometallurgy, battery material process solutions and smelting technologies.  “Strengthening our mineralogy capabilities in Pori further enhances our ability to support early engagement with customers and improve efficiency. This is key to promoting integrated Metso flowsheets built around our core products and technologies. Mineralogical characterization is essential in defining the optimal metallurgical route," says Rodrigo Grau, Vice President, Minerals Processing Solutions at Metso.   Find out more about Metso's research and testing offering on our website.  Further information:  Matthew Hicks, Director, Minerals Processing, Metso, email: matthew.hicks(at)metso.com  Metso Media Desk, tel. +358 20 482 1930, email: media(at)metso.com   Metso is a frontrunner in sustainable technologies, end-to-end solutions and services for the aggregates, minerals processing and metals refining industries globally. We improve our customers’ energy and water efficiency, increase their productivity, and reduce environmental risks with our product and service expertise. We are the partner for positive change.   Metso is headquartered in Espoo, Finland. At the end of 2025 Metso had close to 18,000 employees in around 50 countries, and sales in 2025 were about EUR 5.3 billion. Metso is listed on the Nasdaq Helsinki.  metso.com 

ZINZINO AB (PUBL.): Zinzino launches Collagen Boozt Flex as beauty-from-within enters daily routines

New powder formula combines marine collagen, hyaluronic acid, postbiotics and selected nutrients for flexible daily beauty routines Gothenburg, Sweden – 11 June 2026 – As beauty-from-within moves from trend-led conversation into everyday routines, consumers are increasingly looking for solutions that connect skincare, nutrition and wellbeing. Zinzino today announced the launch of Collagen Boozt Flex – a new marine collagen powder designed to bring beauty-supporting nutrients, wellness and convenience into one daily format. The launch comes at a time when functional beauty products, collagen and holistic wellness routines are becoming more established in consumer lifestyles globally. According to Euromonitor International Consumer Trend Report 2026, beauty-from-within is one of the fastest-growing areas within the global dietary supplement category, while beauty is among the leading growth platforms in consumer health. At the same time, beauty and healthy ageing are identified as key trends influencing product innovation and consumer demand across international wellness markets. Consumer interest continues to grow. Industry insights from Innova Market Insights show that nearly half of consumers are interested in products that support appearance-related benefits, reflecting increasing demand for nutrition-based approaches to skin, hair and nails. Meanwhile, wellness analysts point to growing consumer interest in routines that connect beauty, nutrition and digestive wellbeing as part of a more holistic approach to everyday wellness. Collagen Boozt Flex will be available across European markets from 13 June 2026 and has been developed to meet these evolving consumer preferences. The berry-flavoured powder delivers 8 grams of hydrolysed marine collagen peptides sourced from wild-caught Arctic fish from Norwegian waters, giving the formula a clear Nordic provenance. It also contains 120 mg of hyaluronic acid, vitamin C from acerola cherry, biotin, zinc, rice bran ceramides and the amino acids L-arginine and glycine. A distinguishing feature of the formula is the inclusion of postbiotics – compounds produced through the activity of beneficial bacteria. Their addition reflects growing consumer interest in beauty-from-within routines that take a broader view of wellness and recognise the increasing focus on the relationship between digestive wellbeing and everyday wellness. Designed for active, modern lifestyles, Collagen Boozt Flex can be mixed with water, blended into smoothies or added to breakfast, making it easy to incorporate into daily routines. The launch also expands Zinzino’s existing Collagen Boozt range, giving consumers the choice between a ready-to-drink collagen gel and a flexible powder format. “Beauty is no longer viewed only through the lens of topical skincare. Consumers are increasingly connecting how they care for their skin with nutrition, lifestyle and daily routines,” says Gabriele Helmer, Chief Marketing Officer at Zinzino. “With Collagen Boozt Flex, we have brought together marine collagen, hyaluronic acid, postbiotics and selected nutrients in a flexible format that is easy to use every day.” Vitamin C contributes to normal collagen formation for the normal function of skin, cartilage and bones. Biotin and zinc contribute to the maintenance of normal skin and hair, while zinc also contributes to the maintenance of normal nails. Collagen Boozt Flex will be available across European markets from 13 June 2026 through Zinzino’s global distribution network. For more information, visit http://www.zinzino.com. For more information:Gabriele Helmer CMO Zinzino, gabriele.helmer@zinzino.com Pictures for publication free of charge: marketing@zinzino.com

Wirtek signs non-binding acquisition agreement

Company Announcement no. 6/202611 June 2026 This announcement contains inside information The acquisition target operates a subscription-based SaaS business with predominantly recurring revenue, a blue-chip customer base spanning life sciences, defence, energy, financial services and public-sector organisations, and a track record of profitable growth with zero customer churn in 2025. The expected acquisition is closely aligned with Wirtek’s strategy of scaling through strategic acquisitions. It strengthens Wirtek’s Solutions portfolio with a profitable, subscription-based product line, just as it extends the Group’s customer base with new blue-chip references in regulated industries and creates cross-sell opportunities across the combined North American and European customer base. The final closing of the acquisition is planned for July 2026 and is conditional upon a satisfactory due-diligence result and the negotiation of a binding share purchase agreement. The consideration will be paid in cash. Part of the consideration is fixed and paid at closing; the remainder is structured as a multi-year earn-out linked to the recurring-revenue performance of the acquired company in the financial years 2026, 2027 and 2028. Further details about the acquisition will be published after the final closing. The letter of intent is non-binding, and there can be no assurance that the transaction will be completed. Contact information · Michael Aaen, CEO, Wirtek A/S, Phone: +45 2529 7575, E-mail: ir@wirtek.comNiels Jernes Vej 10, 9220 Aalborg, Denmark, www.wirtek.com · Pernille Friis Andersen, HC Andersen Capital, Certified Advisor, E-mail: pernille@hcandersencapital.dk About Wirtek Wirtek A/S is a Danish IT Services and Solutions company delivering software development, embedded engineering, R&D, quality assurance, and testing services to clients worldwide. We specialise in key industries such as Energy, Wireless Communication, Automation & IoT, and Digitalisation, where emerging technologies drive rapid innovation. In addition, Wirtek offers a growing portfolio of proprietary solutions tailored to the Energy and IoT sectors. At Wirtek, we prioritise long-term client relationships, with some lasting more than a decade. We believe that strong partnerships are as critical as technical excellence in achieving sustainable success. Wirtek operates from offices in Denmark, Romania, and Portugal, and has been listed on Nasdaq First North Copenhagen since 2006. Ticker Code: WIRTEK (DK0060040913) 

Form 8.3 - DCC plc

Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1.KEY INFORMATION +--------------------------------------------------------+---------------------+|(a)Full name of discloser |Ninety One UK Limited|+--------------------------------------------------------+---------------------+|(b)Owner or controller of interests and short positions | ||disclosed, if different from 1(a) | || | ||The naming of nominee or vehicle companies is | ||insufficient. For a trust, the trustee(s), settlor and | ||beneficiaries must be named. | |+--------------------------------------------------------+---------------------+|(c)Name of offeror/offeree in relation to whose relevant|DCC Plc ||securities this form relates | || | ||Use a separate form for each offeror/offeree | |+--------------------------------------------------------+---------------------+|(d)If an exempt fund manager connected with an |No ||offeror/offeree, state this and specify identity of | ||offeror/offeree (Note 1) | |+--------------------------------------------------------+---------------------+|(e)Date position held/dealing undertaken |10 June 2026 || | ||For an opening position disclosure, state the latest | ||practicable date prior to the disclosure | |+--------------------------------------------------------+---------------------+|(f)In addition to the company in 1(c) above, is the |No ||discloser also making disclosures in respect of any | ||other party to the offer? | || | ||If it is a cash offer or possible cash offer, state | ||“N/A” | |+--------------------------------------------------------+---------------------+ 2.INTERESTS AND SHORT POSITIONS If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security. Ap28 Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) (Note 2) +---------------------------------------+----------+------+-+-------------+|Class of relevant security |ORD EUR0.25 (CDI) ||(Note 3) | |+---------------------------------------+----------+------+-+-------------+| |Interests |Short positions|+---------------------------------------+----------+------+-+-------------+|Number |% |Number|%|+---------------------------------------+----------+------+-+-------------+|(1)Relevant securities owned and/or |2,681,100*|3.13 | | ||controlled | | | | |+---------------------------------------+----------+------+-+-------------+|(2)Cash-settled derivatives | | | | |+---------------------------------------+----------+------+-+-------------+|(3)Stock-settled derivatives (including| | | | ||options) and agreements to purchase/ | | | | ||sell | | | | |+---------------------------------------+----------+------+-+-------------+|Total |2,681,100*|3.13 | | |+---------------------------------------+----------+------+-+-------------+ *Ninety One UK Limited does not have discretion over voting rights in respect of 515,491 shares that are included in the total above. All interests and all short positions should be disclosed. Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form8. 3.DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4) Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a)Purchases and sales +-----------------+-------------+----------+--------------+|Class of relevant|Purchase/sale|Number of |Price per unit||security | |securities|(Note 5) |+-----------------+-------------+----------+--------------+|ORD EUR0.25 (CDI)|Sale |4,093 |61.2178 |+-----------------+-------------+----------+--------------+|ORD EUR0.25 (CDI)|Sale |127,456 |61.2000 |+-----------------+-------------+----------+--------------+ Ap29 (b)Cash-settled derivative transactions +--------+-----------+----------------------+----------+-----+|Class of|Product |Nature of dealing |Number of |Price||relevant|description|e.g. opening/ closing |reference |per ||security|e.g. CFD |a long/ short |securities|unit || | |position, increasing/ |(Note 6) |(Note|| | |reducing a long/ short| |5) || | |position | | |+--------+-----------+----------------------+----------+-----+| | | | | |+--------+-----------+----------------------+----------+-----+ (c)Stock-settled derivative transactions (including options) (i)Writing, selling, purchasing or varying +--------+-----------+-----------+----------+--------+---------+------+--------+|Class of|Product |Writing, |Number |Exercise|Type |Expiry|Option ||relevant|description|purchasing,|of |price |e.g. |date |money ||security|e.g. call |selling, |securities|per |American,| |paid/ || |option |varying |to which |unit |European | |received|| | |etc. |option | |etc. | |per unit|| | | |relates | | | | || | | |(Note 6) | | | | |+--------+-----------+-----------+----------+--------+---------+------+--------+| | | | | | | | |+--------+-----------+-----------+----------+--------+---------+------+--------+ (ii)Exercise +--------+-----------+-----------+----------+---------+|Class of|Product |Exercising/|Number of |Exercise ||relevant|description|exercised |securities|price per||security|e.g. call |against | |unit || |option | | |(Note 5) |+--------+-----------+-----------+----------+---------+| | | | | |+--------+-----------+-----------+----------+---------+ (d)Other dealings (including transactions in respect of new securities) (Note 3) +--------+--------------------+-------+------------------+|Class of|Nature of dealing |Details|Price per unit (if||relevant|e.g. subscription, | |applicable) ||security|conversion, exercise| |(Note 5) |+--------+--------------------+-------+------------------+| | | | |+--------+--------------------+-------+------------------+ Ap30 4.OTHER INFORMATION (a)Indemnity and other dealing arrangements +------------------------------------------------------------------------------+|Details of any indemnity or option arrangement, or any agreement or ||understanding, formal or informal, relating to relevant securities which may ||be an inducement to deal or refrain from dealing entered into by the person ||making the disclosure and any party to the offer or any person acting in ||concert with a party to the offer. || ||Irrevocable commitments and letters of intent should not be included. If there||are no such agreements, arrangements or understandings, state “none” |+------------------------------------------------------------------------------+| |+------------------------------------------------------------------------------+ (b)Agreements, arrangements or understandings relating to options or derivatives +------------------------------------------------------------------------------+|Full details of any agreement, arrangement or understanding between the person||disclosing and any other person relating to the voting rights of any relevant ||securities under any option referred to on this form or relating to the voting||rights or future acquisition or disposal of any relevant securities to which ||any derivative referred to on this form is referenced. If none, this should be||stated. |+------------------------------------------------------------------------------+| |+------------------------------------------------------------------------------+ (c)Attachments +----------------------------------+--+|Is a Supplemental Form 8 attached?|NO|+----------------------------------+--+ +------------------+--------------------+|Date of disclosure|11 June 2026 |+------------------+--------------------+|Contact name |Charmaine Haliburton|+------------------+--------------------+|Telephone number |+44 20 3938 2050 |+------------------+--------------------+ Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service. Ap31 NOTES ON FORM 8.3 1.See the definition of “connected fund manager” in Rule 2.2 of Part A of the Rules. 2.See the definition of “interest in a relevant security” in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) and (b) of Part B of the Rules. 3.See the definition of “relevant securities” in Rule 2.1 of Part A of the Rules. 4.See the definition of “dealing” in Rule 2.1 of Part A of the Rules. 5.If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given. 6.See Rule 2.5(d) of Part A of the Rules. 7.If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted. For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel. References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Nimlas Sweden expands in Stockholm through the acquisition of Svenska vvs & elanläggningar

Svenska vvs & elanläggningar was founded four years ago by Jonas Holden and Oskar Jangerstad and has experienced strong growth ever since. The company specializes in construction contracts and offers turnkey solutions in both plumbing and heating (HVAC) as well as electrical installations. Its HVAC operations are primarily focused on residential new-build projects, while its electrical business mainly covers tenant fit-outs and renovation contracts. Svenska vvs & elanläggningar generates annual revenue of SEK 74 million and employs 18 people based in Västberga, serving customers throughout the Stockholm region. “By becoming part of Nimlas, Oskar and I will have better opportunities to streamline our day-to-day administrative work, allowing us to spend more time supporting our operations and project delivery,” says Jonas Holden, Managing Director of Svenska vvs & elanläggningar. Oskar Jangerstad, Project Manager, adds: “Our ambition is to continue growing our electrical business, and together with Nimlas Sweden I see great opportunities to further develop the company and accelerate our growth.” “I would like to warmly welcome Jonas, Oskar and their colleagues to Nimlas. Through the acquisition of Svenska vvs & elanläggningar, we strengthen our position in both HVAC and electrical services in the Stockholm region,” says Anders Buskas, Regional Manager, VS Mid, Nimlas Sweden. Closing of the transaction will take place in June. Nimlas in brief:  Nimlas is on track to become the most successful company in the technical installations industry, uniting close to 140 companies and 5,000 professionals across Sweden, Norway and Finland. The group provides a complete range of technical installation services, including electricity, plumbing, HVAC, automation, fire safety, and other related services. Nimlas has a pro forma turnover of SEK 10 billion and is owned by KLAR Partners. For more information:Louise Schenholm, Marketing and Communication Manager, Nimlas Sweden+46 70 690 73 51, louise.schenholm@nimlas.se  

Announcement from Annual General Meeting

The Chairman of the Board, Magnus Sparrholm, opened the 24[th] Annual General Meeting (AGM) of Talkpool AG and welcomed the persons attending physically and remotely; · Board Members Erik Strömstedt and Magnus Sparrholm attend personally present. Board Member Mats Palving attended remotely. Board candidate Johan Lindqvist is personally attending the meeting. · Sarah Rocco counted votes and took notes with the support from finance executive Erika Loretz. · Notary Dr. Marco Ettisberger and Proxy Joseph Gabrieli attended personally. · Auditor Tu’uyen Maria Lang and Werner Pfäffli from Balmer-Etienne AG attended the meeting remotely. · Shareholders attended remotely through a videolink. The Chairman concludes that this annual shareholder meeting is fully functional and compliant with regulations. The following is noted: 1. invitations have been sent out 20 days prior to this meeting in compliance with stock exchange regulations as well as Swiss regulations. 2. Out of a total 7’655’579 issued shares, 2’324’432 shares (30.4%) are represented in this AGM 3. The audit spans consolidated reports for the Group as well as statutory reports for the parent company. 4. Shareholders that aren’t personally registered as owners in the share registers need to show proof of ownership to vote in the AGM. 5. The AGM was initially planned for an earlier date, but it was delayed due to Swiss regulations regarding approval of a share issue. Before starting with the agenda, the Chief Executive Director made a presentation of Talkpool’s development in 2025. After presenting the main events, Erik Strömstedt showed a market update, financial performance and Vision 2030 including financial targets. A short review of the 2025 annual consolidated results: · EUR 17.8 million in revenues, 12.5% more than EUR 15.8 million in the previous year. · EUR 1.83 million EBITDA, compared to EUR 1.70 million in 2024 · Net Profit of EUR 862 thousand, compared to EUR 605 thousand in 2024 The Board of Directors confirms that the material uncertainty related to going concern no longer exists. The accounting standard (Code of Obligations in Switzerland) has remained unchanged since Talkpool’s IPO in 2016. 1. The auditor Balmer-Etienne AG, represented by Tu’uyen Maria Lang and Werner Pfäffli, presented its findings. The audit reports are part of the annual report. The Annual Accounts and the Remuneration Report for 2025 were approved unanimously. 2. After appropriation of the annual profit in the parent company, the total loss carried-forward amounts to CHF 8’988’354, a decrease from CHF 10‘539‘672 in 2024. 3. All Board members were discharged from liability for the past fiscal year. 4. The existing board with Mats Palving as Non-Executive Director, Erik Strömstedt as Executive Director and Magnus Sparrholm as Executive Director was re-elected. Magnus Sparrholm was re-elected Chairman of the Board. Johan Lindqvist was elected as new member of the board. Erik Strömstedt and Magnus Sparrholm were re-elected as responsible for formulating remuneration guidelines for senior executives in accordance with the Board's proposal. 5. Balmer-Etienne AG was re-elected as auditor. 6. Re-election of independent proxy Josef Gabrieli as Representative for shareholders 7. Approval of Remuneration report as per Swiss regulations, with same levels as last year: 1. Approving 2025 remuneration report (as audited) 2. Unchanged max CHF 30’000 to Board of Directors until next AGM 3. Unchanged max CHF 500’000 fixed remuneration for Executive Management (Erika Loretz, Erik Strömstedt & Magnus Sparrholm) until next AGM 4. CHF 16 748 variable remuneration / bonus was paid to the executive management in year 2025 8. Article of Association amendment: Capital Band increase by max 4’577’621 shares until 2031 9. The concept for a new Advisory Board with focus on sales and business development was presented No miscellaneous topic was brought. The AGM ended on time with positive comments from attendants as the company shifts its focus from financial discipline towards growth. This is a simplified summary published after the AGM. Complete Minutes of Meeting will be published on Talkpool's homepage www.talkpool.com

STOREBRAND ASA: Negotiated agreement to acquire up to 100 percent of the shares in Knif Trygghet Forsikring AS

Reference is made to Storebrand's stock exchange announcement of 29 January 2026 regarding the entry into a letter of intent with Knif AS ("Knif") and Knif Trygghet Forsikring AS ("Knif Trygghet"). Storebrand ASA has now negotiated an agreement to acquire up to 100 percent of the shares in Knif Trygghet, a Norwegian non-life insurer serving the non-profit and voluntary sector, as well as a partnership agreement with Knif to offer insurance, pension and asset management products to the market for non-profit and Christian organisations. It is now up to the owners of Knif and Knif Trygghet to decide whether they wish to enter into the agreements negotiated by the parties. - Over time, Knif has built a strong position in its market. For Storebrand, Knif’s customer base, core portfolio, and employees are all valuable and important. We hope that Knif’s owners see the value of merging, and we look forward to a long and productive collaboration, says Trond Fladvad, CEO of Storebrand Forsikring AS.It is now up to the owners behind Knif and Knif Trygghet to decide whether they wish to accede to the agreements negotiated by the parties.- If the owners of Knif Trygghet endorse the agreement, we will take good care of the employees. The employees’ unique expertise and the strong customer relationships Knif has built are an important part of what we wish to carry forward. It will also be crucial to take good care of Knif’s customers, and we will maintain the insurance coverages, says Fladvad. The consideration for 100 percent of the shares in Knif Trygghet amounts to NOK 560 million and will be settled entirely in new shares in Storebrand ASA. The final number of consideration shares will be determined at the time of completion. The owners behind Knif Trygghet consist of around 50 non-profit and voluntary organisations, with Knif AS as the largest shareholder. Knif Trygghet will be merged with Storebrand Forsikring AS following completion of the transaction. The merger strengthens Storebrand's position within non-life insurance in the Norwegian corporate and retail markets. The transaction is not expected to have a material effect on Storebrand's financial position or results. Completion of the transaction is conditional upon sufficient accession from the shareholders of Knif Trygghet and the required approvals from the Financial Supervisory Authority of Norway and the Norwegian Competition Authority.Lysaker, 11 June 2026

Glaston strengthens its technology portfolio and acquires coating technology IP

Glaston, an innovative technology leader in glass processing, has acquired selected intellectual property rights that were originally developed by the engineering start-up Volframi Oy. The technology offers interesting opportunities for integrating intelligence into glass through advanced coating solutions. As a result of the transaction, patented and patent-pending technologies related to this unique local area coating technology will transfer to Glaston. Initially introduced at the Glass Performance Days1) conference in 2021, the local area coating concept  represents an advanced method for depositing multiple thin-film layers on precisely targeted areas of large glass substrates. The coating technology supports more sustainable glass production by lowering resource consumption and environmental impact. It enables more efficient manufacturing of both existing and new glass applications by reducing equipment needs, minimizing factory space, and decreasing labor intensity. In addition, it cuts material waste, contributing to better resource efficiency. The acquired assets provide a proven scientific foundation that Glaston will leverage to develop high-performance glass solutions together with its customers. The technology enables various glass applications for the mobility, appliance, and architectural industries. “Glaston actively supports the development of new technologies that integrate intelligence into glass, and this acquisition is a concrete example of that approach, says Miika Äppelqvist, CEO at Glaston. “This local area coating concept lets our architectural, appliance, and mobility customers add functionality precisely where it’s needed, using less materials, less process steps and opening new design opportunities.” For more information:Miika Äppelqvist, CEO, +358 10 500 500Daniel Sumelius, Manager, Business Development, +358 10 500 500, daniel.sumelius@glaston.net Media inquiries:Agneta Selroos, Communications Manager, +358 10 500 6105 1)      Organized by Glaston since 1992, Glass Performance Days is a forum dedicated to the development of the global glass industry through an exchange of ideas, concepts, and innovations. Glaston in briefGlaston is the glass processing industry’s innovative technology leader supplying equipment, services and solutions to the architectural, mobility, display and solar industries. The company also supports the development of new technologies integrating intelligence to glass. Glaston is committed to providing its clients with both the best know-how and the latest technologies in glass processing, with the purpose of building a better tomorrow through safer, smarter, and more energy efficient glass solutions. Glaston operates globally with manufacturing, services and sales offices in nine countries and its shares (GLA1V) are listed on Nasdaq Helsinki Ltd.

ZINZINO AB (PUBL.): ZINZINO OPENS COLOMBIA FOLLOWING STRONG PRE-LAUNCH DEMAND AND GROWING LATIN AMERICAN MOMENTUM

Zinzino today announced the official opening of Colombia as a new market on June 11, 2026, further strengthening the company’s presence in Latin America. The launch follows strong pre-market demand, with sales through Zinzino’s global webshop already reaching approximately 2mSEK per month. The decision to establish operations in Colombia reflects Zinzino’s proven market expansion strategy, where customer demand and Partner activity are developed through the company’s global infrastructure before a full market launch is implemented. Colombia has emerged as one of the company’s most promising growth opportunities in the region, supported by increasing customer interest and growing entrepreneurial activity.s With more than 53 million inhabitants, Colombia is the fourth most populous country in Latin America and one of the region’s largest direct selling markets. Industry data indicates that the Colombian direct selling sector generates annual retail sales exceeding USD 2 billion and engages more than 2.6 million independent distributors. Combined with increasing digital adoption and expanding e-commerce behavior, the market offers attractive conditions for Zinzino’s test-based personalized nutrition concept and scalable business model. “Colombia is one of the most attractive direct selling markets in Latin America and has already demonstrated significant demand for both our products and business opportunity,” says Dag Bergheim Pettersen, CEO of Zinzino. “We are entering the market from a position of strength. The combination of proven customer demand, a well-established direct selling culture and growing interest in personalized wellness solutions makes Colombia a natural next step in our international expansion strategy. We see substantial long-term potential in the market and look forward to supporting both customers and Partners as we continue to build our presence in the region.” Latin America remains an important growth region for Zinzino, driven by increasing health awareness, digital engagement and entrepreneurship. The launch in Colombia further strengthens the company’s regional footprint and supports its ambition to make test-based personalized nutrition accessible to more people around the world. The market opening creates new opportunities for Independent Partners to build and grow their businesses locally while leveraging Zinzino’s global platform, digital Partner tools, educational systems and proven business model. Customers and Partners in Colombia will benefit from local market support combined with access to Zinzino’s internationally recognized portfolio of scientifically based health and wellness solutions. The launch further expands Zinzino’s global footprint across more than 100 markets worldwide and marks another milestone in the company’s long-term strategy to drive sustainable international growth through customer-centric innovation, digital scalability and entrepreneurship. For more information:Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, dag@zinzino.comFredrik Nielsen CFO Zinzino +46 (0) 707 900 174, fredrik.nielsen@zinzino.com Pictures for publication free of charge: marketing@zinzino.com Certified Adviser: Tapper Partners AB

Hexagon acquires ITRES to strengthen its capabilities in advanced airborne mapping

Stockholm, Sweden – 12 June 2026 – Hexagon AB has acquired ITRES Research Limited (“ITRES”), a Calgary-based provider of high-performance airborne hyperspectral and thermal imaging systems, strengthening Hexagon’s ability to deliver richer multi-sensor geospatial data for advanced airborne mapping and analysis.The acquisition brings together two complementary portfolios under one provider. Hexagon contributes a market-leading suite of airborne sensing and processing products for geodata development – including LiDAR point clouds, high-resolution optical imagery, digital twins, and integrated workflow software, flight planning tools and data delivery systems. ITRES adds high-performance hyperspectral and thermal imaging sensors that operate across a wide spectrum of wavelengths, enabling precise material identification and temperature analysis that existing visible and near-infrared modalities cannot deliver alone.Together, these capabilities allow customers to collect richer, more analytically powerful datasets from a single airborne survey. Fusing multispectral and thermal data with LiDAR and optical imagery opens new possibilities for ground surface assessment, object classification and thermal property detection, while Hexagon's proven software ecosystem helps teams process and act on that data faster. The result is a more complete multi-sensor mapping platform – and new opportunities for hybrid information collection and data fusion that were previously only possible by combining solutions from multiple vendors.“Geospatial professionals are looking to extract deeper insight from each airborne survey”, said Anders Svensson, President and CEO of Hexagon. “By integrating hyperspectral and thermal sensing into our portfolio, we further expand the range of information that can be captured and analysed. Combining complementary sensing technologies helps geospatial professionals improve classification accuracy, better distinguish materials, and derive more reliable thermal insights, supporting more advanced and specialised applications”.By adding hyperspectral and thermal imaging capabilities to the airborne workflow, customers can gain deeper insight from airborne surveys for environmental applications (such as urban heat mapping, water quality monitoring, wetlands, minerals and geology and forestry mapping) as well as disaster response applications (including locating active fire hotspots, identifying people or objects through heat detection, and rapidly providing responders with georeferenced thermal imagery).“We welcome the ITRES team and its exceptional capabilities within airborne hyperspectral and thermal imaging to the Infrastructure & Geospatial Business Area. From a technology perspective, the portfolios of Hexagon and ITRES are highly complementary, enabling us to meet our customers’ full range of needs in advanced airborne mapping”, said Henning Sandfort, President of the Infrastructure & Geospatial Business Area.ITRES will be reported within Hexagon's Infrastructure & Geospatial (formerly Geosystems) Business Area, within the Scanning & Mapping Division, and is expected to generate revenues of around 13 MEUR in 2026, accretive to net profits from day of completion and with margin initially slightly below the Infrastructure & Geospatial Business Area average.For further information, please contact: Tom Hull, Head of Investor Relations, Hexagon AB, +44 7442 678 437, ir@hexagon.com About Hexagon :Hexagon is the global leader in measurement technologies. Our precision measurement, positioning, and autonomous solutions transform the world’s most vital industries. From aerospace & defence, automotive, construction, general manufacturing, to mining and more, we provide the confidence that customers rely on to build, navigate, and innovate.  Hexagon (Nasdaq Stockholm: HEXA B) has approximately 17,000 employees in 50 countries and net sales of approximately 3.7bn EUR. Learn more at hexagon.com. Learn more at hexagon.com.